# Patent

## Title
Inhibitors of hepatitic C virus

## Abstract

The invention provides compounds of formula (I):




wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

## Background
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention is directed to compounds useful as inhibitors of replication of the hepatitis C virus (HCV). The invention is also directed to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat HCV infection, and processes and intermediates useful for preparing such compounds.
2. State of the Art
Recent estimates place the number of people infected with the hepatitis C virus (HCV) worldwide at more than 170 million, including 3 million people in the United States. The infection rate is thought to be roughly 4 to 5 times that of the human immunodeficiency virus (HIV). While in some individuals, the natural immune response is able to overcome the virus, in the majority of cases, a chronic infection is established, leading to increased risk of developing cirrhosis of the liver and hepatocellular carcinomas. Infection with hepatitis C, therefore, presents a serious public health problem.
Prior to mid-2011, the accepted standard of care for HCV involved the use of a pegylated interferon which is believed to act by boosting the body's immune response, together with ribavirin. Unfortunately, the course of treatment is lengthy, typically 48 weeks, often accompanied by serious adverse side effects, including depression, flu-like symptoms, fatigue, and hemolytic anemia, and ineffective in up to 50% of patients. In mid-2011, two HCV protease inhibitors were approved in the United States to be used in combination with interferon and ribavirin. Although better cure rates have been reported, the course of therapy is still lengthy and accompanied by undesirable side effects. Accordingly, there remains a serious unmet need in HCV treatment.
The virus responsible for HCV infection has been identified as a positive-strand RNA virus belonging to the family Flaviviridae. The HCV genome encodes a polyprotein that during the viral lifecycle is cleaved into ten individual proteins, including both structural and non-structural proteins. The six non-structural proteins, denoted as NS2, NS3, NS4A, NS4B, NS5A, and NS5B have been shown to be required for RNA replication. In particular, the NS5A protein appears to play a significant role in viral replication, as well as in modulation of the physiology of the host cell. Effects of NS5A on interferon signaling, regulation of cell growth and apoptosis have also been identified. (Macdonald et al., Journal of General Virology (2004), 85, 2485-2502.) Compounds which inhibit the function of the NS5A protein are expected to provide a new approach to HCV therapy.
SUMMARY OF THE INVENTION
In one aspect, the invention provides novel compounds which inhibit replication of the HCV virus.
Accordingly, the invention provides a compound of formula (I):




wherein:

R1 is selected from C1-6alkyl, phenyl, C3-6cycloalkyl, heteroaryl, and heterocycle; wherein C1-6alkyl is optionally substituted with —ORq, wherein Rq is hydrogen or C1-3alkyl;
R2 is selected from hydrogen and C1-6alkyl;
R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)OC3-6cycloalkyl, —C(O)NRaRb, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl;
wherein

    
    
        Ra and Rb are independently hydrogen or C1-6alkyl;
    
    


R4 is —C(O)R5 or —S(O)2R6;
R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, —CH2-heteroaryl, and phenyl;
wherein

    
    
        C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORc, —S(O)2C1-3alkyl, —NHC(O)C1-3alkyl, and —NHC(O)OC1-3alkyl;
        C1-6alkoxy is optionally substituted with —ORd;
        C3-6cycloalkyl is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, NRjRm, —ORn, and halo;
        any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —C(O)OC1-3alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, —C(O)NHC3-6cycloalkyl, and —S(O)2C1-3alkyl;
        
            wherein any —C(O)C1-6alkyl is optionally substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle,
            any —C(O)C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl, and
            any —C(O)NHC1-6alkyl is optionally substituted with —ORn or C3-6cycloalkyl;
        
        
        any heteroaryl is optionally substituted with C1-6alkyl;
        Rc is independently selected from hydrogen, C1-6alkyl, and phenyl;
        Rd is independently hydrogen or C1-6alkyl;
        Re is independently hydrogen or C1-6alkyl;
        Rf is independently selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, and —C(O)C1-6alkyl;
        Rn is independently hydrogen or C1-3alkyl;
        Rk is independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl, and —CH2ORn;
        Rg is independently hydrogen or C1-6alkyl;
        Rh is independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, and —S(O)2C1-3alkyl, wherein C1-6alkyl is optionally substituted with —ORd;
        Rj is independently hydrogen or C1-6alkyl;
        Rm is independently selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, and —C(O)C1-6alkyl;
    
    


R6 is selected from C1-6alkyl, C3-6cycloalkyl, phenyl, and a heteroaryl ring;
R7, R8, and R11 are independently selected from halo, C1-6alkyl, C1-6alkoxy, —C(O)ORn, —CH2NRaRb, and —CN, wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, three, four, or five halo, and wherein C1-6alkoxy is optionally substituted with —ORd;
R9 is independently selected from C1-6alkyl, —CH2ORn, —C(O)NRnRp, and C(O)ORn, wherein C1-6alkyl is optionally substituted with —S(O)2C1-3allyl or with —SC1-3alkyl;
Rp is independently hydrogen or C1-3alkyl;
R10 is selected from hydrogen, halo, C1-6alkyl, —C(O)ORc, —C(O)NRaRb, —CH2NRaRb, C3-6cycloalkyl, and —CN;
W′, X′, Y′, and Z′ are independently carbon or nitrogen wherein any carbon atom is bonded to hydrogen or to R11, provided that at least two of W′, X′, Y′, and Z′ are carbon;
W′, X′, Y′, and Z′ are independently carbon or nitrogen wherein any carbon atom is bonded to hydrogen or to R11, provided that at least two of W′, X′, Y′, and Z′ are carbon;
Am is —NHC(O)— or —C(O)NH—;
Q, T, U, and V are independently carbon or nitrogen wherein any carbon atom is bonded to hydrogen or to R8, provided that at least two of Q, T, U, and V are carbon; and
a, b, c, and d are independently 0, 1, or 2;
or a pharmaceutically-acceptable salt or stereoisomer thereof.
As used hereinafter, the phrase “compound of formula (I)” means a compound of formula (I) or a pharmaceutically acceptable salt thereof; i.e., this phrase means a compound of formula (I) in free base form or in a pharmaceutically acceptable salt form unless otherwise indicated.
The invention also provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically-acceptable carrier. In addition, the invention provides a pharmaceutical composition comprising a compound of the invention, a pharmaceutically-acceptable carrier and one or more other therapeutic agents useful for treating hepatitis C viral infections.
The invention also provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound or of a pharmaceutical composition of the invention. In addition, the invention provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a compound or a pharmaceutical composition of the invention and one or more other therapeutic agents useful for treating hepatitis C viral infections. Further, the invention provides a method of inhibiting replication of the hepatitis C virus in a mammal, the method comprising administering a compound or a pharmaceutical composition of the invention.
In separate and distinct aspects, the invention also provides synthetic processes and intermediates described herein, which are useful for preparing compounds of the invention.
The invention also provides a compound of the invention as described herein for use in medical therapy, as well as the use of a compound of the invention in the manufacture of a formulation or medicament for treating a hepatitis C viral infection in a mammal


DETAILED DESCRIPTION OF THE INVENTION
Among other aspects, the invention provides inhibitors of HCV replication of formula (I), pharmaceutically-acceptable salts thereof, and intermediates for the preparation thereof. The following substituents and values are intended to provide representative examples of various aspects of this invention. These representative values are intended to further define such aspects and are not intended to exclude other values or limit the scope of the invention.
In a specific aspect, R1 is selected from C1-6alkyl, phenyl, C3-6cycloalkyl, heteroaryl, and heterocycle; wherein C1-6alkyl is optionally substituted with —ORq; wherein Rq is hydrogen or C1-3alkyl.
In another specific aspect of the invention, R1 is selected from C1-6alkyl, phenyl, C3-6cycloalkyl, heteroaryl, and heterocycle.
In another specific aspect, R1 is selected from C1-6alkyl, phenyl, and C3-6cycloalkyl, wherein C1-6alkyl is optionally substituted with —ORq; wherein Rq is hydrogen or C1-3alkyl.
In another specific aspect, R1 is selected from C1-6alkyl and phenyl.
In a specific aspect, R1 is C1-3 alkyl.
In another specific aspect, R1 is isopropyl.
In a specific aspect, R2 is hydrogen or C1-6alkyl.
In other specific aspects, R2 is hydrogen or C1-3alkyl; or R2 is hydrogen.
In a specific aspect, R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)OC3-6cycloalkyl, —C(O)NRaRb, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl, wherein Ra and Rb are independently hydrogen or C1-6alkyl.
In another specific aspect, R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)NRaRh, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl, wherein Ra and Rb are independently hydrogen or C1-6alkyl.
In yet other specific aspects, R3 is selected from hydrogen, C1-6alkyl, and —C(O)OC1-6alkyl; and R3 is —C(O)OC1-3alkyl.
In a specific aspect, R1 is C1-6alkyl, R2 is hydrogen, and R3 is —C(O)OC1-6alkyl.
In another specific aspect, R1 is isopropyl, R2 is hydrogen, and R3 is —C(O)OCH3.
In yet other specific aspects, R1 is phenyl and R2 and R3 are each C1-3alkyl, or R1 is phenyl and R2 and R3 are each ethyl; or R1 is phenyl, R2 is hydrogen, and R3 is —C(O)OC1-3alkyl.
In a specific aspect, R4 is —C(O)R5 wherein R5 is defined as in formula (I).
In another specific aspect, R4 is —C(O)R5 wherein R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, —CH2-heteroaryl, and phenyl; wherein C1-6alkyl is optionally substituted with —ORc or —S(O)2C1-3alkyl; C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl, or with NRjRm or —ORn; any heterocycle is optionally substituted with one or two substituents selected from C1-3alkyl, halo, —C(O)OC1-3alkyl, —C(O)C1-6alkyl optionally substituted with —NHC(O)OC1-3alkyl, and —C(O)C3-6cycloalkyl optionally substituted with one or two C1-3alkyl; and any heteroaryl is optionally substituted with C1-6alkyl, wherein Rh is selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, and —S(O)2C1-3alkyl, and Rc, Rk, Rd, Re, Rf, Rg, Rj, Rm, and Rn are defined as in formula (I).
In another specific aspect, R4 is —C(O)R5 wherein R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, and —CH2-heteroaryl, wherein any heteroaryl or heterocycle has five or six ring atoms; C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl; any heterocycle is optionally substituted with one or two substituents selected from C1-3alkyl halo, —C(O)OC1-3alkyl, C(O)C1-6alkyl optionally substituted with —NHC(O)OC1-3alkyl, and —C(O)C3-6cycloalkyl optionally substituted with one or two C1-3alkyl; Rk, Rd, Re, Rg, and Rh are each independently hydrogen or C1-3alkyl; and Rf is selected from hydrogen and —C(O)C1-3alkyl.
In another specific aspect, R4 is —C(O)R5 wherein R5 is selected from C3-4cycloalkyl, —CH2NReRf, —NRgRh, imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl; wherein: C3-4cycloalkyl is optionally substituted with one or two C1-3alkyl; pyrrolidinyl is substituted with methyl and a substituent selected from —C(O)OC1-3alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl, wherein —C(O)C1-6alkyl is substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle.
In yet another specific aspect, R4 is —C(O)R5 wherein R5 is selected from, —O-tert-butyl, cyclopropyl, tert-butyl, —NHCH3, 2,2-dimethylcyclopropyl, pyrimidinyl, pyrazolyl, imidazolyl, —CH2-pyrazolyl, 1-acetylpyrrolidinyl, 2-methylpyrrolidine-1-carboxylic acid methyl ester, 1-cyclopropyl-2-methylpyrrolidine, dimethylcyclopropyl)-2-methylpyrrolidine, and [-2-methyl-1-(2-methyl-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester.
In yet another specific aspect, R4 is —C(O)R5 wherein R5 is selected from, —O-tert-butyl, cyclopropyl, tert-butyl, —NHCH3, 2,2-dimethylcyclopropyl, pyrimidinyl, pyrazolyl, imidazolyl, —CH2-pyrazolyl, and 1-acetylpyrrolidinyl.
In another aspect, R4 is —C(O)R5 wherein R5 is a five- or six-membered heteroaryl ring;
In yet another aspect R4 is —C(O)R5 wherein R5 is cyclopropyl or 2,2-dimethylcyclopropyl.
In another aspect, R4 is —C(O)R5 wherein R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl,




In another aspect, R4 is —C(O)R5 wherein R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl, and




In yet another aspect, R4 is —C(O)R5 wherein R5 is —NHCH3.
In a specific aspect, R4 is —S(O)2R6 wherein R6 is selected from C1-6alkyl, C3-6cycloalkyl, and heteroaryl.
In another specific aspect, R4 is —S(O)2R6 wherein R6 is selected from C1-6alkyl, C3-6cycloalkyl, and a five- or six-membered heteroaryl.
In another specific aspect, R4 is —S(O)2R6 wherein R6 is C1-6alkyl.
In yet another specific aspect, R4 is —S(O)2R6 wherein R6 is methyl.
In a specific aspect, R7, R8, and R11 are independently selected from halo, C1-6alkyl, C1-6alkoxy, —C(O)ORn, —CH2NRaRb, and —CN, wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, or three halo and wherein C1-6alkoxy is optionally substituted with —ORd.
In another specific aspect, R7, R8, and R11 are independently selected from halo, C1-6alkyl, C1-6alkoxy, —C(O)ORn, —CH2NRaRb, and —CN, wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, or three halo
In a specific aspect, R7 is independently selected from halo, C1-6alkyl, and C1-6alkoxy wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, or three halo.
In another specific aspect, R7 is halo.
In yet another specific aspect, R7 is chloro or fluoro.
In still another specific aspect, R7 is selected from methyl, —CF3, —OCH3, —OCF3, and fluoro.
In yet another specific aspect, R7 is selected from fluoro, chloro, —CF3, and —OCF3.
In a specific aspect, R9 is selected from C1-6alkyl, —CH2ORn, —C(O)NRnRp, and C(O)ORn, wherein C1-6alkyl is optionally substituted with —S(O)2C1-3alkyl or with —SC1-3alkyl.
In another specific aspect, R9 is selected from C1-6alkyl, —CH2ORn, —C(O)NRnRp, and C(O)ORn.
In another specific aspect, R9 is C1-6alkyl or —CH2ORn.
In another specific aspect, R9 is C1-6alkyl.
In yet another specific aspect, R9 is methyl.
In a specific aspect, R10 is selected from hydrogen, halo, C1-6alkyl, —C(O)ORc, —C(O)NRaRb, —CH2NRaRb, C3-6cycloalkyl, and —CN.
In a specific aspect, R10 is selected from hydrogen, halo, and C1-6alkyl.
In other specific aspects, R10 is halo; or R10 is chloro.
In yet another specific aspect, R10 is hydrogen.
In a specific aspect W′, X′, Y′, and Z′ are each CH.
In a specific aspect, W, X, Y, and Z are independently carbon or nitrogen wherein any carbon atom is bonded to hydrogen or to R7, provided that at least two of W, X, Y, and Z are carbon.
In another specific aspect, W, X, Y, and Z are independently carbon or nitrogen wherein any carbon atom is bonded to hydrogen or R7, provided that at least three of W, X, Y, and Z are carbon.
In another specific aspect, W, X, Y, and Z are each carbon and two of W, X, Y, and Z are CH and two of W, X, Y, and Z are bonded to R7.
In yet another specific aspect, W and Z are independently carbon bonded to R7 and X and Y are CH.
In a specific aspect, Q, T, U, and V are independently selected from CH and N.
In a specific aspect, Q, U, and V are each CH and T is N.
In a specific aspect, a is 1 or 2.
In another specific aspect, a is 1.
In another specific aspect a is 0.
In a specific aspect, b is 0.
In a specific aspect, c is 1 or 2.
In another specific aspect, c is 2.
In another specific aspect, c is 1.
In another specific aspect, c is 0.
In a specific aspect, d is 1.
In a specific aspect, d is 0.
In one aspect, the invention provides compounds of formula (I) disclosed in U.S. Provisional Application No. 61/492,267, filed on Jun. 1, 2011.
In another aspect, the invention provides compounds of formula (II):




wherein the variables of formula (II) are as defined herein.

In another aspect, the invention provides compounds of formula (III)




wherein the variables of formula (III) are as defined herein.

A particular group of compounds of formula (III) is a group wherein:
R1 is selected from C1-6alkyl, phenyl, and C3-6cycloalkyl, wherein C1-6alkyl is optionally substituted with —ORq;
R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)NRaRb, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl;
R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, and CH2-heteroaryl;
wherein:

    
    
        any heteroaryl or heterocycle has 5 or 6 ring atoms;
        C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORc, —NHC(O)C1-3alkyl, and —NHC(O)OC1-3alkyl;
        C1-6alkoxy is optionally substituted with —ORd;
        C3-6cycloalkyl is optionally substituted with one or two substituents independently selected from C1-3alkyl and halo;
        any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —C(O)OC1-3alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, and —C(O)NHC3-6cycloalkyl;
        
            wherein any —C(O)C1-6alkyl is optionally substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle,
            any —C(O)C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl, and
            any —C(O)NHC1-6alkyl is optionally substituted with —ORn or C3-6cycloalkyl;
        
        
        any heteroaryl is optionally substituted with C1-3alkyl;
        Rk, Rd, Re, Rg, and Rh are each independently hydrogen or C1-3alkyl;
        Rf is selected from hydrogen and —C(O)C1-3alkyl;
    
    


R7 is selected from halo, C1-3allyl, and C1-3alkoxy wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, or three halo;
R9 is C1-3allyl;
a is 1 or 2; and
c is 1 or 2; and all other variables are as defined in formula (I).
Another group of compounds of formula (III) is a group wherein:
R5 is selected from C3-4cycloalkyl, —CH2NReRf, —NRgRh, imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl;
wherein:

    
    
        C3-4cycloalkyl is optionally substituted with one or two C1-3allyl;
        pyrrolidinyl is substituted with methyl and a substituent selected from —C(O)OC1-3alkyl, —C(O)C1-6allyl, —C(O)NHC1-6allyl, wherein
        
            —C(O)C1-6allyl is substituted with —NHC(O)OC1-3alkyl, —ORn,
        
        
        —NRdRe, or heterocycle;
        wherein Re, Rg, and Rh are each independently hydrogen or C1-3allyl; and
    
    


Rf is selected from hydrogen and —C(O)C1-3alkyl.
Yet another group of compounds of formula (III) is a group wherein:
R1 is isopropyl, R2 is hydrogen; R3 is —C(O)OCH3;
R7 is selected from fluoro, chloro, —CF3, and —OCF3, R9 is methyl; and
R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl, and




In another aspect, the invention additionally provides compounds of formula (IV):




wherein the variables of formula (IV) are as defined herein.

In still another aspect, the invention provides compounds of formula (V):




wherein the variables are as defined herein.

In one aspect, the invention provides the compounds of Examples 1-77 and Tables 1-34 below.
In yet another aspect, the invention provides a compound selected from the compounds depicted below






















and pharmaceutically-acceptable salts thereof.

In a still further aspect, the invention provides a compound selected from the following compounds




and pharmaceutically-acceptable salts thereof.

The chemical naming convention used herein is illustrated for the compound of Example 1:




which is {(S)-1-[(S)-2-(4-{4′-[4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester according to the IUPAC conventions as implemented in AutoNom software, (MDL Information Systems, GmbH, Frankfurt, Germany).

The compounds of the invention contain one or more chiral centers and therefore, such compounds (and intermediates thereof) can exist as racemic mixtures; pure stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and the like. Chiral compounds shown or named herein without a defined stereochemistry at a chiral center are intended to include any or all possible stereoisomer variations at the undefined stereocenter unless otherwise indicated. The depiction or naming of a particular stereoisomer means the indicated stereocenter has the designated stereochemistry with the understanding that minor amounts of other stereoisomers may also be present unless otherwise indicated, provided that the utility of the depicted or named compound is not eliminated by the presence of another stereoisomer.
Compounds of formula (I) also contain several basic groups (e.g., amino groups) and therefore, such compounds can exist as the free base or in various salt forms, such a mono-protonated salt form, a di-protonated salt form, a tri-protonated salt form, or mixtures thereof. All such forms are included within the scope of this invention, unless otherwise indicated.
This invention also includes isotopically-labeled compounds of formula (I), i.e., compounds of formula (I) where an atom has been replaced or enriched with an atom having the same atomic number but an atomic mass different from the atomic mass that predominates in nature. Examples of isotopes that may be incorporated into a compound of formula (I) include, but are not limited to, 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 35S, 36Cl, and 18F. Of particular interest are compounds of formula (I) enriched in tritium or carbon-14, which compounds can be used, for example, in tissue distribution studies. Also of particular interest are compounds of formula (I) enriched in deuterium especially at a site of metabolism, which compounds are expected to have greater metabolic stability. Additionally of particular interest are compounds of formula (I) enriched in a positron emitting isotope, such as 11C, 18F, 15O and 13N, which compounds can be used, for example, in Positron Emission Tomography (PET) studies.
Definitions
When describing this invention including its various aspects and embodiments, the following terms have the following meanings, unless otherwise indicated.
The term “alkyl” means a monovalent saturated hydrocarbon group which may be linear or branched or combinations thereof. Unless otherwise defined, such alkyl groups typically contain from 1 to 10 carbon atoms. Representative alkyl groups include, by way of example, methyl (Me), ethyl (Et), n-propyl (n-Pr) or (nPr), isopropyl (i-Pr) or (iPr), n-butyl (n-Bu) or (nBu), sec-butyl, isobutyl, tert-butyl (t-Bu) or (tBu), n-pentyl, n-hexyl, 2,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl, 2-ethylbutyl, 2,2-dimethylpentyl, 2-propylpentyl, and the like
When a specific number of carbon atoms are intended for a particular term, the number of carbon atoms is shown preceding the term. For example, the term “C1-3 alkyl” means an alkyl group having from 1 to 3 carbon atoms wherein the carbon atoms are in any chemically-acceptable configuration, including linear or branched configurations.
The term “alkoxy” means the monovalent group —O-alkyl, where alkyl is defined as above. Representative alkoxy groups include, by way of example, methoxy, ethoxy, propoxy, butoxy, and the like.
The term “cycloalkyl” means a monovalent saturated carbocyclic group which may be monocyclic or multicyclic. Unless otherwise defined, such cycloalkyl groups typically contain from 3 to 10 carbon atoms. Representative cycloalkyl groups include, by way of example, cyclopropyl (cPr), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, and the like.
The term “heterocycle”, “heterocyclic”, or “heterocyclic ring” means a monovalent saturated or partially unsaturated cyclic non-aromatic group, having from 3 to 10 total ring atoms, wherein the ring contains from 2 to 9 carbon ring atoms and from 1 to 4 ring heteroatoms selected from nitrogen, oxygen, and sulfur. Heterocyclic groups may be monocyclic or multicyclic (i.e., fused or bridged). Representative heterocyclic groups include, by way of example, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholyl, indolin-3-yl, 2-imidazolinyl, 1,2,3,4-tetrahydroisoquinolin-2-yl, quinuclidinyl, 7-azanorbornanyl, nortropanyl, and the like, where the point of attachment is at any available carbon or nitrogen ring atom. Where the context makes the point of attachment of the heterocyclic group evident, such groups may alternatively be referred to as a non-valent species, i.e. pyrrolidine, piperidine, piperazine, imidazole, etc.
The term “heteroaryl” or “heteroaryl ring” means a monovalent aromatic group having from 5 to 10 total ring atoms, wherein the ring contains from 1 to 9 carbon ring atoms and from 1 to 4 ring heteroatoms selected from nitrogen, oxygen, and sulfur. Heteroaryl groups may be monocyclic or multicyclic. Representative heteroaryl groups include, by way of example, pyrroyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyridyl (or, equivalently, pyridinyl), pyrimidyl, pyridazinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, and the like, where the point of attachment is at any available carbon or nitrogen ring atom. Where the context makes the point of attachment of the heteroaryl group evident, such groups may alternatively be referred to as a non-valent species, i.e. pyrrole, isoxazole, isothiazole, pyrazole, imidazole, etc.
The term “halo” means fluoro, chloro, bromo or iodo.
The term “therapeutically effective amount” means an amount sufficient to effect treatment when administered to a patient in need of treatment.
The term “treatment” as used herein means the treatment of a disease, disorder, or medical condition in a patient (such as hepatitis C viral infection), such as a mammal (particularly a human) which includes one or more of the following:
(a) preventing the disease, disorder, or medical condition from occurring, i.e., preventing the reoccurrence of the disease or medical condition or prophylactic treatment of a patient that is pre-disposed to the disease or medical condition;
(b) ameliorating the disease, disorder, or medical condition, i.e., eliminating or causing regression of the disease, disorder, or medical condition in a patient, including counteracting the effects of other therapeutic agents;
(c) suppressing the disease, disorder, or medical condition, i.e., slowing or arresting the development of the disease, disorder, or medical condition in a patient; or
(d) alleviating the symptoms of the disease, disorder, or medical condition in a patient.
The term “pharmaceutically acceptable salt” means a salt that is acceptable for administration to a patient or a mammal, such as a human (e.g., salts having acceptable mammalian safety for a given dosage regime). Representative pharmaceutically acceptable salts include salts of acetic, ascorbic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, edisylic, fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalene-1,5-disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic and xinafoic acid, and the like.
The term “salt thereof” means a compound formed when the hydrogen of an acid is replaced by a cation, such as a metal cation or an organic cation and the like. For example, the cation can be a protonated form of a compound of formula (I), i.e. a form where one or more amino groups have been protonated by an acid. Typically, the salt is a pharmaceutically acceptable salt, although this is not required for salts of intermediate compounds that are not intended for administration to a patient.
The term “amino-protecting group” means a protecting group suitable for preventing undesired reactions at an amino nitrogen. Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl and tri-fluoroacetyl; alkoxycarbonyl groups, such as tert butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and 1,1-di-(4′-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), [2-(trimethylsilyl)ethoxy]methyl (SEM); and the like. Numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York
General Synthetic Procedures
Compounds of this invention, and intermediates thereof, can be prepared according to the following general methods and procedures using commercially-available or routinely-prepared starting materials and reagents. The substituents and variables (e.g., R1, R2, R3, R4, etc.) used in the following schemes have the same meanings as those defined elsewhere herein unless otherwise indicated. Additionally, compounds having an acidic or basic atom or functional group may be used or may be produced as a salt unless otherwise indicated (in some cases, the use of a salt in a particular reaction will require conversion of the salt to a non-salt form, e.g., a free base, using routine procedures before conducting the reaction).
Although a particular embodiment of the present invention may be shown or described in the following procedures, those skilled in the art will recognize that other embodiments or aspects of the present invention can also be prepared using such procedures or by using other methods, reagents, and starting materials know to those skilled in the art. In particular, it will be appreciated that compounds of the invention may be prepared by a variety of process routes in which reactants are combined in different orders to provide different intermediates en route to producing final products.
In one exemplary method of synthesis, compounds of formula (I-3) in which Am is defined as —NHC(O)— are prepared as shown in Scheme 1:




where R4a is an amino-protecting group Pg or R4a is R4 as defined in formula (I), and G represents the group G1





where R1, R2, and R3 are defined as in formula (I), or as an amino-protecting group Pg. Aniline intermediate 1-1 is reacted with carboxylic acid 1-2 according to typical amide bond formation conditions to provide a compound of formula 1-3 In some instances, the carboxylic acid 1-2 is first converted to an acid chloride and then reacted with aniline intermediate 1-1 to provide a compound of formula 1-3. As shown in the examples below, the amide bond formation reaction may utilize coupling agents, such as N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU), or as 1,3 dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), or benzotriazol-1-yloxytripyrrolidino-phosphonium hexafluorophosphate (PyBop), optionally combined with 1-hydroxy-7-azabenzotriazole (HOAt). Preferably, the process of Scheme 1 is used to prepare compounds of formula 1-3 in which R7 is absent (a is 0) or R7 is an electron rich substituent such as an unsubstituted-alkyl or unsubstituted-alkoxy, and the reaction is performed in the presence of coupling agents EDC and HOAt at a temperature of about 50 to about 60° C. Preferably, only one of G and R4a is a protecting group, or, if two protecting groups are present, groups removable under different conditions are used.

When the variable R4a is defined as R4 and the variable G is defined as G1, then the product 1-3 of the reaction of Scheme 1 is a final compound of formula (I).
Alternatively, when R4a is defined as R4 and G is defined as protecting group Pg, for example Boc, the product 1-3 of the reaction of Scheme 1 is a protected intermediate which is then deprotected, for example, by treatment with an acid, and reacted with a reagent X-G1, where X is a halogen leaving group, or with a carboxylic acid of formula HO-G1, the latter under amide bond formation conditions as described above, to provide the desired product.
In another exemplary method of synthesis, compounds of formulas 2-2 and 2-3 are prepared as shown in Scheme 2:




When G represents G1 in intermediate 2-1, then the reaction of Scheme 2, directly provides compounds of the invention. To prepare a compound of formula 2-2 where R4 is defined as —C(O)R5, intermediate 2-1 is reacted with an acid chloride (reaction (i)) or, where R5 is defined as —NRgRh, with an isocyanate (reaction (iii)) in the presence of base. Alternatively, intermediate 2-1 is reacted with a carboxylic acid (reaction (ii)) under amide bond formation conditions to prepare a compound of formula 2-2. Similarly, to prepare a compound of formula 2-3 where R4 is defined as —S(O)2R6, intermediate 2-1 is typically reacted with a sulfonyl chloride in the presence of base (reaction (iv)).
As described above, when G represents a protecting group a subsequent deprotection step, and coupling with an intermediate X-G1 or HO-G1 provides the final product.
The intermediates of the above Schemes may be prepared by conventional synthetic reactions. For example, the biaryl aniline intermediate 1-1 may be prepared by the Suzuki coupling reaction in the presence of a palladium catalyst (Miyaura and Suzuki, Chem. Rev. 1995, 95, 2457-2483). As shown in Scheme 3 below, either coupling partner may bear the boronate moiety. Alternatively, a boronic acid reagent may be used in place of a boronate reagent, such as the pinacol boronate depicted below.




An exemplary process for the preparation of intermediate 1-2 in which R4a represents Pg (compound 1-2′′) or R4a represents, for example, —C(O)R5 (compound 1-2′) is shown in Scheme 4.




The reaction of a piperazine with a fluorobenzoic ester or fluoronicotinic ester 4-1, typically a methyl or ethyl ester, may be performed in dimethylsulfoxide in the presence of potassium carbonate at elevated temperature, typically about 100° C. to about 130° C. The resulting intermediate 4-2 is subsequently hydrolyzed to provide protected intermediate 1-2′′. To prepare intermediate 1-2′, protected intermediate 1-2′′, where preferably the protecting group is Boc, can be deprotected and then reacted with an acid chloride, carboxylic acid, or isocyanate as in Scheme 2 to provide intermediate 1-2′.
An alternative process for the preparation of intermediate 1-2 in which T represents nitrogen and R4a represents Pg (compound 1-2a′′) or R4a represents —C(O)R5 (compound 1-2a′) is shown in Scheme 5.




The reaction of a fluoronicotinic acid 5-1 with the protected piperazine 5-2 to provide intermediate 1-2a′′ is typically performed using isopropylmagnesium chloride at a temperature below about −20° C.

To prepare intermediate 1-2a′, protected intermediate 1-2a′′, where preferably the protecting group is Boc, can be deprotected and esterified by reaction with sulfuric acid in methanol to provide an ester intermediate 5-3, which is reacted with an acid chloride, carboxylic acid, or isocyanate as in Scheme 2 and subsequently hydrolyzed to provide intermediate 1-2a′.
Intermediate 2-1 where G represents G1 may be prepared by the process of Scheme 1 where the variable R4a is defined as protecting group Pg. In this instance, formula 1-3 describes a protected intermediate, which is deprotected to provide intermediate 2-1.
An alternative process for the preparation of intermediate 2-1 in which T represents nitrogen (compound 2-1a) is shown in Scheme 6.




In a first step, biphenyl aniline 1-1 is reacted with a fluoropyridine carbonyl chloride 6-1 in the presence of base to provide fluoro intermediate 6-2, which is reacted with an excess of protected piperidine 5-2 to provide protected intermediate 6-3. The reaction typically is performed in the presence of base with heating to a temperature of about 80° C. to about 120° C. for a period of about 4 to about 48 hours. Finally, intermediate 6-3 is deprotected, for example, by treatment with hydrochloric acid in an organic solvent to provide intermediate 2-1a as the HCl salt.
Yet another alternative process for the preparation of intermediate 2-1a utilizes a Suzuki coupling reaction of the boronate reagent 3-2 with intermediate 7-1, followed by a deprotection step, under conditions described above, as shown in Scheme 7.




If protected intermediate 7-1 were replaced by an intermediate 7-1′ bearing the substituent R4




then the Suzuki coupling of the boronate 3-2 in the first step of Scheme 7 would directly provide a final compound of the invention.

In the Suzuki coupling reaction of Scheme 7, alternatively, the opposite coupling partner could bear the boronate moiety, as shown in Scheme 3.
The bromo intermediate 7-1 may be prepared, for example, by amide coupling of arylamine 8-1 with a fluoropyridine carbonyl chloride 6-1, followed by reaction with a protected piperazine 5-2 as shown in Scheme 8.




Alternatively, intermediate 7-1 may be prepared by the reaction of 8-1 with the carboxylic acid intermediate 1-2′′ as given in Scheme 9.




Intermediates 3-1 and 3-2 used in the Suzuki reaction of Scheme 3 may be prepared, for example, as shown in Schemes 10 and 11.




Reagent 10-1, where X represents bromo or chloro is reacted with a protected proline carboxylic acid 10-2 to provide intermediate 10-3 which is converted to intermediate 3-1′′, where the variable G represents a protecting group, in the presence of an excess of ammonium acetate. The ring closure reaction typically is performed at a temperature between about 100° C. and about 120° C. for a period of about 4 to about 24 hours. To provide compound 3-1′ where the variable G represents G1, intermediate 3-1′′ is typically deprotected to provide intermediate 10-4, which is then coupled with a reagent HO-G1 to provide compound 3-1′.
Finally, to provide boronate intermediate 3-2, intermediate 3-1 is reacted with 11-1 in the presence of a palladium catalyst as shown in Scheme 11.




For the preparation of intermediate 2-1a in Scheme 7, boronate intermediate 3-2 may be prepared in situ according to the process of Scheme 11 and then reacted with intermediate 7-1 to provide intermediate 6-3 in a single pot process.
Compounds of Formula 12-3 in which the variable Am is defined as —C(O)NH— are prepared by processes analogous to those described above. One exemplary process for the preparation of compounds of Formula 12-3 is shown in Scheme 12.




The acid 12-1 and aniline or aminopyridine 12-2 are reacted under amide bond formation conditions. As above, when the variable R4a represents R4 and the variable G represents G1, then the reaction of Scheme 12 directly provides final compounds of formula (I).
Alternatively, when R4a represents R4 and G represents protecting group Pg, for example Boc, the reaction provides a protected intermediate of formula 12-3 which is then deprotected and reacted with a reagent X-G1, where X is a halogen leaving group, or with a carboxylic acid of formula HO-G1, to provide the desired product.
In yet another alternative route, a compound of formula 12-3 in which G is defined as G1 and R4a is a protecting group Pg, provides a useful intermediate, which is deprotected and reacted, for example, with an acid chloride, carboxylic acid, or isocyanate, as in Scheme 2 to provide final compounds of formula (I).
The intermediates of Scheme 12 may be prepared by conventional synthetic reactions. For example, the biaryl acid intermediate 12-1 may be prepared by the Suzuki coupling reaction of Scheme 13




A useful process for the preparation of the aminopyridine intermediate 12-2 of Scheme 12 utilizes a nitro substituted-chloropyridine or chlorophenyl 14-1 which is reacted with a protected piperazine 5-2 to provide a protected intermediate 14-2 as shown in Scheme 14.




Reduction of the nitro group to the amine provides intermediate 12-2′′ where R4a represents a protecting group. Deprotection of compound 12-2′′ and reaction, for example, with an acid chloride, carboxylic acid, or isocyanate, as in schemes above provides intermediate 12-2′, in which R4a represents R4.

It will be understood by those of skill in the art, that other compounds of the invention having heterocyclic rings in place of the phenyl rings of the structures in the above schemes may be prepared by similar methods starting with appropriate starting materials. Details regarding specific reaction conditions and other procedures for preparing representative compounds of the invention or intermediates thereto are described in the examples below.
It will further be understood, this disclosure encompasses compounds of formula (I) when prepared by synthetic processes such as those described above and below or by metabolic processes including those occurring in vivo in human or animal body or in vitro.
Pharmaceutical Compositions
The compounds of the invention and pharmaceutically-acceptable salts thereof are typically used in the form of a pharmaceutical composition or formulation. Such pharmaceutical compositions may be administered to a patient by any acceptable route of administration including, but not limited to, oral, rectal, vaginal, nasal, inhaled, topical (including transdermal) and parenteral modes of administration.
Accordingly, in one of its compositions aspects, the invention is directed to a pharmaceutical composition comprising a pharmaceutically-acceptable carrier or excipient and a compound of formula (I), where, as defined above, “compound of formula (I)” means a compound of formula (I) or a pharmaceutically-acceptable salt thereof. Optionally, such pharmaceutical compositions may contain other therapeutic and/or formulating agents if desired. When discussing compositions and uses thereof, the “compound of the invention” may also be referred to herein as the “active agent”. As used herein, the term “compound of the invention” is intended to include all compounds encompassed by formula (I) as well as the species embodied in formulas (II), (III), (IV), and (V), and pharmaceutically-acceptable salts thereof.
The pharmaceutical compositions of the invention typically contain a therapeutically effective amount of a compound of the present invention. Those skilled in the art will recognize, however, that a pharmaceutical composition may contain more than a therapeutically effective amount, i.e., bulk compositions, or less than a therapeutically effective amount, i.e., individual unit doses designed for multiple administration to achieve a therapeutically effective amount.
Typically, such pharmaceutical compositions will contain from about 0.1 to about 95% by weight of the active agent; preferably, from about 5 to about 70% by weight; and more preferably from about 10 to about 60% by weight of the active agent.
Any conventional carrier or excipient may be used in the pharmaceutical compositions of the invention. The choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state. In this regard, the preparation of a suitable pharmaceutical composition for a particular mode of administration is well within the scope of those skilled in the pharmaceutical arts. Additionally, the carriers or excipients used in the pharmaceutical compositions of this invention are commercially-available. By way of further illustration, conventional formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Md. (2000); and H. C. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & White, Baltimore, Md. (1999).
Representative examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, such as microcrystalline cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical compositions.
Pharmaceutical compositions are typically prepared by thoroughly and intimately mixing or blending the active agent with a pharmaceutically-acceptable carrier and one or more optional ingredients. The resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills and the like using conventional procedures and equipment.
The pharmaceutical compositions of the invention are preferably packaged in a unit dosage form. The term “unit dosage form” refers to a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units. For example, such unit dosage forms may be capsules, tablets, pills, and the like, or unit packages suitable for parenteral administration.
In one embodiment, the pharmaceutical compositions of the invention are suitable for oral administration. Suitable pharmaceutical compositions for oral administration may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present invention as an active ingredient.
When intended for oral administration in a solid dosage form (i.e., as capsules, tablets, pills and the like), the pharmaceutical compositions of the invention will typically comprise the active agent and one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate. Optionally or alternatively, such solid dosage forms may also comprise: fillers or extenders, such as starches, microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as cetyl alcohol and/or glycerol monostearate; absorbents, such as kaolin and/or bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and/or mixtures thereof; coloring agents; and buffering agents.
Release agents, wetting agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the pharmaceutical compositions of the invention. Examples of pharmaceutically-acceptable antioxidants include: water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, alpha-tocopherol, and the like; and metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid, sorbitol, tartaric acid, phosphoric acid, and the like. Coating agents for tablets, capsules, pills and like, include those used for enteric coatings, such as cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic acid methacrylic acid ester copolymers, cellulose acetate trimellitate, carboxymethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, and the like.
Pharmaceutical compositions of the invention may also be formulated to provide slow or controlled release of the active agent using, by way of example, hydroxypropyl methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or microspheres. In addition, the pharmaceutical compositions of the invention may optionally contain opacifying agents and may be formulated so that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active agent can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Suitable liquid dosage forms for oral administration include, by way of illustration, pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. Liquid dosage forms typically comprise the active agent and an inert diluent, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (esp., cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Suspensions, in addition to the active ingredient, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
The compounds of this invention can also be administered parenterally (e.g. by intravenous, subcutaneous, intramuscular or intraperitoneal injection). For parenteral administration, the active agent is typically admixed with a suitable vehicle for parenteral administration including, by way of example, sterile aqueous solutions, saline, low molecular weight alcohols such as propylene glycol, polyethylene glycol, vegetable oils, gelatin, fatty acid esters such as ethyl oleate, and the like. Parenteral formulations may also contain one or more anti-oxidants, solubilizers, stabilizers, preservatives, wetting agents, emulsifiers, buffering agents, or dispersing agents. These formulations may be rendered sterile by use of a sterile injectable medium, a sterilizing agent, filtration, irradiation, or heat.
Alternatively, the pharmaceutical compositions of the invention are formulated for administration by inhalation. Suitable pharmaceutical compositions for administration by inhalation will typically be in the form of an aerosol or a powder. Such compositions are generally administered using well-known delivery devices, such as a metered-dose inhaler, a dry powder inhaler, a nebulizer or a similar delivery device.
When administered by inhalation using a pressurized container, the pharmaceutical compositions of the invention will typically comprise the active ingredient and a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. Additionally, the pharmaceutical composition may be in the form of a capsule or cartridge (made, for example, from gelatin) comprising a compound of the invention and a powder suitable for use in a powder inhaler. Suitable powder bases include, by way of example, lactose or starch.
The compounds of the invention can also be administered transdermally using known transdermal delivery systems and excipients. For example, the active agent can be admixed with permeation enhancers, such as propylene glycol, polyethylene glycol monolaurate, azacycloalkan-2-ones and the like, and incorporated into a patch or similar delivery system. Additional excipients including gelling agents, emulsifiers and buffers, may be used in such transdermal compositions if desired.
Utility
The compounds of the invention have been shown to inhibit viral replication in HCV replicon assays and therefore are expected to be useful for the treatment of hepatitis C viral infections.
In one aspect, therefore, the invention provides a method of inhibiting replication of the hepatitis C virus in a mammal (e.g., a human), the method comprising administering to the mammal a therapeutically-effective amount of a compound of the invention or of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of the invention.
The invention further provides a method of treating hepatitis C viral infections in a mammal (e.g., a human), the method comprising administering to the mammal a therapeutically-effective amount of compound of the invention or of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of the invention.
The compounds of the invention may inhibit viral replication by inhibiting the function of the NS5A protein encoded by the HCV genome. In one aspect, therefore, the invention provides a method of inhibiting the NS5A protein of HCV in a mammal, the method comprising administering to the mammal, a compound or a composition of the invention.
When used to treat HCV infections, the compounds of the invention will typically be administered orally in a single daily dose or in multiple doses per day, although other forms of administration may be used. The amount of active agent administered per dose or the total amount administered per day will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
Suitable doses for treating HCV infections will range from about 1 to about 2000 mg/day of active agent, including from about 5 to about 200 mg/day and from about 10 to about 130 mg per day of active agent for an average 70 kg human.
Combination Therapy
Compounds of the invention may also be used in combination with one or more agents which act by the same mechanism or by different mechanisms to effect treatment of HCV. Useful classes of agents for combination therapy include, but are not limited to, HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase inhibitors, helicase inhibitors, NS4B protein inhibitors, HCV viral entry inhibitors, cyclophyllin inhibitors, toll-like receptor agonists, inhibitors of heat shock proteins, interfering RNA, antisense RNA, HCV internal ribosome entry site (IRES) inhibitors, thiazolides, nucleoside analogs such as ribavirin and related compounds, interferons and other immunomodulatory agents, inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors, and other NS5A protein inhibitors. Agents which act to inhibit HCV replication by any other mechanism may also be used in combination with the present compounds.
HCV NS3 protease inhibitors which may be used in combination therapy include, but are not limited to, telaprevir (VX-950), boceprevir (SCH-503034), TMC-435, narlaprevir (SCH-900518), vaniprevir (MK-7009), danoprevir (ITMN-191, R-7227), BI-201335, ABT-450, BMS-650032, GS-9256, ACH-1625, ACH-2684, BMS-605339, VX-985, PHX-1766, BMS-791325, and IDX-320.
Examples of HCV NS5B nucleoside polymerase inhibitors include, but are not limited to, RG7128, IDX-184, PSI-7977, PSI-7851, PSI-938, INX-189 (INX-08189), RG7348, MK-0608, TMC-649128, and HCV-796, while, non-nucleoside HCV NS5B polymerase inhibitors, include but are not limited to, filibuvir (PF-8685540), tegobuvir (GS-9190), VX-222, VX-759, ANA-598 (setrobuvir), ABT-072, ABT-333, BI-207127, BMS-791325, MK-3281, IDX-37, and BMS-824393.
A wide variety of interferons and pegylated interferons, including alpha, beta, omega, and gamma interferons, having antiviral, antiproliferative or immunomodulatory effects, can be combined with the present compounds. Representative examples include, but are not limited to, Intron® A (interferon-alpha2b), Actimmune® (interferon-gamma-1b), Alferon N, Advaferon®, Roferon-A (interferon alpha-2a) PegIntron® (peginterferon-alpha 2b), Alfaferone, Pegasys® (peginterferon alpha-2a), Alfanative (interferon alpha), ZalbinTM (albinterferon alpha-2b), Infergon® (interferon alfacon-1), Omega DUROS® (omega interferon), LocteronTM (interferon alpha), PEG-rIL-29 (pegylated interferon lambda), and Rebif® (interferon beta-1a).
Nucleoside analog antiviral agents include, but are not limited to, ribavirin (Copegus®, Rebetol®, Virazole®) and Viramidine (taribavirin). Interferons and ribavirin are also provided in the form of kits which include, for example, but are not limited to, Rebetron® (interferon alpha-2b/ribavirin) and Pegetron® (Peginterferon alpha-2b/ribavirin)
Useful compounds acting by other mechanisms include, but are not limited to: cyclophilin inhibitors, such as DEB-025, SCY-635, NIM-811, and cyclosporine and derivatives; toll-like receptor agonists, such as resiquimod, IMO-2125, and ANA-773, HCV viral entry inhibitors, such as civacir, thiazolides, such as nitazoxanide, and broad-spectrum viral inhibitors, such as, inosine-5′-monophosphate dehydrogenase (IMPDH) inhibitors.
In addition, compounds of the invention may be combined with an NS5A inhibitor, for example, BMS-790052, AZD-7295, PPI-461, PPI-1301, GS-5885, or GSK2336805.
In another aspect, therefore, the invention provides a therapeutic combination for use in the treatment of hepatitis C viral infections, the combination comprising a compound of the invention and one or more other therapeutic agents useful for treating HCV. For example, the invention provides a combination comprising a compound of the invention and one or more agents selected from HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase inhibitors, interferons and pegylated interferons, and ribavirin and related nucleoside analogs. Also provided, therefore, is a pharmaceutical composition comprising a compound of the invention and one or more other therapeutic agents useful for treating HCV.
Further, in a method aspect, the invention provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a compound of the invention and one or more other therapeutic agents useful for treating HCV.
In another method aspect, the invention provides a method of inhibiting replication of the hepatitis C virus in a mammal, the method comprising administering to the mammal a compound of the invention and one or more other therapeutic agents useful for inhibiting replication of the hepatitis C virus.
For example, in one method aspect, the invention provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a compound of the invention, an interferon or pegylated interferon, and ribavirin.
In another exemplary method aspect, the invention provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a compound of the invention, an interferon or pegylated interferon, ribavirin, and an HCV NS3 protease inhibitor.
In still another method aspect, the invention provides a method of treating a hepatitis C viral infection in a mammal, the method comprising administering to the mammal a compound of the invention, ribavirin, and an HCV NS3 protease inhibitor.
Still other combination therapies, include, for example, a compound of the invention, an HCV NS3 protease inhibitor, an HCV NS5B nucleoside polymerase inhibitor, and an HCV NS5B non-nucleoside polymerase inhibitor; and a compound of the invention, an HCV NS5B nucleoside polymerase inhibitor, and an HCV NS5B non-nucleoside polymerase inhibitor.
In another method aspect, the invention provides a method of inhibiting replication of the hepatitis C virus in a mammal, using a compound of the invention in combination with other agents, as described above.
When used in combination therapy, the agents may be formulated in a single pharmaceutical composition, as disclosed above, or the agents may be provided in separate compositions that are administered simultaneously or at separate times, by the same or by different routes of administration. When administered separately, the agents are administered sufficiently close in time so as to provide a desired therapeutic effect. Such compositions can be packaged separately or may be packaged together as a kit. The two or more therapeutic agents in the kit may be administered by the same route of administration or by different routes of administration.
Finally, the compounds of the invention may also find utility as research tools, for example, for discovering new HCV NS5A protein inhibitors or explicating mechanisms of HCV replication.
Compounds of the invention have been demonstrated to be potent inhibitors of HCV replication in HCV replicon assays, as described in the following examples.
EXAMPLES
The following synthetic and biological examples are offered to illustrate the invention, and are not to be construed in any way as limiting the scope of the invention. In the examples below, the following abbreviations have the following meanings unless otherwise indicated. Abbreviations not defined below have their generally accepted meanings.

    
    
        ACN=acetonitrile
        DCM=dichloromethane
        DMA=N,N-dimethylacetamide
        DMF=N,N-dimethylformamide
        DMSO=dimethyl sulfoxide
        EDC=N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
        EtOAc=ethyl acetate
        h=hour(s)
        HATU=N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate
        HCTU=2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
        HOAt=1-hydroxy-7-azabenzotriazole
        min=minute(s)
        Pd(dppf)Cl2=dichloro(1,1′-bis(diphenylphosphino)-ferrocene)dipalladium(II)
        MTBE=methyl tert-butyl ether
        RT=room temperature
        TFA=trifluoroacetic acid
        THF=tetrahydrofuran
    
    


Reagents and solvents were purchased from commercial suppliers (Aldrich, Fluka, Sigma, etc.), and used without further purification. Reactions were run under nitrogen atmosphere, unless noted otherwise. Progress of reaction mixtures was monitored by thin layer chromatography (TLC), analytical high performance liquid chromatography (anal. HPLC), and mass spectrometry. Reaction mixtures were worked up as described specifically in each reaction; commonly they were purified by extraction and other purification methods such as temperature-, and solvent-dependent crystallization, and precipitation. In addition, reaction mixtures were routinely purified by preparative HPLC, typically using C18 or BDS column packings and conventional eluents. Typical preparative HPLC conditions are described below.
Characterization of reaction products was routinely carried out by mass and 1H-NMR spectrometry. For NMR analysis, samples were dissolved in deuterated solvent (such as CD3OD, CDCl3, or d6-DMSO), and 1H-NMR spectra were acquired with a Varian Gemini 2000 instrument (400 MHz) under standard observation conditions. Mass spectrometric identification of compounds was performed by an electrospray ionization method (ESMS) with an Applied Biosystems (Foster City, Calif.) model API 150 EX instrument or an Agilent (Palo Alto, Calif.) model 1200 LCMSD instrument.
General Preparative HPLC Conditions


    Column: C18, 5 μm. 21.2×150 mm or C18, 5 μm 21×250 or C14 21×150
    Column temperature: Room Temperature
    Flow rate: 20.0 mL/min
    Mobile Phases: A=Water+0.05% TFA
    
        B=ACN+0.05% TFA,
    
    
    Injection volume: (100-1500 μL)
    Detector wavelength: 214 nm


Crude compounds were dissolved in 1:1 water:acetic acid at about 50 mg/mL. A 4 minute analytical scale test run was carried out using a 2.1×50 mm C18 column followed by a 15 or 20 minute preparative scale run using 100 μL injection with the gradient based on the % B retention of the analytical scale test run. Exact gradients were sample dependent. Samples with close running impurities were checked with a 21×250 mm C18 column and/or a 21×150 mm C14 column for best separation. Fractions containing desired product were identified by mass spectrometric analysis.
Analytical HPLC Methods A, B, C
Column: Zorbax Bonus-RP 3.5 μm. 4.6×150 mm
Column temperature: 35° C.
Flow rate: 1.0 mL/min
Mobile Phases: A=Water/ACN (98:2)+0.1% TFA

    
    
        B=Water/ACN (10:90)+0.1% TFA,
    
    


Injection volume: 100-1500 μL
Detector wavelength: 254 nm (Methods A and B) 214 nm (Method C)
Sample preparation: Dissolve in 1:1 ACN:water
Gradient Method a
21 min total (time (min) % B): 0.510, 1560, 16.580, 1780, 1810, 2110.
Gradient Method B
40 min total (time (min) % B): 0.515, 2840, 3080, 3380, 3515, 4015.
Gradient Method C
29 min total (time (min) % B): 0.510, 2490, 2590, 2610, 2910
Preparation 1
4-(4-bromo-phenyl)-2-(S)-pyrrolidin-2-yl-1H-imidazole




(a) 2-Bromo-1-(4-bromo-phenyl)-ethanone
Bromine (80 g, 500 mmol) was added dropwise to a solution of 1-(4-bromo-phenyl)-ethanone (100 g, 500 mmol) in dichloromethane (1500 mL) at ambient temperature. The reaction mixture was stirred for 3 h and then concentrated. The residue was washed with dichloromethane (100 mL) to give the crude title compound (120 g, 86% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.78 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 4.32 (s, 2H).
(b) (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester
Diisopropylethylamine (67 g, 518 mmol) was added dropwise to a solution of the product of the previous step (120 g, 432 mmol) and (S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (L-Boc proline) (102 g, 475 mmol) in acetonitrile (2 L) at room temperature. The reaction mixture was stirred overnight and concentrated to dryness. The residue was dissolved in ethyl acetate (2 L) and washed with water (2 L). The organic layer was dried over sodium sulfate and concentrated to give crude title compound (178 g, 100% yield).
(c) (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester
A solution of the product of the previous step (178 g, 432 mmol) and ammonium acetate (500 g, 6.5 mol) in toluene (2 L) was heated at reflux overnight. The solvent was removed and the residue was dissolved in ethyl acetate (2 L) and washed with water (2 L). The organic layer was dried over sodium sulfate and concentrated. The residue was purified by silica gel column chromatography in 1:3 petroleum ether: ethyl acetate to give the title compound (120 g, 71% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.56 (s, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.24 (m, 1H), 7.14 (s, 1H), 4.88 (m, 1H), 3.33 (m, 2H), 2.94 (s, 1H), 2.07 (m, 2H), 1.88 (m, 1H), 1.42 (s, 9H).
(d) 4-(4-bromo-phenyl)-2-(S)-pyrrolidin-2-yl-1H-imidazole
To a solution of (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester (3 g, 7.6 mmol) in methanol (3 mL) was added 4N HCl in methanol (60 mL) at 0° C. The reaction mixture was stirred for 2 h and then concentrated to give crude hydrochloride salt of the title compound (2.51 g 100% yield) as a yellow solid.
Preparation 2
(S)-2-Methoxycarbonylamino-3-methyl-butyric acid




A mixture of (S)-2-amino-3-methyl-butyric acid (10 g, 85 mmol), NaOH (10.3 g, 255 mmol) in water (100 mL) was treated with methylchloridocarbonate (8 g, 85 mmol) at 0° C. The reaction mixture was stirred for 24 h at room temperature and then 5 N aqueous HCl was added to the reaction mixture to adjust pH to 4. The mixture was filtered through a pad of Celite to give the product (10 g, 67% yield) as a white solid. 1H NMR(CH3OD, 400 MHz) δ (ppm) 4.05 (d, 1H), 3.65 (s, 3H), 2.14 (m, 1H), 0.95 (m, 6H).
Preparation 3
((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Triethylamine (2.3 g, 11.4 mmol) was added to a solution of 4-(4-bromo-phenyl)-2-(S)-pyrrolidin-2-yl-1H-imidazole hydrochloride (2 g, 11.4 mol), (S)-2-methoxycarbonylamino-3-methyl-butyric acid (2.5 g, 7.6 mmol), and HATU (4.3 g, 11.4 mmol) in dimethylformamide (50 mL) at 0° C. under nitrogen. The reaction mixture was stirred at room temperature overnight and treated with ethyl acetate (100 mL) and water (1000 mL). The organic layer was washed with water (2×100 mL) and brine (100 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography in 1:1 petroleum ether:ethyl acetate to give the title compound (2.5 g 74% yield) as a yellow solid. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 7.63 (d, J=8.8 Hz, 2H), 7.54 (m, 1H), 7.47 (m, 2H), 7.26 (d, J=8.4 Hz, 1H), 5.03 (m, 1H), 4.02 (t, J=8.4 Hz, 1H), 3.76 (m, 2H), 3.51 (s, 3H), 2.10 (m, 2H), 1.93 (m, 3H), 0.85 (d, J=6.8 Hz, 3H), 0.81 (d, J=6.8 Hz, 3H).
Preparation 4
((S)-1-{(S)-2-[4-(4′-Amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




To a mixture of 4-(benzyloxycarbonylamino)phenylboronic acid (1.57 g, 5.79 mmol) and ((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (1.74 g, 3.86 mmol) in N,N-dimethylformamide (30 mL, 400 mmol) was added water (21.91 mL, 1216 mmol) and sodium bicarbonate (2.43 g, 28.96 mmol). The resulting mixture was purged with nitrogen. Tetrakis(triphenylphosphine)palladium(0) (468 mg, 0.41 mmol) was added. The reaction mixture was purged with nitrogen and then heated at 90° C. overnight. The reaction mixture was cooled to RT, diluted with methanol (10 mL), then filtered. The filtrate was concentrated and the crude product was purified by preparative HPLC to give a white solid. (1.28 g) The crude material was dissolved in methanol (40 mL) and then pumped through a continuous flow hydrogenator at 70° C. using a palladium hydroxide on carbon (20% w/w) cartridge. The resulting solution was concentrated to  ̃10 mL, treated with StratospheresTM PL-CO3 resin and stirred at room temperature for 30 min. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (680 mg).
Preparation 5
((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
To a solution of ((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (9.10 g, 20.34 mmol) in dioxane:water (3:1) (200 mL), was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (4.9 g, 22.37 mmol), sodium carbonate (4.3 g, 40.68 mmol) and Pd(dppf)2Cl2 (0.83 g, 5%). The reaction mixture was warmed to reflux under nitrogen, stirred for 4 h, cooled to RT, filtered, and concentrated. The residue was extracted with ethyl acetate and water, dried with sodium sulfate and concentrated. The crude product was purified by silica gel chromatography eluting with 1:1 hexane:ethyl acetate, to provide the title compound (7 g, 75% yield) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.62-7.55 (m, 1H), 7.50 (d, J=8.0 Hz, 2H), 7.40 (m, 3H), 7.18 (s, 1H), 6.75 (d, J=8.4 Hz, 2H), 5.50 (d, J=9.2 Hz, 1H), 5.25-5.23 (m, 1H), 4.31 (t, J=2.4 Hz, 1H), 3.83-3.80 (m, 1H), 3.67 (s, 3H), 3.59-3.53 (m, 1H), 3.05-2.95 (m, 1H), 2.40-2.30 (m, 1H), 2.19-2.11 (m, 1H), 2.08-2.03 (m, 1H), 1.98-1.93 (m, 1H), 1.07-1.01 (m, 1H), 0.85 (d, J=6.8 Hz, 6H).
Preparation 6
4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid




(a) 4-(4-Ethoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
A mixture of piperazine-1-carboxylic acid tert-butyl ester (18.6 g, 0.1 mol), 4-fluoro-benzoic acid ethyl ester (16.8 g, 1 mol) and potassium carbonate (0.15 mol) in dimethylsulfoxide (100 mL) was stirred at 120° C. for 24 h. The reaction mixture was cooled to room temperature and poured into water (1 L). The solid precipitate was filtered, washed with water, and concentrated to dryness to provide the title compound (20 g, 60% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.91 (d, 2H), 6.83 (d, 2H), 4.30 (q, 2H), 3.55 (m, 4H), 3.26 (m, 4H), 1.46 (s, 9H), 1.32 (t, 3H).
(b) 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid
To a mixture of 4-(4-ethoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (10 g, 29.9 mmol) in ethanol (200 mL was added 1 N sodium hydroxide (100 mL). The reaction mixture was stirred at 70° C. overnight. The solvent was removed under vacuum and the residue washed twice with ethyl acetate, acidified to pH 6 with 5 N HCl, filtered, and concentrated to dryness to provide the title compound (8 g, 87% yield) as a white solid. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 7.74 (m, 2H), 6.92 (m, 2H), 3.90 (m, 2H), 3.42 (m, 2H), 3.25 (m, 4H), 1.38 (s, 9H).
Preparation 7
4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid




(a) 4-piperazin-1-yl-benzoic acid
A mixture of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (28 g, 91 mmol) in hydrochloric acid in methanol (300 mL) was stirred at room temperature for 4 h. The resulting precipitate was collected by filtration and concentrated to dryness to provide the title compound (17 g, 61% yield) as a white solid.
(b) 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid
To a mixture of 4-piperazin-1-yl-benzoic acid (20 g, 71.6 mmol) and triethylamine (58 g, 573 mmol) in dichloromethane (500 mL) was added cyclopropanecarbonyl chloride dropwise at 0° C. The reaction mixture was stirred at RT overnight. The solvent was removed by rotary evaporation. The residue was diluted with water, treated with sodium hydroxide, and washed with ethyl acetate and dichloromethane. The aqueous phase was acidified to pH 6 with 5 N HCl. The resulting precipitate was collected by filtration and concentrated to dryness to provide the title compound (10 g, 51% yield) as a white solid. 1H NMR(CH3OD, 400 MHz) δ (ppm) 7.87 (m, 2H), 6.95 (m, 2H), 3.90 (s, 2H), 3.73 (s, 2H), 3.29 (m, 4H), 1.99 (m, 1H), 0.86 (m, 4H).
Preparation 8
[(S)-2-Methyl-1-((S)-2-{4-[4′-(4-piperazin-1-yl-benzoylamino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester




To a solution of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (365 mg, 1.19 mmol) in dichloromethane (18 mL, 280 mmol) and N,N-dimethylformamide (92.3 uL, 1.19 mmol) was added oxalyl chloride (101 uL, 1.19 mmol). The reaction mixture was stirred for 20 min at room temperature and then N,N-diisopropylethylamine (1.42 mL, 8.14 mmol) was added followed by ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (500.0 mg, 1.083 mmol) and the mixture was allowed to react overnight with stirring.
A second solution of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (365 mg, 1.19 mmol) and oxalyl chloride (101 uL, 1.19 mmol) in dichloromethane (18 mL, 280 mmol) and N,N-dimethylformamide (92.3 uL, 1.19 mmol) was prepared and added to the reaction mixture which was stirred for 1 h. Methanol (10 mL) was added. The mixture was concentrated under vacuum and then dissolved in DCM (25 mL) and washed with saturated aqueous sodium bicarbonate (10 mL). The organic layer was concentrated, dissolved in 2.0 M hydrogen chloride in 1,4-dioxane (16.2 mL, 16.2 mmol) and ethanol (1.0 mL, 0.17 mmol) and stirred at room temperature overnight. The reaction mixture was dissolved in 1:1 acetic acid:water (8.0 mL), and purified by preparative HPLC using a BDS column to provide the trifluoroacetic acid salt of the title compound. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 10.11 (s, 1H), 8.99-8.77 (m, 2H), 7.92 (dd, J=15.0, 8.9 Hz, 4H), 7.84 (m, 4H), 7.76 (t, J=9.3 Hz, 2H), 7.37-7.25 (m, 2H), 7.09 (d, J=9.1 Hz, 2H), 7.02 (d, J=8.9 Hz, 1H), 6.96 (d, J=9.1 Hz, 1H), 5.12 (t, J=7.1 Hz, 1H), 4.15-4.06 (m, 1H), 3.90-3.81 (m, 1H), 3.66-3.56 (m, 1H), 3.55-3.46 (m, 6H), 3.46-3.39 (m, 2H), 3.39-3.29 (m, 2H), 2.43-2.32 (m, 1H), 2.22-1.91 (m, 4H), 0.82 (d, J=6.7 Hz, 3H), 0.77 (d, J=6.6 Hz, 3H).
The TFA salt was dissolved in methanol (10 mL) and treated with StratospheresTM PL-CO3 resin and stirred at room temperature for 30 min. The reaction mixture was filtered and the filtrate was concentrated to provide the title compound (0.354 g).
Preparation 9
[(S)-2-Methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (50 g, 0.11 mol), 4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2]bi[[1,3,2]dioxaborolanyl] (57 g, 0.22 mol) and potassium acetate (108 g, 1.1 mol) in dioxane (1000 mL) was added Pd(dppf)Cl2.CH2Cl2 (4.5 g, 5.5 mmol) under nitrogen. The reaction mixture was stirred at 85° C. overnight and then ethyl acetate (100 mL) and water (1000 mL) were added. The organic layer was washed with water (2×1000 mL) and brine (1000 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (1:1 petroleum ether:ethyl acetate) to give the title compound (22.5 g) as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.71 (m, 3H), 7.32 (m, 1H), 7.19 (m, 1H), 5.56 (m, 1H), 5.18 (m, 1H), 4.23 (m, 1H), 3.73 (m, 1H), 3.61 (s, 3H), 3.55 (m, 1H), 2.95 (m, 1H), 2.38 (s, 1H), 2.13 (m, 1H), 2.02 (m, 1H), 1.89 (m, 2H), 1.22 (s, 12H), 0.79 (d, 6H).
Preparation 10
((S)-1-{(S)-2-[4-(4′-Amino-2′-fluoro-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




[(S)-2-Methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (60 mg, 0.12 mmol) and 4-bromo-3-fluoroaniline (23 mg, 0.12 mmol) were dissolved in 1,2-dimethoxyethane (1.2 mL, 12 mmol) and water (0.44 mL, 24 mmol). The reaction mixture was purged with nitrogen. Sodium carbonate (41.6 mg, 0.39 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018 mmol) and the mixture was purged with nitrogen, sealed and heated at 85° C. overnight. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (5 mL), and washed with water (5 mL). The organic layer was concentrated, dissolved in 1:1 acetic acid:water (8 mL) and purified by preparative HPLC to produce the TFA salt which was passed through StratoSpheresTM PL-CO3 resin (0.36 mmol) to provide the title compound (15 mg). (m/z): [M+H]+ calcd for C26H30FN5O3 480.23 found 480.4.
Preparation 11
4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-carboxylic acid




To a mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (1.05 g, 2.12 mmol) and 4-iodo-benzoic acid methyl ester (665 mg, 2.54 mmol) in N,N-dimethylformamide (9.0 mL, 120 mmol) at RT was added water (2.0 mL, 110 mmol) and sodium bicarbonate (711 mg, 8.46 mmol). The reaction mixture was flushed with nitrogen, and tetrakis(triphenylphosphine)palladium(0) (122 mg, 0.106 mmol) was added under nitrogen. The reaction mixture was flushed with nitrogen and then heated at 90° C. overnight under an atmosphere of nitrogen.
The reaction mixture was cooled to RT and partitioned between EtOAc (60.0 mL) and water (20.0 mL). The organic layer was washed with water (2×20.0 mL), dried over sodium sulfate, filtered and concentrated to give a black oil, which was purified by silica gel chromatography (24 g silica gel, 0-100% EtOAc:hexanes). Desired fractions were combined and concentrated to give a yellowish oil and further dried under vacuum to give a yellowish foam. (956.9 mg).
The product from the previous step was combined with the corresponding product of a previous run (total 1.13 g), dissolved in methanol (10.0 mL) and water (2.1 mL) and treated with lithium hydroxide monohydrate (564.5 mg) at 60° C. for 3 h. The reaction mixture was concentrated and the residue was treated with 1:1 acetic acid:water (8.0 mL), and sonicated. Additional TFA (3.0 mL) was and the reaction mixture was sonicated, resulting in a greyish solid precipitate. The reaction mixture was stirred at RT for 10 min and then filtered. The filtrate was extracted with EtOAc (20.0 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give a yellowish oil which was dissolved in 1:1 acetic acid:water (6.0 mL), and purified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give a white solid (107.6 mg). The solid from the filtration was taken up into EtOAc (60.0 mL) and washed with water (2×15.0 mL), aqueous saturated sodium bicarbonate (20.0 mL), and brine (15.0 mL), dried over sodium sulfate, filtered and concentrated to give the title compound as a yellowish solid (490 mg) (m/z): [M+H]+ calcd for C27H30N4O5 491.22 found 491.6.
Preparation 12
N-(4-Bromo-phenyl)-4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzamide




A solution of 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid (1.0 g, 3.6 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.70 g, 3.6 mmol) and 1-hydroxy-7-azabenzotriazole (0.50 g, 3.6 mmol) in dichloromethane (39 mL, 610 mmol) was stirred for 20 min at room temperature and then α-bromoaniline (0.52 g, 3.0 mmol) and N,N-diisopropylethylamine (2.6 mL, 15 mmol) were added and the reaction mixture was stirred for 2 days. The reaction mixture was filtered; the filtrate was dissolved in 1:1 acetic acid:water (8 mL). A precipitate formed. This material was filtered to provide the title product as the acetic acid salt (225 mg). (m/z): [M+H]+ calcd for C21H22BrN3O2 428.09 found 428.0.
Preparation 13
4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-N-[4′-((S)-2-pyrrolidin-2-yl-1H-imidazol-4-yl)-biphenyl-4-yl]-benzamide




(a) (S)-2-(4-{4′-[4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester
To a mixture of (S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester (1.40 g, 3.19 mmol) and N-(4-bromo-phenyl)-4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzamide (0.910 g, 2.12 mmol) in N,N-dimethylformamide (16.53 mL, 213.5 mmol) at RT was added sodium bicarbonate (1.338 g, 15.93 mmol). Water (12.06 mL, 669.2 mmol) was then added. Nitrogen was bubbled through the resulting mixture for 5 min and then tetrakis(triphenylphosphine)palladium(0) (0.258 g, 0.223 mmol) was added. The reaction mixture was heated at 90° C. under nitrogen overnight, cooled to RT, diluted with methanol (30.0 mL), and filtered. The filtrate was concentrated and dissolved in ethyl acetate ( ̃3 mL) and hexanes (2 mL) was slowly added to give a precipitate of crude product. This material was filtered to provide 150 mg of the product. The filtrate was concentrated and subjected to the same precipitation conditions to provide an additional 50 mg of product. This material was combined with the first precipitation crop and was used without further purification in the next step.
(b) 4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-N-[4′-((S)-2-pyrrolidin-2-yl1H-imidazol-4-yl)-biphenyl-4-yl]-benzamide
The product of the previous step (200 mg, 0.3 mmol) was dissolved in 4 M HCl in 1,4-dioxane (0.6 mL, 2 mmol). The reaction mixture was stirred for 4 h, and concentrated under vacuum to provide the title compound as the HCl salt. (176 mg). (m/z): [M+H]+ calcd for C34H36N6O2 561.29 found 561.4.
Preparation 14
(R)-Diethylamino-phenyl-acetic acid




Sodium cyanoborohydride (15 g, 238 mmol) was added in portions over a few minutes to a cooled (ice/water) mixture of (R)-amino-phenyl-acetic acid (6.00 g, 39.7 mmol) and methanol (150 mL), and stirred for 5 min. Acetaldehyde (40 mL) was added drop-wise over 10 min. The reaction mixture was stirred at the cooled temperature for 45 min and at ambient temperature for 6.5 hr. The reaction mixture was again cooled to 0° C. Additional acetaldehyde (60 mL) was then added drop-wise over 10 min. The reaction mixture was stirred at 0° C. for 45 min and at ambient temperature overnight. The reaction mixture was cooled with an ice-water bath and treated with water (3 mL). Concentrated HCl was added dropwise over 45 min until the pH of the mixture was 1.5-2.0. The cooling bath was removed and stirring was continued while adding concentrated HCl to maintain the pH of the mixture  ̃1.5-2.0. The reaction mixture was stirred overnight, filtered, and the filtrate was concentrated under vacuum. The crude material was purified by preparative HPLC and washed with ethyl acetate to afford the title compound as a shiny white solid (5 g, 61% yield). 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 7.47 (m, 2H), 7.36 (m, 3H), 4.34 (s, 1H), 2.90 (m, 2H), 2.86 (m, 2H), 1.03 (t, 6H).
Preparation 15
{(S)-1-[(S)-2-(5-{4′-[(6-Fluoro-pyridine-3-carbonyl)-amino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[5-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (2000 mg, 4 mmol) dissolved in dichloromethane (27.8 mL) and N,N-dimethylacetamide (2.82 mL, 30.3 mmol) was added a solution of 2-fluoropyridine-5-carbonyl chloride (691 mg, 4.33 mmol) dissolved in dichloromethane (6.0 mL) and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, dissolved in a minimal amount of dichloromethane and ethyl ether was slowly added until a white precipitate formed. The mixture was sonicated and filtered to produce the HCl salt of the desired product. The solid was dissolved in ethyl acetate (20 mL), stirred at room temperature for 30 min, and filtered to produce the HCl salt of the title product as a free flowing yellow solid (2.5 g). (m/z): [M+H]+ calcd for C32H33FN6O4 585.26 found 585.5.
Preparation 16
((S)-2-Methyl-1-{(S)-2-[4-(4′-{[6-((S)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




A mixture of the hydrochloride salt of {(S)-1-[(S)-2-(5-{4′-[(6-fluoro-pyridine-3-carbonyl)-amino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester (600.0 mg, 0.966 mmol) and (S)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (0.290 g, 1.449 mmol) in dimethyl sulfoxide (1.5 mL) and N,N-diisopropylethylamine (1.01 mL, 5.80 mmol) was heated at 120° C. overnight. The reaction mixture was cooled to RT and water (5.0 mL) was added. The resulting mixture was centrifuged and filtered. To the solid was added 4.0 M hydrogen chloride in 1,4-dioxane (4.9 mL, 20 mmol) and the reaction mixture was stirred at RT for 30 min, and then concentrated. The residue was coevaporated with ethyl acetate (3×5.0 mL), dissolved in 1:1 acetic acid:water (8 mL), filtered, and purified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give the title compound as the trifluoroacetic acid salt (320 mg). (m/z): [M+H]+ calcd for C37H44N8O4 665.36 found 665.4.
Preparation 17
(R)-4-[5-(4-Bromo-3-methyl-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




(a) N-(4-Bromo-3-methyl-phenyl)-6-fluoro-nicotinamide
To a solution of 4-bromo-3-methylaniline (200 mg, 1 mmol) dissolved in DCM (4 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (170 mg, 1.1 mmol) dissolved in DCM (1 mL). A white precipitate was observed. The reaction mixture was concentrated to produce the HCl salt of the desired product.
(b) (R)-4-[5-(4-Bromo-3-methyl-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
The white solid from the previous step was dissolved in dimethyl sulfoxide (2 mL, 30 mmol), (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (220 mg, 1.1 mmol) was added, followed by N,N-diisopropylethylamine (2 mL, 10 mmol. The reaction mixture was heated at 120° C. overnight, cooled to RT, and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title compound as a light yellow solid (200 mg, 40% yield). (m/z): [M+H]+ calcd for C23H29BrN4O3 489.15 found 489.4.
Preparation 18
((S)-2-Methyl-1-{(S)-2-[4-(2′-methyl-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




(a) (R)-4-[5-(4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-methyl-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (200 mg, 0.41 mmol) and (R)-4-[5-(4-bromo-3-methyl-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (200 mg, 0.4 mmol; Preparation 17) was dissolved in 1,2-dimethoxyethane (4.25 mL, 40.9 mmol) and water (0.74 mL, 40.9 mmol) and the mixture was sparged under nitrogen. Sodium bicarbonate (129 mg, 1.53 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (70.8 mg, 0.0613 mmol). The reaction mixture was further sparged with nitrogen, sealed under nitrogen and heated at 90° C. overnight. The reaction mixture was extracted with ethyl acetate (5 mL) and water (3 mL); the organic layer was dried over sodium sulfate, filtered and concentrated to produce a brown oil, which was purified by reverse phase HPLC to produce the di-TFA salt of the title intermediate. (m/z): [M+H]+ calcd for C43H84N8O6 779.43 found 779.5.
(b) ((S)-2-Methyl-1-{(S)-2-[4-(2′-methyl-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester
The TFA salt of the previous step was treated with 4 M HCl in 1,4-dioxane (3 mL, 10 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated and evaporated with ethyl acetate (2×) to produce the tri-HCl salt of the title compound as a yellow solid (180 mg, 60% total yield). (m/z): [M+H]+ calcd for C38H46N8O4 679.37 found 679.7.
Preparation 19
(S)-1-Acetyl-2-methyl-pyrrolidine-2-carboxylic acid




To a solution of (S)-2-methyl-pyrrolidine-2-carboxylic acid (50.0 mg, 0.387 mmol) dissolved in N,N-dimethylacetamide (1.5 mL, 16 mmol) was added a solution of acetyl chloride (31.9 mg, 0.406 mmol) dissolved in N,N-dimethylacetamide (0.5 mL), and then N,N-diisopropylethylamine (1 mL, 6 mmol) was added and the reaction mixture stirred at room temperature for 30 minutes. The reaction mixture was concentrated to produce the title compound as a light brown oil (30 mg, 40% yield). (m/z): [M+H]+ calcd for C8H11NO3 172.10 found 172.2.
Preparation 20
(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid




To a solution of (S)-2-methoxycarbonylamino-3-butyric acid (543 mg, 3.10 mmol) dissolved in N,N-dimethylacetamide (10 mL, 11 mmol) was added HATU (1413 mg, 3.72 mmol) followed by N,N-diisopropylethylamine (1.62 mL, 9.29 mmol). The reaction mixture stirred for 10 min and then (S)-2-methyl-pyrrolidine-2-carboxylic acid (400 mg, 3.10 mmol) was added. The reaction mixture was stirred at room temperature overnight, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (5 mL), filtered, and purified by preparative HPLC. Fractions with desired molecular weight were combined and lyophilized to give the title compound (604 mg 68% yield). [M+H]+ calcd for C13H22N2O5 287.15 found 287.0
Preparation 21
(R)-4-[5-(4-Bromo-3-ethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




(a) N-(4-Bromo-3-ethoxy-phenyl)-6-fluoro-nicotinamide
To a solution of 4-bromo-3-ethoxyaniline hydrochloride (500 mg, 2 mmol) dissolved in DCM (7 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (240 mg, 1.5 mmol) dissolved in DCM (1.2 mL). A white precipitate was observed. The reaction mixture was stirred for 1 h, and concentrated to produce the HCl salt of the title intermediate.
(m/z): [M+H]+ calcd for C14H12BrFN2O2 339.01 found 339.0.
(b) (R)-4-[5-(4-Bromo-3-ethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
The white solid from the previous step was dissolved in DMSO (3.2 mL, 44 mmol), (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (300 mg, 1.5 mmol) was added, followed by N,N-diisopropylethylamine (2.6 mL, 14.8 mmol). The reaction mixture was heated at 120° C. overnight, cooled to room temperature, and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title compound as a light yellow solid (324 mg, 42% yield). (m/z): [M+H]+ calcd for C24H31BrN4O4 519.15 found 519.5.
Preparation 22
((S)-1-{(S)-2-[4-(2′-Ethoxy-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) (R)-4-[5-(2-Ethoxy-4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (253 mg, 0.52 mmol) and the TFA salt of (R)-4-[5-(4-bromo-3-ethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (324 mg, 0.52 mmol; Preparation 21) was dissolved in 1,2-dimethoxyethane (5.32 mL, 51.2 mmol) and water (0.92 mL, 51.2 mmol) and the mixture was sparged under nitrogen. Sodium bicarbonate (161 mg, 1.92 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (89 mg, 0.077 mmol). The reaction mixture was further sparged with nitrogen, sealed under nitrogen and heated at 90° C. overnight. The reaction mixture was extracted with ethyl acetate and water. The organic layer was dried over sodium sulfate, filtered and concentrated to produce the title intermediate as a brown oil. (m/z): [M+H]+ calcd for C44H56N8O7 809.43 found 809.6.
(b) ((S)-1-{(S)-2-[4-(2′-Ethoxy-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
The brown oil of the previous step was treated with 4 M HCl in 1,4-dioxane (3.8 mL, 15.3 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated and evaporated with ethyl acetate (2×) to produce to produce a brown solid. The solid was dissolved in 1:1 acetic acid:water solution (4 mL), filtered, and purified by reverse phase HPLC to produce the tri-TFA salt of the title compound as a yellow solid. (m/z): [M+H]+ calcd for C39H48N8O5 709.37 found 709.9.
Preparation 23-1
(R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




(a) N-(4-Bromo-3-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide
To a solution of 4-bromo-3-trifluoromethoxy-phenylamine (300 mg, 1 mmol) dissolved in DCM (5 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (190 mg, 1.2 mmol) dissolved in DCM (1 mL). A white precipitate was observed. The reaction mixture was concentrated to produce the HCl salt of the title intermediate. (m/z): [M+H]+ calcd for C13H7BrF4N2O2 378.96 found 379.0.
(b) (R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
The white solid from the previous step was dissolved in DMSO (2 mL) and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (230 mg, 1.2 mmol) was added, followed by N,N-diisopropylethylamine (2 mL, 10 mmol). The reaction mixture was heated at 120° C. overnight, cooled to room temperature, and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title compound as a light yellow solid (200 mg, 40% yield). (m/z): [M+H]+ calcd for C23H26BrF3N4O4 559.11, 561.11 found 561.0.
Preparation 23-2
(R)-4-[5-(4-Bromo-3-trifluoromethyl-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




Following the procedure of Preparation 23-1 substituting 5-amino-2-bromobenzotrifluoride (300 mg, 1 mmol) for 4-bromo-3-trifluoromethoxy-phenylamine (300 mg, 1 mmol), the title intermediate was prepared (m/z): [M+1-1]+ calcd for C23H26BrF3N4O3 543.11, 545.11. found 545.4.
Preparation 24
((S)-2-Methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (360 mg, 0.64 mmol) and (R)-4-[5-(4-bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (360 mg, 0.64 mmol; Preparation 23-1) was dissolved in 1,2-dimethoxyethane (6.69 mL, 64.4 mmol) and water (1.16 mL, 64.4 mmol) and the mixture was sparged under nitrogen. Sodium bicarbonate (203 mg, 2.41 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (112 mg, 0.097 mmol). The reaction mixture was further sparged with nitrogen, sealed under nitrogen and heated at 90° C. overnight. The reaction mixture was extracted with ethyl acetate (5 mL) and water (3 mL); the organic layer was dried over sodium sulfate, filtered and concentrated to produce a brown oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (4 mL, 20 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated and evaporated with ethyl acetate (2×) to produce the HCl salt of the title compound as a yellow solid which was purified by preparative HPLC to provide the tri-TFA salt of the title compound (150 mg, 21% overall yield). (m/z): [M+H]+ calcd for C38H43F3N8O5 749.33 found 749.5.
Preparation 25
((S)-2-Methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (280 mg, 0.57 mmol) and (R)-4-[5-(4-bromo-3-trifluoromethyl-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (300 mg, 0.72 mmol; Preparation 23-2) was dissolved in 1,4-dioxane (5.8 mL, 75 mmol) and water (0.83 mL, 46 mmol). Cesium carbonate (560 mg, 1.7 mmol) was added, the reaction mixture was sparged with nitrogen and then chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-isopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) methyl-t-butylether adduct (28 mg, 0.034 mmol) was added. The reaction mixture was sealed with nitrogen and heated at 95° C. for 3 h. The reaction mixture was extracted with ethyl acetate and water; the organic layer was dried over sodium sulfate, filtered and concentrated to produce an orange oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (4 mL, 20 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated and evaporated with ethyl acetate (2×) to produce the HCl salt of the title compound as a yellow solid which was purified by preparative HPLC to provide the tri-TFA salt of the title compound (150 mg, 24% overall yield). (m/z): [M+H]+ calcd for C38H43F3N8O4 733.34 found 733.5.
Preparation 26
(2S,5R)-4-(5-Carboxy-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




(a) (2S,5R)-4-(5-Methoxycarbonyl-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of 6-fluoronicotinic acid methyl ester (200 mg, 1.29 mmol) and (2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester was heated at 120° C. in DMSO (2.0 mL) with potassium carbonate (178 mg, 1.29 mmol) for 2 h. The reaction mixture was partitioned between ethyl acetate (20.0 mL) and water (5.0 mL). The organic layer was washed with water (2×5.0 mL), dried over sodium sulfate, filtered and concentrated to give the title intermediate as a yellowish oil.
(b) (2S,5R)-4-(5-Carboxy-pyridin-2-O-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
The oil of the previous step was dissolved in methanol (10.0 mL, 247 mmol) and water (2.5 mL, 140 mmol) and treated with lithium hydroxide monohydrate (108 mg, 2.58 mmol) at 40° C. overnight. The reaction mixture was concentrated; the residue was dissolved in 1:1 acetic acid:water solution (6 mL), filtered, and purified by reverse phase HPLC. Desired fractions were combined and freeze dried to give the tri-TFA salt of the title compound as a white solid (327 mg, yield 56%). (m/z): [M+H]+ calcd for C17H28N3O4 336.18 found 336.5.
Preparation 27
(2S,5R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




To a solution of 4-bromo-3-trifluoromethoxy-phenylamine (190 mg, 0.74 mmol) and N,N-diisopropylethylamine (0.65 mL, 3.73 mmol; in N,N-dimethylacetamide (3 mL) was added a solution of (2S,5R)-4-(5-carboxy-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester TFA (330 mg, 0.74 mmol; Preparation 26) and HCTU (401 mg, 0.97 mmol) in N,N-dimethylacetamide (3 mL). The reaction mixture was heated at 50° C. overnight. The reaction mixture was concentrated by rotary evaporation, extracted with ethyl acetate/sat. sodium carbonate, dried over sodium sulfate, filtered, concentrated and purified by silica gel chromatography (0-50% ethyl acetate:hexanes) to provide the title compound (155 mg, yield 36%). (m/z): [M+H]+ calcd for C24H28BrF3N4O4 573.12, 575.12. found 575.5.
Preparation 28
((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (86 mg, 0.17 mmol) and (2S,5R)-4-[5-(4-bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.2 mmol, Preparation 27) was dissolved in 1,4-dioxane (1.8 mL, 23 mmol) and water (0.25 mL, 14 mmol). Cesium carbonate (170 mg, 0.52 mmol) was added. The reaction mixture was sparged with nitrogen and then tetrakis(triphenylphosphine)palladium(0) (12.1 mg, 0.011 mmol) was added. The reaction mixture was sealed under nitrogen and heated at 95° C. overnight. The reaction mixture was extracted with ethyl acetate/water, the organic layer was dried over sodium sulfate and concentrated to produce an orange oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (2 mL, 7 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated and evaporated with ethyl acetate (2×) to produce the HCl salt of the title compound as a yellow solid which was purified by preparative HPLC to provide the tri-TFA salt of the title compound (150 mg, 30% overall yield). (m/z): [M+H]+ calcd for C39H45F3N8O5 763.35 found 763.7.
Preparation 29-A
((S)-1-{(S)-2-[4-(4-Bromo-3-methyl-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) 4-Bromo-N-methoxy-3,N-dimethyl-benzamide
A mixture of 4-bromo-3-methyl-benzoic acid (15 g, 0.069 mol), O,N-dimethyl hydroxylamine (6.5 g, 0.1 mol) HATU (38 g, 0.1 mol), and triethylamine (20 g, 0.2 mol) dissolved in DMF (50 mL) was stirred at RT for 12 h, concentrated, and purified by silica gel chromatography (1:1 EtOAc:petroleum ether) to provide the title intermediate (11 g, 61% yield) 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.52 (m, 2H), 7.32 (m, 1H), 3.50 (s, 3H), 3.29 (m, 3H), 2.38 (s, 3H).
(b) 1-(4-Bromo-3-methyl-phenyl)-ethanone
Methyl lithium (24 mL, 0.038 mol) was added to a solution of the product of the previous step (9 g, 0.035 mol) in THF (20 mL) at −78° C. and the reaction mixture was stirred at RT for 12 h. The organic layer was washed with aqueous ammonium chloride (20 mL), dried over sodium sulfate, filtered, concentrated and purified by silica gel chromatography (1:5 EtOAc:petroleum ether) to provide the title intermediate (6 g, 81% yield) 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.79 (m, 1H), 7.59 (m, 2H), 2.55 (d, J=2.8 Hz, 3H), 2.43 (d, J=0.4 Hz, 3H)
(c) 2-Bromo-1-(4-bromo-3-methyl-phenyl)-ethanone
Trimethyl phenylammonium tribromide (13 g, 0.036 mol) was added to a solution of 1-(4-bromo-3-methyl-phenyl)-ethanone (6.3 g, 0.030 mol) in THF (30 mL) and the reaction mixture was stirred at RT for 12 h, filtered, and concentrated to provide the title intermediate (8.6 g, 100% yield). 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.82 (m, 1H), 7.66 (m, 2H), 4.38 (s, 2H), 2.56 (s, 3H)
(d) (S)-Pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-3-methyl-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester
A mixture of the product of the previous step (8.6 g, 0.03 mol), (S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (9.5 g, 0.044 mol), and potassium carbonate (12.4 g, 0.09 mol) was dissolved in ACN (50 mL) and the reaction mixture was stirred at RT for 12 h and concentrated to provide the title intermediate (13 g, 100% yield) (m/z): [M+H-Boc]+ calcd for C19H24BrNO3 326.04 found 326.0.
(e) (S)-2-[4-(4-Bromo-3-methyl-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester
A mixture of the product of the previous step (13 g, 0.029 mol) and ammonium acetate (47 g, 0.61 mol) dissolved in toluene (100 mL) was stirred at 110° C. for 12 h, concentrated, and purified by silica gel chromatography (1:1 EtOAc:petroleum ether) to provide the title intermediate (8 g, 68% yield). 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.40 (m, 3H), 7.13 (m, 1H), 4.89 (m, 1H), 3.34 (m, 2H), 2.94 (m, 1H), 2.34 (s, 3H), 2.10 (m, 2H), 1.88 (m, 1H), 1.58 (m, 10H).
(f) 4-(4-Bromo-3-methyl-phenyl)-2-(S)-pyrrolidin-2-yl-1H-imidazole
To a solution of the product of the previous step (8 g, 0.020 mol) in methanol (3 mL) was added 4 N HCl in methanol (50 mL) at 0° C. The reaction mixture was stirred at RT for 4 h, and concentrated to give the title intermediate (6 g, 100% yield) as a yellow solid. (m/z): [M+H]+ calcd for C14H16BrN3 306.06 found 307.7.
(g) ((S)-1-{(S)-2-[4-(4-Bromo-3-methyl-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
A mixture of the product of the previous step (6 g, 0.018 mol), (S)-2-methoxycarbonylamino-3-methyl-butyric acid (4.6 g, 0.026 mol), HATU (10 g, 0.026 mol), and triethylamine (5.3 g, 0.078 mol) dissolved in DCM (50 mL) was stirred at RT for 12 h, concentrated and purified by silica gel chromatography (1:1 EtOAc:petroleum ether) to provide the title intermediate (5.5 g, 69% yield). 1H NMR (CDCl3, 400 MHz) δ (ppm): 10.4 (s, 1H), 7.64 (m, 1H), 7.46 (m, 2H), 7.17 (m, 1H), 5.50 (m, 1H), 5.39 (m, 1H), 4.34 (m, 1H), 3.86 (m, 1H), 3.69 (s, 3H), 3.60 (m, 1H), 2.45-2.01 (m, 6H), 1.07 (m, 1H), 0.851 (m, 6H).
Preparation 29-B
((S)-1-{(S)-2-[4-(4′-Amino-2,2′-dimethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Potassium carbonate (224 mg, 1.619 mmol) was added to a mixture of ((S)-1-{(S)-2-[4-(4-bromo-3-methyl-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (150 mg, 0.324 mmol) and 3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (90.6 mg, 0.389 mmol) in toluene (0.6 mL, 6 mmol) and water (0.3 mL, 20 mmol). The reaction mixture was degassed and flushed with nitrogen. Tetrakis(triphenylphosphine)palladium(0) (44.9 mg, 0.039 mmol) was added under nitrogen and then the reaction mixture was capped and heated at 100° C. overnight, cooled to RT and partitioned between ethyl acetate (10 mL) and water (2 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give a brownish oil, which was purified by silica gel chromatography (12 g silica gel, 0-100% EtOAc/hexanes). Desired fractions were combined and concentrated to give the title compound as a light yellowish foam (135 mg, 85% yield). (m/z): [M+H]+ calcd for C28H35N5O3 490.27 found 490.6.
Preparation 30
((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2,2′-dimethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) (2S,5R)-4-[5-(4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2,2′-dimethyl-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of (2S,5R)-4-(5-carboxy-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester TFA (80.8 mg, 0.180 mmol), EDC (34.4 mg, 0.180 mmol), and HOAt (24.5 mg, 0.180 mmol) in DMA (2.0 mL, 22 mmol)) was stirred at RT for 20 min and then ((S)-1-{(S)-2-[4-(4′-amino-2,2′-dimethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (80.0 mg, 0.163 mmol; Preparation 29-α) was added followed by N,N-diisopropylethylamine (0.142 mL, 0.817 mmol). The resulting mixture was heated at 50° C. overnight. The reaction mixture was partitioned between EtOAc (10 mL) and water (2 mL). The organic layer was washed with water (2 mL), dried over sodium sulfate, filtered and concentrated to give a yellowish oil. (m/z): [M+H]+ calcd for C45H58N8O6 807.45 found 807.6.
(b) ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2,2′-dimethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
The oily residue from the previous step was treated with 4 M HCl in 1,4-dioxane (1.5 mL, 6.0 mmol) at RT for 30 min. The reaction mixture was concentrated, the residue was dissolved in 1:1 acetic acid:water solution (8 mL), filtered, and purified by reverse phase HPLC. Desired fractions were combined and freeze dried to give the tri-TFA salt of the title compound as a white solid (66 mg, yield 39%). (m/z): [M+H]+ calcd for C40H50N8O4 707.40 found 707.8.
Preparation 31
(R)-4-[5-(4-Bromo-3,5-difluoro-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




To a solution of 4-bromo-3,5-difluoroaniline (250 mg, 1.2 mmol) dissolved in DCM (5 mL) was added a solution of 2-fluoropyridine-5-carbonyl chloride (190 mg, 1.2 mmol) dissolved in DCM (2 mL) followed by addition of N,N-diisopropylethylamine (100 uL, 0.60 mmol). The reaction mixture was stirred at RT for 1 h, and concentrated to produce a clear oil.
The oil from the previous step was dissolved in DMSO (2.6 mL, 36 mmol) and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (240 mg, 1.2 mmol) and N,N-diisopropylethylamine (2.1 mL, 12 mmol) was added. The reaction mixture was heated at 120° C. overnight and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title product as a white solid (yield 62%). (m/z): [M+H]+ calcd for C22H25BrF2N4O3 511.11. 513.11 found 513.4.
Preparation 32
((S)-1-{(S)-2-[4-(2′,6′-Difluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Following the procedure of Preparation 24 at the 0.4 mmol scale substituting the product of Preparation 31 for the product of Preparation 23-1, the tri-TFA salt of the title compound was prepared. (m/z): [M+H]+ calcd for C32H42P2N8O4 701.33 found 701.4.
Preparation 33
(R)-4-(5-Carboxy-pyridin-2-yl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




A mixture of 6-fluoronicotinic acid (150 g, 1.063 mol) and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (234.2 g, 1.169 mol) in tetrahydrofuran (1.75 L) was cooled to −40° C. and then 2 M isopropylmagnesium chloride in tetrahydrofuran (1.196 L, 2.39 mol) was added slowly maintaining the temperature less than −20° C. The reaction mixture was slowly warmed to RT, stirred at RT for 4 h and then 1 N HCl (1.75 L) and water (1.175 L) were added. The reaction mixture was extracted with ethyl acetate (4 L). The organic phase was evaporated to provide crude solid (534 g). To the crude solid was added acetone (2 L) and water (200 mL). The resulting reaction mixture was heated to 50° C. and then water (2.8 L) was added slowly. Seed crystals from a previous run at smaller scale were added after  ̃1 L of water. The reaction mixture was cooled to 20° C. over 3 h, stirred at 20° C. overnight and filtered. The solid was washed with 2:3 acetone:water (2×500 mL) and dried under vacuum to provide the title compound (329 g, 96% yield) as an off-white solid. HPLC Method A: Retention time 9.73 min.
Preparation 34
(R)-4-[5-(4-Bromo-3-fluoro-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




A solution of (R)-4-(5-carboxy-pyridin-2-yl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.47 mmol, Preparation 33), EDC (130 mg, 0.70 mmol), and HOAt (95 mg, 0.70 mmol) dissolved in DMA (4.3 mL, 47 mmol) was stirred at RT for 30 min and then 4-bromo-3-fluoroaniline (89 mg, 0.47 mmol) was added, followed by N,N-diisopropylethylamine (0.2 mL, 1.2 mmol). The reaction mixture was stirred at RT overnight and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluted: 0-40% EtOAc:hexanes) to provide the title compound as a light yellow oil (100 mg, 40% yield). (m/z): [M+H]+ calcd for C22H26BrFN4O3 493.12 found 493.2.
Preparation 35
((S)-1-{(S)-2-[4-(2′-Fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (99 mg, 0.20 mmol) and (R)-4-[5-(4-bromo-3-fluoro-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.2 mmol, Preparation 34) was dissolved in 1,2-dimethoxyethane (2.06 mL, 19.9 mmol) and Water (0.358 mL, 19.9 mmol) and the mixture was sparged under nitrogen. Sodium bicarbonate (62.6 mg, 0.75 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (34.4 mg, 0.030 mmol). The reaction mixture was further sparged with nitrogen, sealed under nitrogen, and heated at 90° C. overnight. The reaction mixture was extracted with ethyl acetate (5 mL) and water (3 mL); the organic layer was dried over sodium sulfate, filtered, and concentrated to produce a brown oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (3 mL, 10 mmol), stirred at room temperature for 1 h, concentrated, and evaporated with ethyl acetate (2×) to produce the HCl salt of the title compound as a yellow solid, which was purified by reverse phase HPLC to yield the tri-TFA salt of the title compound (100 mg). (m/z): [M+H]+ calcd for C37H43FN8O4 683.34 found 683.8.
Preparation 36
6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-nicotinic acid




(a) 6-((R)-2-Methyl-piperazin-1-yl)-nicotinic acid methyl ester
To a mixture of (R)-4-(5-carboxy-pyridin-2-yl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (50 g, 0.156 mol) and methanol (500 mL) was slowly added concentrated sulfuric acid (37 mL). The reaction mixture was warmed to 64° C., stirred at 64° C. overnight, cooled to RT and then ice water (800 mL) was added followed by 50% aqueous sodium hydroxide (60 mL). The reaction mixture was extracted with ethyl acetate (3×800 mL). Combined organic layers were dried over sodium sulfate and evaporated to give the title intermediate as an oil. HPLC Method A: Retention time 3.50 and 3.72 min.
(b) 6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-nicotinic acid methyl ester
To a cooled solution of the oil from the previous step in dimethylformamide (600 mL) was added (S)-2,2-dimethyl-cyclopropanecarboxylic acid (16.89 g, 0.148 mol) and HCTU (61.23 g 0.148 mol), followed by N,N-diisopropylethylamine (51.6 mL, 0.296 mol). The reaction mixture was stirred at RT overnight, diluted with ethyl acetate (1 L) and washed with 1:1 sodium carbonate:water. The aqueous phase was extracted with ethyl acetate (500 mL). Combined organic phases were washed with saturated aqueous sodium bicarbonate (500 mL) and water (1 L). The organic layer was extracted with 3 N HCl (2×500 mL, 300 mL) and then 50% aqueous NaOH (169 g) was added to the combined aqueous extract. After 30 min, the reaction mixture was filtered to give a solid (51.1 g). To the crude solid was added acetone (300 mL), followed by water (450 mL). The reaction mixture was stirred at RT overnight and filtered to give the title intermediate (36.86 g, 71.5% y over two steps) as a slightly yellow solid. HPLC Method B: Retention time 15.05 min.
(c) 6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-nicotinic acid
To a mixture of the product of the previous step (35.0 g, 0.106 mol) and methanol (280 mL) was added 2 M LiOH in water (106 mL, 0.211 mol) keeping the temperature under 30° C. The reaction mixture was stirred at RT overnight, concentrated under reduced pressure, and then ethanol (64 mL) was added, followed by 1 N HCl (230 mL). Seed crystals from a previous run at smaller scale were added after 160 mL HCl. After 1 h, the mixture was filtered to give the title compound (33.2 g, 99% yield) as a pale yellow solid. HPLC Method B: Retention time 8.27 min.
Preparation 37
((S)-1-{(S)-2-[4-(4′-Amino-2′-chloro-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Saturated aqueous sodium carbonate (0.2 mL) was added to a mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (100 mg, 0.20 mmol), 4-bromo-3-chloroaniline (46 mg, 0.22 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol), and water (0.3 mL). The reaction mixture was purged with nitrogen and then 1,4-dioxane (0.7 mL) was added. The reaction mixture was degassed, stirred, and heated at 90° C. overnight. Water and ethyl acetate were added; the reaction mixture was concentrated; dissolved in 1:1 acetic acid:water (1 mL) and purified by preparative HPLC. Fractions were combined, adjusted to pH 8-9 with aqueous sodium bicarbonate, and extracted with DCM. Extracts were washed with water, dried with sodium sulfate, and concentrated. The concentrate was dissolved in methanol and concentrated under vacuum to provide the title compound (m/z): [M+H]+ calcd for C26H30ClN5O3 496.20 found 496.7.
Preparation 38-A
((S)-1-{(S)-2-[4-(4-Bromo-3-fluoro-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) 1-(4-Bromo-3-fluoro-phenyl)-2-chloro-ethanone
Oxalyl dichloride (6.1 g, 48 mmol) was added to a solution of 4-bromo-3-fluoro-benzoic acid (7 g, 32 mmol) in DCM (80 mL) at 0° C. followed by DMF (0.2 mL) and the reaction mixture was stirred at RT for 2 h and then concentrated under vacuum to provide crude 4-bromo-3-fluoro-benzoyl chloride.
To the crude product dissolved in DCM (50 mL) was added 2 N trimethylsilyldiazomethane (48 mL, 96 mmol) at 0° C. and the reaction mixture was stirred at RT for 3 h. Acetic acid was added and the reaction mixture was diluted with DCM, washed with brine, and concentrated to provide crude 1-(4-bromo-3-fluoro-phenyl)-2-diazenyl-2-trimethylsilanyl-ethanone (8.0 g).
To a solution of the product of the previous step (8.0 g) in THF (50 mL) was added 4 N HCl in dioxane (20 mL) at 0° C. and the reaction mixture was stirred at RT for 3 h, concentrated, and EtOAc (100 mL) was added. The solution was washed with sodium bicarbonate, dried, concentrated, and purified by silica gel chromatography (eluted with 5:1 petroleum ether:EtOAc) to give the title intermediate (6.5 g, 81% yield). (m/z): [M+H]+ calcd for C8H5BrClFO 252.93 found 252.7. 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.72-7.76 (2H, M), 7.63-7.65 (1H, m), 4.64 (2H, s).
(b) (S)-Pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-3-fluoro-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester
To a solution of the product of the previous step (6.1 g, 28.4 mmol) in DMF (100 mL) was added (S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (6.5 g, 25.8 mmol) and cesium carbonate (16.8 g, 51.6 mmol) and the reaction mixture was stirred at RT for 2 h. Ethyl acetate (500 mL) was added and the solution was washed with brine (4×50 mL), dried, and concentrated to give the title intermediate as a dark oil (10 g). (m/z): [M+H-Boc]+ calcd for C18H21BrFNO5 330.02 found 331.9.
(c) (S)-2-[4-(4-Bromo-3-fluoro-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester
Ammonium acetate (39.8 g, 516 mmol) was added to a solution of the product of the previous step (10 g, 25.8 mmol) in toluene (150 mL) and the reaction mixture was stirred at reflux overnight. Ethyl acetate (200 mL) was added, and the solution was washed with water (3×50 mL), dried, concentrated, and purified by silica gel chromatography (eluted with 4:1 petroleum ether: EtOAc) to give the title product as a yellow solid (4.2 g). (m/z): [M+H]+ calcd for C18H21BrFN3O2 410.09 found 409.9. 1H NMR (CDCl3, 400 MHz) δ (ppm): 7.41-7.56 (3H, m), 7.25 (1H,$), 4.97 (1H, d), 3.43 (2H, m), 3.01 (1H,$), 2.10 (2H, m), 1.98 (2H. m). 1.42-1.51 (10H, m).
(d) ((S)-1-{(S)-2-[4-(4-Bromo-3-fluoro-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
To a solution of the product of the previous step (4.2 g, 10.24 mmol) in methanol was added 4 N HCl in dioxane (30 mL) and the reaction mixture was stirred at RT for 2 h and concentrated to give crude 4-(4-bromo-3-fluoro-phenyl)-2-(S)-pyrrolidin-2-yl-1H-imidazole (4.1 g)
To a solution of the crude product (4.1 g, 10.24 mmol) in DMF (70 mL) was added (S)-2-methoxycarbonylamino-3-methyl-butyric acid (1.97 g, 11.26 mmol), HATU (4.67 g, 12.29 mmol) and triethylamine (3.11 g, 30.72 mmol) and the reaction mixture was stirred at RT overnight. Ethyl acetate (200 mL) was added, and the solution was washed with brine (3×40 mL), dried, filtered, concentrated, and purified by silica gel chromatography (eluted with 2:1 petroleum ether:EtOAc) to give the title product as a yellow solid (2.6 g, 54% yield) (m/z): [M+H]+ calcd for C20H24BrN4O3 467.11 found 468.9. 1H NMR (CD3OD, 400 MHz) δ (ppm): 7.51-7.62 (m, 2 H), 7.40-7.42 (m, 2 H), 5.12-5.16 (m, 1 H), 4.22-4.20 (m, 1 H), 4.05-3.95 (m, 1 H), 3.88-3.82 (m, 1 H), 3.65 (s, 3 H), 2.41-2.11 (m, 3 H), 2.05-1.99 (m, 1 H), 0.97-0.88 (m, 7 H).
Preparation 38-α
((S)-1-{(S)-2-[4-(4′-Amino-2,2′-difluoro-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Potassium carbonate (300 mg, 2.1 mmol) was added to a solution of ((S)-1-{(S)-2-[4-(4-bromo-3-fluoro-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (200 mg, 0.4 mmol) and 3-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (130 mg, 0.55 mmol) dissolved in toluene (0.91 mL, 8.6 mmol) and water (0.38 mL, 21 mmol). The reaction mixture was sparged under nitrogen. Tetrakis(triphenylphosphine)palladium(0) (59 mg, 0.051 mmol) was added and the reaction mixture was sparged with nitrogen and heated at 100° C. overnight. The reaction mixture was diluted in ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated to produce a red solid. (m/z): [M+H]+ calcd for C26H29F2N5O3 498.20 found 498.5
The red solid was purified by silica gel chromatography (0-100% ethyl acetate:hexanes) to produce the desired product as a yellow solid, containing triphenylphosphine oxide. A portion of the yellow solid (50 mg) was dissolved in 1:1 acetic acid:water (5 mL) and purified by reverse phase HPLC to produce the TFA salt of the title intermediate as a white powder (210 mg, 99.3% purity).
Preparation 39
((S)-1-{(S)-2-[4-(4′-Amino-5′-fluoro-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




A mixture of 4-bromo-2-fluoro-5-(trifluoromethyl)aniline (78 mg, 0.302 mmol) and [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (150 mg, 0.302 mmol) in toluene (0.6 mL, 6 mmol) and water (0.4 mL, 20 mmol) was purged with nitrogen. Potassium carbonate (208.8 g, 1.511 mmol) and tetrakis(triphenylphosphine)-palladium(0) (35 mg, 0.030 mmol) were added under an atmosphere of nitrogen. The reaction mixture was capped and heated at 100° C. overnight, cooled to RT, and partitioned between ethyl acetate (5.0 mL) and water (1.5 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated to give a yellowish oil, which was purified by silica gel chromatography (12 g silica gel, 0-100% EtOAc/hexanes). Desired fractions were combined and concentrated to give the title intermediate as a yellowish solid (128 mg, 77% yield). (m/z): [M+H]+ calcd for C27H24F4N5O3 548.22 found 548.6.
Preparation 40
{(S)-1-[(S)-2-(4-{5′-Fluoro-4′-[(6-fluoro-pyridine-3-carbonyl)-amino]-2′-trifluoromethyl-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(4′-amino-5′-fluoro-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (128 mg, 0.234 mmol; Preparation 39) in DCM (3 mL, 47 mmol) and DMA (0.3 mL, 3 mmol) was added 2-fluoropyridine-5-carbonyl chloride (37 mg, 0.234 mmol), and the resulting solution was stirred at RT overnight. The reaction mixture was concentrated by rotary evaporation to give the monoHCl salt of the title intermediate as a brownish oil (163 mg), which was used without further purification. (m/z): [M+H]+ calcd for C33H31F5N6O4 671.23 found 671.7.
Preparation 41
((S)-1-{(S)-2-[4-(5′-Fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




A solution of {(S)-1-[(S)-2-(4-{5′-fluoro-4′-[(6-fluoro-pyridine-3-carbonyl)-amino]-2′-trifluoromethyl-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester HCl (100 mg, 0.141 mmol, Preparation 40), (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (283 mg, 1.414 mmol), and N,N-diisopropylethylamine (246.3 uL, 1.414 mmol) was stirred in DMSO (1.5 mL, 21 mmol) at 120° C. overnight. The reaction mixture was concentrated by rotary evaporation to provide a crude intermediate which was treated with 4.0 M HCl in 1,4-dioxane (1.0 mL, 4.0 mmol) for 1 h, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (8 mL), filtered and purified by reverse phase HPLC. Fractions were combined and lyophilized to give the tri-TFA salt of the title intermediate (54 mg, 35% yield). (m/z): [M+H]+ calcd for C38H42F4N8O4 751.33 found 751.7.
Preparation 42
4-Bromo-2-fluoro-5-trifluoromethoxy-phenylamine




To a mixture of 2-fluoro-5-(trifluoromethoxy)aniline (1 g, 5 mmol) dissolved in DMF (2 mL) was slowly added a solution of N-bromosuccinimide (1.1 g, 6.2 mmol) dissolved in DMF (2 mL). The reaction mixture was stirred at room temperature for 1 h, concentrated and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated and purified by silica gel chromatography (eluted 0-10% ethyl acetate:hexanes) to produce the title intermediate as a red oil (818 mg, 58% yield). (m/z): [M+H]+ calcd for C7H4BrF4NO 273.94, 275.94. found 276.1.
Preparation 43
((S)-1-{(S)-2-[4-(4′-Amino-5′-fluoro-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Potassium carbonate (350 mg, 2.5 mmol) was added to a solution of [(S)-2-methyl-1-((S)-2-{4-[4-(4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (250 mg, 0.50 mmol) and 4-bromo-2-fluoro-5-trifluoromethoxy-phenylamine (140 mg, 0.50 mmol; Preparation 42) dissolved in toluene (2 mL) and water (0.54 mL). The reaction mixture was sparged under nitrogen. Tetrakis(triphenylphosphine)palladium(0) (70 mg, 0.06 mmol) was added and the reaction mixture was sparged with nitrogen and heated at 100° C. overnight. The reaction mixture was diluted in ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to produce a red solid, which was purified by silica gel chromatography (0-100% ethyl acetate:hexanes) to produce the desired product as a white solid with some triphenylphosphine oxide impurity. (m/z): [M+H]+ calcd for C27H29F4N5O4 564.2 found 564.4.
The solid (50 mg) was dissolved in 1:1 acetic acid:water (5 mL) and purified by reverse phase HPLC to produce the TFA salt of the title intermediate as a white solid
Preparation 44
((S)-1-{(S)-2-[4-(5′-Fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) {(S)-1-[(S)-2-(4-{5′-Fluoro-4′-{(6-fluoro-pyridine-3-carbonyl)-amino}-2′-trifluoromethoxy-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester
To a solution of ((S)-1-{(S)-2-[4-(4′-amino-5′-fluoro-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (50 mg, 0.09 mmol, Preparation 43) in DCM (0.6 mL, 9 mmol) was slowly added 2-fluoropyridine-5-carbonyl chloride (10 mg, 0.09 mmol;) and the reaction mixture was stirred at room temperature for 5 min and then concentrated to provide a colored solid.
(b) (R)-4-[5-(5-Fluoro-4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert butyl ester
The solid from the previous step was dissolved in a mixture of dimethyl sulfoxide (0.20 mL, 2.8 mmol) and N,N-diisopropylethylamine (0.32 mL, 1.8 mmol) and then (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (180 mg, 0.91 mmol) was added and the reaction mixture was heated at 120° C. overnight and concentrated by rotary evaporation to produce a dark colored oil.
(c) ((S)-1-{(S)-2-[4-(5′-Fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (2 mL, 8 mmol) and heated at 50° C. for 1 h. The reaction mixture was concentrated, and evaporated with ethyl acetate (2×) to produce the HCl salt of the desired product as a solid, which was purified by reverse phase HPLC to produce the tri-TFA salt of the desired product as a white solid (53 mg, 50% yield). (m/z): [M+H]+ calcd for C38H42F4N8O5 767.32 found 767.7
Preparation 45
4-Bromo-3-trifluoromethoxy-benzoic acid methyl ester




(a) 4-Amino-3-trifluoromethoxy-benzoic acid methyl ester
A mixture of 4-amino-3-(trifluoromethoxy)benzoic acid (5 g, 22.61 mmol), methanol (75 mL) and 4.0 M HCl in 1,4-dioxane (56.53 mL, 226.1 mmol) was stirred at RT for 2 days. The reaction mixture was concentrated and the resulting residue was evaporated with EtOAc (3×20 mL) and dried under vacuum to provide the HCl salt of the title intermediate (6.9 g).
(b) 4-Bromo-3-trifluoromethoxy-benzoic acid methyl ester
The product of the previous step (2.00 g, 7.36 mmol) was dissolved in a mixture of acetonitrile (89 mL) and water (9.2 mL) at RT. Copper(II) bromide (2.27 g, 10.2 mmol) was added followed by tert-butyl nitrite (1.51 mL, 12.7 mmol) dropwise. The resulting mixture was heated at 70° C. for 1 hour, cooled to RT, and treated with saturated sodium bicarbonate (30 mL). The mixture was extracted with EtOAc (100 mL). The aqueous layer was extracted with EtOAc (100 mL). Combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated to give a brownish oil, which was purified by silica gel chromatography, (0-30% EtOAc/hexanes). Desired fractions were combined and concentrated to give the title intermediate as a light yellowish oil (1.57 g, 71% yield) which was confirmed by NMR.
Preparation 46
4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carboxylic acid




To a mixture of 4-Bromo-3-trifluoromethoxy-benzoic acid methyl ester (331 mg, 1.11 mmol; Preparation 45) and [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (500 mg, 1.01 mmol) in toluene (1 mL) and water (1 mL) at RT was added potassium carbonate (696 mg, 5.04 mmol). The mixture was degassed and flushed with nitrogen. Tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.101 mmol) was added under nitrogen and then the reaction mixture was capped and was heated at 100° C. overnight, cooled to RT and partitioned between EtOAc (20 mL) and water (5 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give a brownish oil.
The oily residue from the previous step was treated with methanol (6 mL) and water (1 mL) and lithium hydroxide monohydrate (254 mg, 6.04 mmol) at 65° C. for 1 hour. The reaction mixture was concentrated and the resulting residue was treated with 1:1 acetic acid:water (20 mL), filtered, and purified by reverse phase HPLC. Desired fractions were combined and freeze dried to give the TFA salt of the title intermediate as a white solid (190 mg). (m/z): [M+H]+ calcd for C28H29F3N4O6 575.20 found 575.5.
Preparation 47
(R)-2-Methyl-1-(5-nitro-pyridin-2-yl)-piperazine




(a) (R)-3-Methyl-4-(5-nitro-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester
A mixture of 2-chloro-5-nitropyridine (1.0 g, 6.3 mmol), (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (1.4 g, 6.9 mmol) and potassium carbonate (1.308 g, 9.46 mmol) in DMSO (20 mL) was heated at 100° C. overnight. The reaction mixture was cooled to RT, and filtered through a pad of silica gel, eluted with EtOAc (150 mL). The filtrate was washed with water (2×20 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated to give a brownish oil which was purified by silica gel chromatography (80 g silica gel, 0-60% EtOAc/hexanes). Desired fractions were combined and concentrated to give the title intermediate as a yellowish solid. (m/z): [M+H]+ calcd for C15H22N4O4 323.16 found 323.3.
(b) (R)-2-Methyl-1-(5-nitro-pyridin-2-yl)-piperazine
The solid from previous step was treated with 4 M HCl in 1,4-dioxane (47.3 mL) and HCl (11.6 mL) and the reaction mixture was stirred at RT for 2 h and concentrated to produce a yellow solid, which was evaporated twice with ethyl acetate to yield the diHCl salt of the title intermediate (940 mg, 50% yield) as a yellow solid. (m/z): [M+H]+ calcd for C10H14N4O2 223.11 found 223.2.
Preparation 48
((S)-1-{(S)-2-[(R)-4-(5-Amino-pyridin-2-yl)-3-methyl-piperazine-1-carbonyl]-2-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methylester




(a) ((S)-2-Methyl-1-{(S)-2-methyl-2-[(R)-3-methyl-4-(5-nitro-pyridin-2-yl)-piperazine-1-carbonyl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester
(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid (770 mg, 2.7 mmol) was dissolved in DMA (17 mL) and HATU (1.0 g, 2.7 mmol) was added. The reaction mixture was stirred for 20 min and then (R)-2-methyl-1-(5-nitro-pyridin-2-yl)-piperazine di-HCl (700 mg, 2 mmol; Preparation 47) was added followed by N,N-diisopropylethylamine (2.0 mL, 11 mmol) and the reaction mixture was stirred at 55° C. overnight, cooled to RT, concentrated by rotary evaporation and extracted with EtOAc/water. The organic layer was washed with water, and then brine, dried over sodium sulfate, concentrated under vacuum, and purified by silica gel chromatography (0-100% ethyl acetate:hexanes) to yield the title intermediate (970 mg) as a yellow oil. (m/z): [M+H]+ calcd for C23H34N6O6 491.25 found 491.7.
(b) ((S)-1-{(S)-2-[(R)-4-(5-Amino-pyridin-2-yl)-3-methyl-piperazine-1-carbonyl]-2-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methylester
The oil from the previous step was dissolved in methanol (15 mL) and treated with 50% wet palladium hydroxide on carbon (20% w/w) (13 mg, 0.45 mmol) and stirred for 2 h at RT. The reaction mixture was filtered through Celite, and concentrated under vacuum to produce a dark red oil, which was purified by silica gel chromatography (0-100% ethyl acetate:hexanes for 15 min then 0-5% methanol:EtOAc for another 15 min) to yield the title intermediate (375 mg; 40% yield) as a reddish solid. (m/z): [M+H]+ calcd for C23H36N6O4 461.28 found 461.6.
Preparation 49
(2S,5R)-4-[5-(4-Bromo-2-fluoro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




To a solution of 4-bromo-2-fluoro-5-trifluoromethoxy-phenylamine (500 mg, 2 mmol) dissolved in DCM (1 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (290 mg, 1.8 mmol) in DCM (1 mL). A few drops of DMA were added and the reaction mixture was concentrated to form N-(4-bromo-2-fluoro-5-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide as a purple solid.
The solid from the previous step was dissolved in a mixture of N,N-diisopropylethylamine (0.7 mL, 4 mmol) and DMSO (0.7 mL, 10 mmol) and (2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (590 mg, 2.7 mmol) was added and the reaction mixture heated at 120° C. overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-40% ethyl acetate:hexanes) to produce the title intermediate (613 mg, 57% yield) as a white solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.12 found 591.4.
Preparation 50
((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-5′-fluoro-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Potassium carbonate (470 mg, 3.4 mmol) was added to a solution of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (340 mg, 0.68 mmol) and (2S,5R)-4-[5-(4-bromo-2-fluoro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (400 mg, 0.68 mmol; Preparation 49) dissolved in toluene (2.5 mL) and water (0.73 mL). The reaction mixture was sparged under nitrogen. Tetrakis(triphenylphosphine)palladium(0) (94 mg, 0.081 mmol) was added and the reaction mixture was sparged with nitrogen and heated at 100° C. for 4 h. The reaction mixture was diluted in ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to produce (2S,5R)-4-[5-(5-fluoro-4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester as a red solid.
The solid from the previous step was treated with 4 M HCl in 1,4-dioxane (5 mL, 20 mmol) and stirred at 50° C. for 30 min. The reaction mixture was concentrated, dissolved in 1:1 acetic acid:water (8 mL) and purified by reverse phase HPLC. Fractions containing desired compound were combined and lyophilized to produce the tri-TFA salt of the title intermediate (490 mg, 64% yield) as a white powder. (m/z): [M+H]+ calcd for C39H44F4N8O5 781.34 found 781.6.
Preparation 51
5-Amino-2-bromo-4-chlorobenzotrifluoride




A solution of N-bromosuccinimide (1.0 g, 5.6 mmol) dissolved in DMF (3 mL) was slowly added to a mixture of 3-amino-4-chlorobenzotrifluoride (1 g, 5 mmol) dissolved in DMF (2 mL) and the reaction mixture was stirred at RT for 20 min, concentrated, and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by flash chromatography (eluted with 100% hexanes) to produce the title intermediate as a reddish colored oil (970 mg, 70% yield). (m/z): [M+H]+ calcd for C7H4BrClF3N 273.92, 275.92. found 276.2.
Preparation 52
((S)-1-{(S)-2-[4-(4′-Amino-5′-chloro-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Potassium carbonate (280 mg, 2.0 mmol) was added to a solution of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (200 mg, 0.40 mmol) and 5-amino-2-bromo-4-chlorobenzotrifluoride (110 mg, 0.40 mmol; Preparation 51) dissolved in toluene (1.3 mL) and water (0.43 mL). The reaction mixture was sparged under nitrogen. Tetrakis(triphenylphosphine)palladium(0) (56 mg, 0.48 mmol) was added and the reaction mixture was sparged with nitrogen and heated at 100° C. for 4 h. The reaction mixture was diluted in ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to produce a red solid, which was purified by silica gel chromatography (0-100% ethyl acetate:hexanes) to produce the desired product as a yellow solid.
The solid ( ̃30 mg) was dissolved in 1:1 acetic acid:water (5 mL) and purified by reverse phase HPLC to produce the di-TFA salt of the title intermediate (31.1 mg). (m/z): [M+H]+ calcd for C27H29ClF3N5O3 564.19 found 564.2.
Preparation 53
((S)-1-{(S)-2-[4-(5′-Chloro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acidmethyl ester




To a solution of ((S)-1-{(S)-2-[4-(4′-amino-5′-chloro-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (50 mg, 0.09 mmol; Preparation 52) dissolved in DCM (0.3 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (14 mg, 0.091 mmol) dissolved in DCM (0.3 mL). The reaction mixture was stirred at RT for 5 min and concentrated to produce {(S)-1-[(S)-2-(4-{5′-chloro-4′-[(6-fluoro-pyridine-3-carbonyl)-amino]-2′-trifluoromethyl-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester as a yellow solid.
The yellow solid from the previous step was dissolved in a mixture of DMSO (0.3 mL, 4 mmol) and N,N-diisopropylethylamine (0.3 mL, 2 mmol) and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (180 mg, 0.91 mmol) was added. The reaction mixture was heated at 100° C. for 72 h, and concentrated by rotary evaporation to produce (R)-4-[5-(5-chloro-4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethyl-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester as a dark colored oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (2 mL, 8 mmol) and the reaction mixture was stirred at 50° C. for 1 h, and concentrated under vacuum to produce the HCl salt of the desired product, which was dissolved in 1:1 acetic acid:water (5 mL) and purified by reverse phase HPLC. Fractions containing desired product were combined and lyophilized to produce the tri-TFA salt of the title intermediate (30 mg, 30% yield) as a white powder. (m/z): [M+H]+ calcd for C38H42ClF3N8O4 767.30 found 767.5.
Preparation 54
(2S,5R)-4-[5-(4-Bromo-2-chloro-5-trifluoromethyl-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




To a solution of 5-amino-2-bromo-4-chlorobenzotrifluoride (466 mg, 1.70 mmol) dissolved in DCM (1 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (270 mg, 1.70 mmol) in DCM (1 mL). A few drops of DMA were added and the reaction mixture was concentrated to form N-(4-bromo-2-chloro-5-trifluoromethyl-phenyl)-6-fluoro-nicotinamide as a purple solid.
Half of the solid from the previous step was treated with N,N-diisopropylethylamine (0.5 mL, 3 mmol), DMSO (0.5 mL, 7 mmol) and (2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (273 mg, 1.27 mmol) and the reaction mixture was heated at 120° C. overnight, concentrated by rotary evaporation, dissolved in a small amount of DCM and purified by silica gel chromatography (0-50% ethyl acetate:hexanes) to produce the title intermediate (288 mg, 29% yield) as a yellow solid. (m/z): [M+H]+ calcd for C24H27F4N4O4 591.09, 593.09. found 593.2.
Preparation 55
((S)-1-{(S)-2-[4-5′-Chloro-(4′-{[6-((2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Following the procedure of Preparation 50 at the 0.24 mmol scale, substituting (2S,5R)-4-[5-(4-bromo-2-chloro-5-trifluoromethyl-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (140 mg, 0.24 mmol, Preparation 54) for (2S,5R)-4-[5-(4-bromo-2-fluoro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (Preparation 49), the tri-TFA salt of the title intermediate (490 mg, 64% yield) was prepared as a white powder. (m/z): [M+H]+ calcd for C39H44ClF3N8O4 781.31 found 781.6.
Preparation 56
{(S)-2-Methyl-1-[(S)-2-(4-{4′-[6-((R)-2-methyl-piperazin-1-yl)-pyridin-3-ylcarbamoyl]-2′-trifluoromethoxy-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester




A mixture of 4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carboxylic acid TFA (600 mg, 0.9 mmol) and HATU (364 mg, 0.96 mmol) in DMA (8 mL) was stirred at RT for 15 min and then 0.5 M (R)-4-(5-amino-pyridin-2-yl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester in DMA (1.7 mL) was added followed by N,N-diisopropylethylamine (0.76 mL, 4.36 mmol). The resulting mixture was heated at 55° C. overnight, washed with EtOAc (100 mL) and water (25 mL). The organic layer was washed again with water and then with brine, dried over sodium sulfate, filtered, and concentrated to yield a dark reddish oil which was purified by silica gel chromatography (40 g silica column, 0-80% hexane:EtOAc) to provide (R)-4-{5-[(4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carbonyl)-amino]-pyridin-2-yl}-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (646 mg) as a light brownish solid.
The solid product was treated with 4.0 M HCl in 1,4-dioxane (6.5 mL, 26.14 mmol) and HCl (1.6 mL) and the reaction mixture was stirred at RT for 1 h, concentrated, and evaporated with EtOAc (2×1 mL) to provide the tri-HCl salt of the title intermediate (693 mg) as a beige solid. (m/z): [M+H]+ calcd for C38H43F3N8O5 749.33 found 749.8.
Preparation 57
((S)-2-Methyl-1-{(S)-2-[4-(4′-{6-[(R)-2-methyl-4-((S)-2-methyl-pyrrolidine-2-carbonyl)-piperazin-1-yl]-pyridin-3-ylcarbamoyl}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




To a mixture of (S)-2-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (222 mg, 0.97 mmol) dissolved in DMA (6 mL) was added HATU (369 mg, 0.97 mmol) and the reaction mixture was stirred for 20 min and then {(S)-2-methyl-1-[(S)-2-(4-{4′-[6-((R)-2-methyl-piperazin-1-yl)-pyridin-3-ylcarbamoyl]-2′-trifluoromethoxy-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester 3 HCl (693 mg, 0.81 mmol; Preparation 56) was added followed by N,N-diisopropylethylamine (0.71 mL, 4.04 mmol). The reaction mixture was stirred at 55° C. overnight, concentrated by rotary evaporation, and extracted with EtOAc (80 mL) and water (20 mL). The organic layer was washed again with water and then with brine, dried over sodium sulfate, filtered, and concentrated under vacuum, and purified by silica gel chromatography (40 g silica column, 0-100% ethyl acetate:hexanes) to yield 537 mg of a light brown solid.
The light brown solid from the previous step was treated with 4 M HCl in 1,4-dioxane (6.1 mL, 24.23 mmol) and HCl (1.5 mL) and stirred at RT for 1 h, concentrated, and evaporated with ethyl acetate (2×1 mL) to produce the tri-HCl salt of the title intermediate (569 mg) as a light yellow solid. (m/z): [M+H]+ calcd for C44H52F3N9O6 860.40 found 860.6.
Preparation 58
(2S,5R)-4-[5-(6-Bromo-2-methyl-pyridin-3-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




(a) (2S,5R)-4-(5-Methoxycarbonyl-pyridin-2-yl)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of 6-fluoronicotinic acid methyl ester (1.0 g, 6.4 mmol), (2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester HCl (1.6 g, 6.4 mmol), and potassium carbonate (1.78 g, 12.9 mmol) were stirred in DMSO (10 mL) at 120° C. for 2 h, cooled, diluted with ethyl acetate (50 mL), washed with water (2×10 mL), dried over magnesium sulfate, filtered and concentrated.
(b) (2S,5R)-4-(5-Carboxy-pyridin-2-O-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
Lithium hydroxide (618 mg, 12.9 mmol) was added to a solution of the product of the previous step in methanol (15 mL) and water (3 mL), and the resulting mixture was stirred at 40° C. for 5 h, concentrated, and acidified with 1N HCl to pH 4. The resulting mixture was extracted with ethyl acetate (2×50 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, dissolved in 1:1 acetic acid:water (8 mL), filtered and purified by reverse phase HPLC to give the TFA salt of the title intermediate (1.55 g, 54% yield). (m/z): [M+H]+ calcd for C17H25N3O4 336.18 found 336.4.
(c) (2S,5R)-4-[5-(6-Bromo-2-methyl-pyridin-3-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
The product of the previous step (180.2 mg, 0.40), EDC (115.3 mg, 0.60 mmol), and HOAt (81.9 mg, 0.60 mmol) were stirred in DMF (2 mL) at RT for 10 min and then 6-bromo-2-methyl-pyridin-3-ylamine (75 mg, 0.40 mmol) and N,N-diisopropylethylamine (0.35 mL, 2.01 mmol) were added, and the reaction mixture was stirred at 50° C. overnight, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (5 mL), filtered, and purified by reverse phase HPLC. Fractions containing desired product were combined and lyophilized to give the TFA salt of the title intermediate (91 mg, 37% yield). (m/z): [M+H]+ calcd for C23H30BrN5O3 504.15 found 504.3.
Preparation 59
[(S)-1-((S)-2-{4-[4-(5-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-6-methyl-pyridin-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




(a) (2S,5R)-4-{5-[6-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-phenyl)-2-methyl-pyridin-3-ylcarbamoyl]-pyridin-2-yl}-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
A mixture of [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (73.0 mg, 0.147 mmol;), (2S,5R)-4-[5-(6-bromo-2-methyl-pyridin-3-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester TFA (91.0 mg, 0.147 mmol; Preparation 58), and 2 M sodium carbonate in water (0.29 mL, 0.588 mmol)DMF (0.9 mL, 10 mmol) was sparged with nitrogen and then tetrakis(triphenylphosphine)palladium(0) (11.9 mg, 0.010 mmol) was added. The reaction mixture was purged with nitrogen, heated at 100° C. overnight, cooled, diluted with ethyl acetate (25 mL), washed with water (2×5 mL), dried over magnesium sulfate, filtered, concentrated, dissolved in 1:1 acetic acid:water (5 ml), filtered and purified by reverse phase HPLC. Fractions containing the desired product were combined and lyophilized to provide the tri-TFA salt of the title intermediate (100.3 mg) (m/z): [M+H]+ calcd for C43H55N9O6 794.46 found 794.6.
(b) [(S)-1-((S)-2-{4-[4-(5-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-6-methyl-pyridin-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamicacid methyl ester
The product of the previous step was treated with 4 M HCl in 1,4-dioxane (1 mL, 4.0 mmol) for 1 h and the reaction mixture was concentrated by rotary evaporation to give the 4-HCl salt of the title intermediate (75 mg, 61% yield). (m/z): [M+H]+ calcd for C38H47N9O4 694.38 found 694.6.
Preparation 60
[(S)-1-((S)-2-{4-[6-(4-Amino-2-trifluoromethoxy-phenyl)-pyridin-3-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




(a) 2-Bromo-1-(6-bromo-pyridin-3-yl)-ethanone
A solution of bromine (4 g, 25 mmol) in DCM (10 mL) was added drop wise over 5 min to a cooled (0° C.) solution of 1-(6-bromo-pyridin-3-yl)-ethanone (5 g, 25 mmol) and HBr (48%, 0.2 mL). The cooling bath was removed 40 min later and stirring was continued at RT for 66 h. The solid that formed was filtered, washed with DCM and dried at room temperature to give the impure title intermediate (8.1 g) as a yellow solid. 1H NMR (CD3OD, 400 MHz) δ (ppm): 8.96 (m, 1H), 8.28-8.25 (m, 1H), 7.82-7.79 (m, 1H), 4.7 (s, 2H).
(b) ((S)-1-{(S)-2-[4-(6-Bromo-pyridin-3-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Following the general procedure of Preparation 29-A, substituting the product of step a (7.6 g) for 2-bromo-1-(4-bromo-3-methyl-phenyl)-ethanone, the title intermediate was prepared (3.5 g) as a yellow foam. 1H NMR (CDCl3, 400 MHz) δ (ppm): 8.73-8.68 (m, 1H), 7.93-7.9 (m, 1H), 7.45-7.43 (m, 1H), 7.25 (s, 1H), 5.52-5.49 (m, 1H), 5.24-5.21 (m, 1H), 4.34-4.29 (m, 1H), 3.87-3.81 (m, 1H), 3.69 (s, 1H), 2.36-2.31 (m, 1H), 2.29-2.20 (m, 1H), 2.19-2.07 (m, 1H), 1.98-1.92 (m, 1H), 1.08-1.01 (m, 1H), 0.92-0.81 (m, 6H).
(c) [4-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-pyridin-2-yl)-3-trifluoromethoxy-phenyl]-carbamic acid tert-butyl ester
A mixture of the product of the previous step (469 mg, 1.04 mmol), [4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-trifluoromethoxy-phenyl]-carbamic acid tert-butyl ester (420 mg, 1.04 mmol), Na2CO3 (331 mg, 3.12 mmol) and Pd(dppf)Cl2 (50 mg) in dioxane (9 mL) and water (3 mL) was refluxed for 5 h. After filtration, the filtrate was concentrated under vacuum to give the crude product (700 m).
(d) [(S)-1-((S)-2-{4-[6-(4-Amino-2-trifluoromethoxy-phenyl)-pyridin-3-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester
The product of the previous step (700 mg, 1.08 mmol) was dissolved in HCl/dioxane (10 mL) and the mixture was stirred at RT for 3 h. The mixture was concentrated under vacuum to give the residue, which was purified by preparative HPLC to give the title intermediate (140 mg, yield 24%). 1H NMR (CD3OD, 400 MHz) δ (ppm): 9.18 (s, 1H), 8.69-8.67 (m, 1H), 8.2-8.15 (m, 2H), 7.68 (d, J=8.4 Hz, 1H), 7.02-6.98 (m, 2H), 5.26 (m, 1H), 4.23-4.21 (m, 1H), 4.09-4.05 (m, 1H), 3.9-3.88 (m, 1H), 3.65 (s, 3H), 2.64-2.5 (m, 1H), 2.38-2.0 (m, 4H), 0.92 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H).
Preparation 61
[(S)-2-Methyl-1-((S)-2-{4-[6-(4-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2-trifluoromethoxy-phenyl)-pyridin-3-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester




To a mixture of [(S)-1-((S)-2-{5-[6-(4-amino-2-trifluoromethoxy-phenyl)-pyridin-3-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester (140 mg, 0.26 mmol, Preparation 60) in DCM (2.56 mL) and DMA (0.25 mL) was added N,N-diisopropylethylamine (0.14 mL, 0.77 mmol) followed by 2-fluoropyridine-5-carbonyl chloride (40.9 mg, 0.26 mmol). The reaction mixture was stirred at RT for 1 h and concentrated.
The resulting residue was dissolved in DMSO (0.5 mL) and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (128 mg, 0.64 mmol), N,N-diisopropylethylamine (0.11 mL, 0.64 mmol) was added and the resulting mixture was heated at 120° C. overnight. cooled to RT, and partitioned between EtOAc (10 mL) and water (2 mL). The organic layer was washed with water (2 mL), dried over sodium sulfate, filtered and concentrated to give a brownish oil, which was treated with 4 M of HCl in 1,4-dioxane (1 mL) at RT for 1 h. The reaction mixture was concentrated, dissolved in 1:1 acetic acid:water (7 mL), filtered and purified by reverse phase prep HPLC to provide the tri-TFA salt of the title intermediate as a yellowish solid (57 mg, 20% yield). (m/z): [M+H]+ calcd for C37H42F3N9O5 750.33 found 750.8.
Preparation 62
(R)-4-[5-(4-Bromo-2-chloro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester




(a) 4-Bromo-2-chloro-5-trifluoromethoxy-phenylamine
To a mixture of 4-bromo-3-trifluoromethoxy-phenylamine (2.0 g, 7.8 mmol) in ACN (60 mL) was slowly added a solution of N-chlorosuccinimide (1.0 g, 7.8 mmol) in ACN (40 mL). The reaction mixture was heated at 60° C. overnight and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate and purified by flash chromatography (40 g column, 100% hexanes to 10% EtOAc: hexanes) to produce the desired product as an orange-ish_colored oil (1.4 g, 64% yield).
(b) N-(4-Bromo-2-chloro-5-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide
To a solution of the product of the previous step (1.2 g, 4.1 mmol) in DCM (5 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (0.66 g, 4.1 mmol) in DCM (3 mL) and 20 drops of DMA were added. The reaction mixture was concentrated to form a yellowish solid (2 g). (m/z): [M+H]+ calcd for C13H6BrClF4N2O2 412.92, 414.92. found 413, 415.
(c) (R)-4-[5-(4-Bromo-2-chloro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester
To a reaction mixture of the product of the previous step (999 mg, 2.42 mmol) in a mixture of N,N-diisopropylethylamine (0.84 mL, 4.83 mmol) and DMSO (0.86 mL, 12.08 mmol) was added (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (726 mg, 3.62 mmol) and the reaction mixture was heated at 120° C. overnight and extracted with ethyl acetate/water. The organic layer was dried over sodium sulfate and concentrated under vacuum. The dark oil was dissolved in a small amount of DCM and purified by silica gel chromatography (24 g column, 0-40% ethyl acetate:hexanes) to produce the title intermediate as a white solid (916 mg, 64% yield). (m/z): [M+H]+ calcd for C23H25BrClF3N4O4 593.07, 595.07. found 595.4.
Preparation 63
((S)-1-{(S)-2-[4-(5′-Chloro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Following the procedure of Preparation 50, the product of Preparation 62 (534 mg, 0.9 mmol) was reacted to provide the tri-TFA salt of the title compound as a white powder (186 mg,  ̃18% yield). (m/z): [M+H]+ calcd for C38H42ClF3N8O5 783.29 found 784.3
Example 1
{(S)-1-[(S)-2-(4-{4′-[4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




To a solution of 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid (0.015 g, 0.055 mmol) in dichloromethane (2 mL, 30 mmol) were added N,N-dimethylformamide (0.004 mL, 0.055 mmol) and oxalyl chloride (0.014 mL, 0.164 mmol). The reaction mixture was stirred for 25 min and then N,N-diisopropylethylamine (0.048 mL, 0.273 mmol) was added, followed by ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (0.025 g, 0.055 mmol). The reaction mixture was stirred for 90 min, dried by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (7.9 mg). (m/z): [M+H]+ calcd for C41H47N7O5 718.36. found 718.2. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 10.07 (s, 1H), 8.09 (s, 1H), 7.90 (dd, J=8.9, 2.1 Hz, 4H), 7.83 (dd, J=18.2, 8.5 Hz, 4H), 7.74 (d, J=8.8 Hz, 2H), 7.32 (d, J=8.7 Hz, 1H), 7.04 (d, J=9.1 Hz, 2H), 5.11 (t, J=7.1 Hz, 1H), 4.10 (t, J=7.9 Hz, 1H), 3.96-3.55 (m, 9H), 3.53 (s, 3H), 3.42-3.22 (m, 4H), 2.45-2.28 (m, 1H), 2.20-1.92 (m, 5H), 0.82 (d, J=6.7 Hz, 3H), 0.80-0.69 (m, 6H).
Example 2
((S)-1-{(S)-2-[4-(4′-{4-[4-(2,2-Dimethyl-propionyl)-piperazin-1-yl]-benzoylamino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




A reaction mixture of 4-[4-(2,2-dimethyl-propionyl)-piperazin-1-yl]-benzoic acid (10.3 mg, 0.036 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (8.17 mg, 0.043 mmol), 1-hydroxy-7-azabenzotriazole (6.77 mg, 0.050 mmol) in dichloromethane (0.3 mL, 4 mmol) was stirred to dissolution and for an additional 20 min. Then ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (8.2 mg, 0.018 mmol) and N,N-diisopropylethylamine (7.43 uL, 0.0426 mmol) were added at room temperature. The reaction mixture was stirred overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the title compound as the trifluoroacetic acid salt (5.6 mg). (m/z): [M+H]+ calcd for C42H51N7O5 734.40 found 734.4.
Example 3
4-[4-(4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-ylcarbamoyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester




To a solution of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (24.7 mg, 0.081 mmol) in dichloromethane (0.89 mL, 14 mmol) and N,N-dimethylformamide (0.4 mL, 6 mmol) was added N,N-diisopropylethylamine (0.071 mL, 0.407 mmol) and methyl chloroformate (0.006 mL, 0.081 mmol). The reaction mixture was stirred for 15 min at room temperature, then ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (25.0 mg, 0.054 mmol) was added and the mixture was allowed to stir overnight. The reaction mixture was concentrated and then dissolved in DCM (5 mL) and washed with saturated aqueous sodium bicarbonate (2 mL). The organic layer was concentrated. Approximately 15 mg of the crude material was concentrated, dissolved in 1:1 acetic acid:water (1.5 mL), and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (7.3 mg). (m/z): [M+H]+ calcd for C42H51N7O6 750.39 found 750.4.
Example 4
{(S)-1-[(S)-2-(4-{4′-[4-(4-Methanesulfonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




Methylenesulfonyl chloride (1.19 mg, 0.015 mmol) was added to a solution of [(S)-2-methyl-1-((S)-2-{4-[4′-(4-piperazin-1-yl-benzoylamino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester (10.0 mg, 0.015 mmol) in dichloromethane (0.75 mL, 12 mmol), N,N-dimethylacetamide (0.75 mL, 8.1 mmol) and triethylamine (25 uL, 0.18 mmol). The reaction mixture was stirred for 15 min at room temperature, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and then purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (12.3 mg). (m/z): [M+H]+ calcd for C38H45N7O6S 728.32 found 728.2.
Example 5
((S)-1-{(S)-2-[4-(4′-{[6-(4-Cyclopropanecarbonyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) {(S)-2-Methyl-1-[(S)-2-(4-{4′-[(6-piperazin-1-yl-pyridine-3-carbonyl)-amino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester
Oxalyl chloride (44.0 uL, 0.520 mmol) was added to a solution of 4-(5-carboxy-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (70.3 mg, 0.229 mmol) in dichloromethane (6.67 mL, 104 mmol) and N,N-dimethylformamide (2.01 uL, 0.026 mmol) The reaction mixture was stirred at room temperature for 20 min and then N,N-diisopropylethylamine (0.181 mL, 1.04 mmol) was added followed by ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (100.0 mg, 0.217 mmol). The reaction mixture was stirred for 2 h at room temperature, then dried by rotary evaporation. The crude material was dissolved in dichloromethane (1 mL) and then washed with saturated aqueous sodium bicarbonate (1 mL). The organic layer was concentrated, dissolved in 4.0 M hydrogen chloride in 1,4-dioxane (6.7 mL, 27 mmol) and stirred for 1 h at room temperature until completely deprotected. The reaction mixture was concentrated and used directly in the next step.
(b) ((S)-1-{(S)-2-[4-(4′-{[6-(4-Cyclopropanecarbonyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Cyclopropanecarboxylic acid (26.86 mg, 0.312 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (59.81 mg, 0.312 mmol), and 1-hydroxy-7-azabenzotriazole (42.46 mg, 0.312 mmol) were dissolved in N,N-dimethylacetamide (3.868 mL, 41.60 mmol) and stirred for 5 min. Then half of the material from the previous step was added to the reaction mixture followed by N,N-diisopropylethylamine (0.269 g, 2.080 mmol. The reaction mixture was stirred overnight at room temperature, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (39.9 mg). (m/z): [M+H]+ calcd for C40H46N8O5 719.36 found 719.2. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 10.14 (s, 1H), 8.77 (d, J=2.5 Hz, 1H), 8.12 (dd, J=9.7, 3.1 Hz, 2H), 7.95-7.78 (m, 6H), 7.75 (d, J=8.8 Hz, 2H), 7.32 (d, J=8.4 Hz, 1H), 6.95 (d, J=9.3 Hz, 1H), 5.15-5.07 (m, 1H), 4.15-4.05 (m, 1H), 3.90-3.55 (m, 11H), 3.53 (s, 3H), 2.28-2.40 (m, 1H), 2.23-1.87 (m, 5H), 0.75-0.85 (m, 3H), 0.79-0.63 (m, 6H).
Example 6
4-{4-[(4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester




A mixture of 4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-biphenyl-4-carboxylic acid (15.0 mg, 0.031 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (11.6 mg, 0.031 mmol) in N,N-dimethylformamide (0.5 mL, 6 mmol) was added to 4-(4-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester (28.2 mg, 0.102 mmol) followed by N,N-diisopropylethylamine (10.6 uL, 0.061 mmol). The reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL), filtered and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (26.2 mg). (m/z): [M+H]+ calcd for C42H51N7O6 750.39 found 750.4.
Example 7
{(S)-1-[(S)-2-(4-{4′-[4-(4-cyclopropanecarbonyl-piperazin-1-yl)-phenylcarbamoyl]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




(a) [(S)-2-Methyl-1-((S)-2-{4-[4′-(4-piperazin-1-yl-phenylcarbamoyl)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester
To a solution of [4-{4-[(4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (42.4 mg, 0.0565 mmol) in dichloromethane (0.67 mL, 10 mmol) was added trifluoroacetic acid (0.3 mL, 0.004 mmol). The reaction mixture was stirred for 1 h at room temperature, concentrated, dissolved in methanol (1 mL), passed through a StratospheresTM PL-CO3 resin, and the filtrate was concentrated to provide the title compound. (m/z): [M+H]+ calcd for C37H43N7O4 650.34 found 650.8.
(b) {(S)-1-[(S)-2-(4-{4′-[4-(4-cyclopropanecarbonyl-piperazin-1-yl)-phenylcarbamoyl]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester
Cyclopropanecarboxylic acid (7.30 mg, 0.085 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (21.6 mg, 0.113 mmol), and 1-hydroxy-7-azabenzotriazole (15.4 mg, 0.113 mmol) were combined with dichloromethane (0.8 mL, 10 mmol), stirred to dissolution and then stirred for an additional 20 min. To the reaction mixture was added a solution of the product of the previous step in 1:1 dichloromethane:N,N-diisopropylethylamine (0.5 mL, 3 mmol) at room temperature. The resulting reaction mixture was stirred at RT overnight, concentrated under vacuum, dissolved in 1:1 acetic acid:water (1.5 mL), filtered and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (8.2 mg). (m/z): [M+H]+ calcd for C41H47N7O5 718.36 found 718.4.
Example 8
{(S)-1-[(S)-2-(4-{4′-[4-(4-cycloproanecarbonyl-piperazin-1-yl)-benzoylamino]-2′-fluoro-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




To a solution of 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid (13 mg, 0.047 mmol) in dichloromethane (1.0 mL, 16 mmol) and one drop of N,N-dimethylformamide was added oxalyl chloride (0.0119 mL, 0.141 mmol). The reaction mixture was stirred for 25 min and then N,N-diisopropylethylamine (0.027 mL, 0.16 mmol) was added, followed by ((S)-1-{(S)-2-[4-(4′-amino-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (15 mg, 0.031 mmol). The reaction mixture was stirred overnight, concentrated under vacuum, dissolved in 1:1 acetic acid:water and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (1.9 mg). (m/z): [M+H]+ calcd for C41H46FN7O5 735.85. found 736.4.
Example 9
4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-N-(4′-{2-[(S)-1-((R)-2-diethylamino-2-phenyl-acetyl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-benzamide




A combination of (R)-diethylamino-phenyl-acetic acid (6.654 mg, 0.032 mmol) N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (6.154 mg, 0.032 mmol) and 1-hydroxy-7-azabenzotriazole (4.370 mg, 0.032 mmol) in N,N-dimethylacetamide (0.498 mL, 5.350 mmol) was stirred to dissolution and then for an additional 20 min. 4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-N-[4′((S)-2-pyrrolidin-2-yl-1H-imidazol-4-yl)-biphenyl-4-yl]-benzamide (15 mg, 0.027 mmol) and N,N-diisopropylethylamine (0.023 mL, 0.134 mmol) were added to the reaction mixture which was stirred at room temperature overnight. The reaction mixture was then concentrated and dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound to provide the title compound (6.4 mg). (m/z): [M+H]+ calcd for C46H51N7O3 750.41. found 750.4.
Example 10
((S)-2-Methyl-1-{(S)-2-[4-(4′-{[6-(4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester




Half of the crude material from Example 5 step (a) was dissolved in N,N-dimethylformamide (3.22 mL, 41.6 mmol) and N,N-diisopropylethylamine (36.2 uL, 0.208 mmol) and then methyl isocyanate (12.36 uL, 0.208 mmol) was added. The reaction mixture was stirred overnight at room temperature, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (35.7 mg). (m/z): [M+H]+ calcd for C38H45N9O5 708.35 found 708.2. 1H NMR (d6-DMSO, 400 MHz) δ (ppm) 10.13 (s, 1H), 8.75 (d, J=2.6 Hz, 1H), 8.11 (dd, J=8.5, 3.0 Hz, 2H), 7.91-7.79 (m, 6H), 7.75 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.6 Hz, 1H), 6.95 (d, J=9.1 Hz, 1H), 6.52 (br. s, 1H), 5.15-5.03 (m, 1H), 4.10 (t, J=7.9 Hz, 1H), 3.90-3.75 (m, 3H), 3.66-3.55 (m, 4H), 3.56-3.50 (m, 3H), 3.42-3.34 (m, 3H), 2.58 (s, 3H), 1.90-2.25 (m, 1H), 2.18-1.89 (m, 4H), 0.81 (d, J=6.8 Hz, 3H), 0.77 (d, J=6.7 Hz, 3H).
Example 11
{(S)-1-[(S)-2-(5-Chloro-4-{4′-[4-(4-methylcarbamoyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




The TFA-salt of {(S)-2-methyl-1-[(S)-2-(4-{4′-[4-(4-methylcarbamoyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester (22.0 mg, 0.0311 mmol) was dissolved in methanol (5 mL) and treated with StratospheresTM PL-CO3 resin and stirred for 15 min. The reaction mixture was filtered and the filtrate was concentrated. This crude material was dissolved in N,N-dimethylformamide (1.5 mL, 19 mmol) and then N-chlorosuccinimide (6.23 mg, 0.0467 mmol) was added. The reaction mixture was heated at 50° C. and stirred overnight at 50° C., concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the trifluoroacetic acid salt of the title compound (4.5 mg). (m/z): [M+H]+ calcd for C39H45ClN8O5 741.32 found 741.5.
Example 12
((S)-1-{(S)-2-[4-(4′-{[6-((R)-4-Cyclopropanecarbonyl-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




(a) ((S)-2-Methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester
A mixture of the hydrochloride salt of {(S)-1-[(S)-2-(5-{4′-[(6-fluoro-pyridine-3-carbonyl)-amino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester (728.1 mg, 1.17 mmol) [Reactant A] and (R)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester (0.352 g, 1.76 mmol) [Reactant B] in dimethyl sulfoxide (3.7 mL) and N,N-diisopropylethylamine (1.23 mL, 7.03 mmol) was heated at 120° C. overnight. The reaction mixture was cooled to RT and water (5.0 mL) was added. The resulting mixture was centrifuged and filtered. The solid was combined with the product from a previous reaction in which Reactant A (237.8 mg, 0.383 mmol) was reacted with Reactant B (115.0 mg, 0.574 mmol) under the same conditions. The combined solids were dissolved in 1:1 acetic acid:water (20 mL), filtered, and split into three equal portions which were purified separately by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give a white solid. (805.5 mg total).
To the product of the previous step was added 4.0 M hydrogen chloride in 1,4-dioxane (6.0 mL, 24 mmol) and the reaction mixture was stirred at RT for 30 min, and then concentrated. The residue was coevaporated with ethyl acetate (3×5.0 mL) and dried under vacuum to give the tri-hydrochloride salt of the title intermediate as a light yellowish solid (655.9 mg).
(b) ((S)-1-{(S)-2-[4-(4′-{[6-((R)-4-Cyclopropanecarbonyl-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Material from the previous step (350 mg) was dissolved in N,N-dimethylacetamide (2.7 mL, 29 mmol) at RT and N,N-diisopropylethylamine (0.52 mL, 3.0 mmol) was added followed by cyclopropanecarbonyl chloride (0.041 mL, 0.45 mmol). The reaction mixture was stirred for 10 min and additional acid chloride was added to consume all the starting material. The reaction mixture was concentrated and the residue was dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC. Desired fractions were combined and freeze dried to give a white solid.
The white solid was dissolved in ethanol (15.0 mL) at RT and 4.0 M hydrogen chloride in 1,4-dioxane (6.0 mL) was added. The reaction mixture was stirred for 10 min, and concentrated. The residue was dissolved in 1:1 acetic acid:water (8 mL), filtered, and purified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give the trifluoroacetic acid salt of the title compound as a white solid (194.6 mg) (m/z): [M+H]+ calcd for C41H48N8O5 733.38 found 733.5. 1H NMR (CD3OD, 400 MHz) δ (ppm): 8.65 (s, 1H), 8.08-8.10 (dd, 1H, J=10, 4), 7.67-7.77 (m, 7H), 7.60-7.62 (m, 2H), 6.86-6.88 (d, 1H, J=8), 5.13-5.17 (t, 1H, J=15.2), 4.52-4.56 & 4.64-4.68 (m, total 1H), 3.99-4.37 (m, 5H), 3.74-3.80 (m, 1H), 3.56 (s, 3H), 2.96-3.00 & 3.13-3.23 & 3.38-3.60 (m, total 3H), 2.45-2.52 (m, 1H), 1.91-2.20 (m, 4H), 1.09-1.18 (m, 4H), 0.76-0.90 (m, 10H).
Example 13
[(S)-1-((S)-2-{4-[4′-({6-[(S)-4-((S)-2,2-Dimethyl-cyclopropane-carbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a mixture of the TFA salt of ((S)-2-methyl-1-{(S)-2-[4-(4′-{[6-((S)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester (320.0 mg, 0.318 mmol, Preparation 16) and (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (39.9 mg, 0.350 mmol) in N,N-dimethylformamide (30.0 mL, 387.4 mmol) at RT was added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (0.133 g, 0.350 mmol) followed by N,N-diisopropylethylamine (0.277 mL, 1.589 mmol).
The reaction mixture was diluted with water (40.0 mL) and extracted with ethyl acetate (2×20.0 mL). Combined organic layers were washed with water (20.0 mL) and brine (20.0 mL), dried over sodium sulfate, filtered and concentrated to give a yellowish oil. The residue was dissolved in 1:1 acetic acid:water (8 mL), filtered and purified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried. Material was repurified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give the trifluoroacetic acid salt of the title compound as a white solid. (205.1 mg). (m/z): [M+H]+ calcd for C43H52N8O3 761.42 found 761.7. 1H NMR (CD3OD, 400 MHz) δ (ppm): 8.65 (s, 1H), 8.12-8.15 (m, 1H), 7.67-7.77 (m, 7H), 7.6-7.62 (m, 2H), 6.94-6.96 (d, 1H, J=8), 5.13-5.17 (t, 1H, J=16), 4.56-4.65 (m, 1H), 4.33-4.36 (m, 1H), 3.99-4.25 (m, 4H), 3.75-3.81 (m, 1H), 3.56 (s, 3H), 3.4-3.53 (m, 1H), 3.24-3.3 (m, 1H), 2.95-3.11 (m, 1H), 2.45-2.52 (m, 1H), 1.93-2.21 (m, 4H), 1.65-1.71 (m, 1H), 1.16-1.24 (m, 4H), 1.00-1.09 (m, 4H), 0.79-0.93 (m, 8H), 0.68-0.71 (m, 1H).
EXAMPLE 14
[(S)-1-((S)-2-{4-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropane-carbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a mixture of the hydrochloride salt of ((S)-2-methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester (60.0 mg, 0.0775 mmol) and (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (10.6 mg, 0.093 mmol) in N,N-dimethylformamide (1.5 mL, 19 mmol) at RT was added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (35.4 mg, 0.093 mmol) and N,N-diisopropylethylamine (54.0 uL, 0.310 mmol). The reaction mixture was stirred at RT overnight, and then concentrated. The residue was redissolved in 1:1 acetic acid:water (6 mL), filtered and purified by reverse phase preparative HPLC. Desired fractions were combined and freeze dried to give a white solid 34.1 mg). (m/z): [M+H]+ calcd for C43H52N8O5 761.42 found 761.7. 1H NMR (CD3OD, 400 MHz) δ (ppm): 8.76 (s, 1H), 8.18-8.20 (m, 1H), 7.76-7.86 (m, 7H), 7.68-7.7 (m, 2H), 6.95-6.99 (m, 1H), 5.22-5.26 (t, 1H, J=16), 4.59-4.73 (m, 1H), 4.03-4.38 (m, 5H), 3.82-3.89 (m, 1H), 3.69-3.74 (m, 1H), 3.65 (s, 3H), 3.12-3.2 & 3.3-3.5 (m, total 2H), 2.53-2.6 (m, 1H), 2.0-2.3 (m, 4H), 1.75-1.78 & 1.82-1.85 (m, total 1H), 1.25 (s, 3H), 1.12 (s, 3H), 1.07-1.1 & 1.14-1.17 (m, total 1H), 0.96 (s, 3H), 0.88-0.96 & 1.21-1.27 (m, total 6H), 0.76-0.8 (m, 1H).
EXAMPLE 15
[(S)-1-((S)-2-{5-[4′-({6-[(R)-4-((S)-1-Acetyl-2-methyl-pyrrolidine-2-carbonyl)2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′-methyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of [(((S)-2-methyl-1-{(S)-2-[5-(2′-methyl-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester tri-HCl (15 mg, 0.019 mmol; Preparation 18) and N,N-diisopropylethylamine (33.1 uL, 0.190 mmol) dissolved in DMA (0.6 mL, 7 mmol) was added (S)-1-acetyl-2-methyl-pyrrolidine-2-carboxylic acid (3.2 mg, 0.019 mmol, Preparation 19) and HATU (11 mg, 0.028 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (4 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (9.1 mg). (m/z): [M+H]+ calcd for C46H57N9O6 832.44 found 832.4.
EXAMPLES 16-20
Following the procedure of Example 15, the intermediate of Preparation 19 (20 mg, 0.02 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







16




0.5M (S)-(+)-2,2-dimethyl- cyclopropane carboxylic acid in DMA (38 uL, 0.019 mmol) HATU (11 mg, 0.028)
2 TFA salt (11.4 mg) (m/z): [M + H]+ calcd for C44H54N8O5 775.42 found 775.4


 


17




cyclopropanecarbonyl chloride (1.7 uL, 0.019 mmol)
2 TFA salt (16.3 mg) (m/z): [M + H]+ calcd for C42H50N8O5 747.39 found 747.4


 


18
NHCH3
1M methyl isocyanate in toluene
2 TFA salt (14.8 mg)




(19 uL, 0.019 mmol)
(m/z): [M + H]+ calcd for





C40H49N9O5 736.39 found 736.4


 


19




imidazol-4-carboxylic acid (2.1 mg, 0.019 mmol), EDC (5.5 mg, 0.028 mmol), and HOAt (3.9 mg, 0.028 mmol)
3 TFA salt (7.6 mg) (m/z): [M + H]+ calcd for C42H48N10O5 773.38 found 773.4


 


20




(R)-1-acetyl-2-methyl-pyrrolidine- 2-carboxylic acid (3.2 mg, 0.019 mmol HATU (11 mg, 0.028 mmol).
2 TFA salt (12.1 mg) (m/z): [M + H]+ calcd for C46H57N9O6 832.44 found 832.4









EXAMPLE 21
[(S)-1-((S)-2-{4-[2′-Ethoxy-4′-({6-[(R)-4-((S)-1-{(S)-2-methoxycarbonylamino-3-methyl-butyryl}-2-methyl-pyrrolidine-2-carbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




The tri-TFA salt of (S)-1-{(S)-2-[4-(2′-ethoxy-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (30 mg, 0.03 mmol; Preparation 22) was dissolved in DMA (1.0 mL, 11 mmol) and N,N-diisopropylethylamine (0.015 mL, 0.086 mmol) was added followed by a solution containing 0.5 M (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid in DMA (68.5 uL, 0.034 mmol) and HATU (13.0 mg, 0.034 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (13.5 mg). (m/z): [M+H]+ calcd for C52H68N10O9 977.52 found 977.6.
EXAMPLES 22-24
Following the procedure of Example 21, the intermediate of Preparation 22 (30 mg, 0.03 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







22




0.5M (S)-(+)-2,2-dimethyl- cyclopropane carboxylic acid in DMA (69.5 uL, 0.034 mmol), HATU (13 mg, 0.034)
2 TFA salt (23.8 mg) (m/z): [M + H]+ calcd for C45H56N8O6 805.43 found 805.4


 


23
NHCH3
1M methyl isocyanate in
2 TFA salt (26.2 mg)




toluene (34.2 μL, 0.034 mmol)
(m/z): [M + H]+ calcd for





C41H51N9O6 766.40 found 766.4


 


24




imidazol-4-carboxylic acid (3.84 mg, 0.034 mmol), HATU (13 mg, 0.034)
3 TFA salt (24 mg) (m/z): [M + H]+ calcd for C43H50N10O6 803.39 found 803.4









EXAMPLE 25
[(S)-1-((S)-2-{5-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′-trifluoromethoxy-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of ((S)-2-methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester 3[C2HF3O2] (15 mg, 0.014 mmol; Preparation 24) and N,N-diisopropylethylamine (24 uL, 0.14 mmol) dissolved in DMA (0.5 mL, 5 mmol) was added 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (28 uL, 0.014 mmol) and HATU (7.8 mg, 0.021 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (11.4 mg). (m/z): [M+H]+ calcd for C44H51F3N8O6 845.39 found 845.4.
EXAMPLES 26-28
Following the procedure of Example 25, the intermediate of Preparation 24 (15 mg, 0.014 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







26
NHCH3
1M methyl isocyanate in toluene
2 TFA salt (11.7 mg)




(14 uL, 0.014 mmol)
(m/z): [M + H]+ calcd for





C40H46F3N9O6 806.35 found 806.4


 


27




imidazol-4-carboxylic acid (1.5 mg, 0.014 mmol), EDC (4.0 mg, 0.021 mmol), and HOAt (2.8 mg, 0.021 mmol)
3 TFA salt (14.2 mg) (m/z): [M + H]+ calcd for C42H45F3N10O6 843.35 found 843.2


 


28




cyclopropanecarbonyl chloride (1.2 uL, 0.014 mmol)
2 TFA salt (8.8 mg) (m/z): [M + H]+ calcd for C42H47F3N8O6 817.36 found 817.2









EXAMPLE 29
((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tri-TFA (11.4 mg, 0.011 mmol; Preparation 28) and N,N-diisopropylethylamine (18 uL, 0.11 mmol) dissolved in DMA (0.4 mL, 4 mmol) was added 1.0 M methyl isocyanate in toluene (10 uL, 0.01 mmol). The reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (7.1 mg). (m/z): [M+H]+ calcd for C41H48F3N9O6 820.37 found 820.5.
EXAMPLES 30-33
Following the procedure of Example 29, the intermediate of Preparation 28 (11.4 mg, 0.011 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







30




cyclopropanecarbonyl chloride (0.94 uL, 0.01 mmol)
2 TFA salt (9.7 mg) (m/z): [M + H]+ calcd for C43H49F3N8O6 831.37 found 831.2


 


31




0.5M (S)-2-methyl-pyrrolidine- 1,2-dicarboxylic acid 1-methyl ester in DMA (20.6 uL, 0.0103 mmol) HATU (5.9 mg, 0.0215 mmol).
2 TFA salt (2.9 mg) (m/z): [M + H]+ calcd for C47H56F3N9O8 932.42 found 932.4


 


32




imidazol-4-carboxylic acid (2.1 mg, 0.019 mmol), EDC (3 mg, 0.015 mmol), and HOAt (2.1 mg, 0.015 mmol)
3 TFA salt (12.2 mg) (m/z): [M + H]+ calcd for C43H47F3N10O6 857.36 found 857.2


 


33




0.5M (S)-(+)-2,2-dimethyl- cyclopropane carboxylic acid in DMA (21 uL, 0.010 mmol) HATU (5.9 mg, 0.015)
2 TFA salt (8.2 mg) (m/z): [M + H]+ calcd for C45H53F3N8O5 859.40 found 859.4









EXAMPLE 34
[(S)-1-((S)-2-{5-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′-trifluoromethyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of ((S)-2-methyl-1-{(S)-2-[4-(4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester tri-TFA (17 mg, 0.016 mmol; Preparation 25) and N,N-diisopropylethylamine (27.5 uL, 0.158 mmol) dissolved in DMA (0.5 mL, 6 mmol) was added 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (32 uL, 0.016 mmol) and HATU (9 mg, 0.024 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (8.3 mg). (m/z): [M+H]+ calcd for C44H51F3N8O5 829.39 found 829.4.
EXAMPLES 35-38
Following the procedure of Example 34, the intermediate of Preparation 25 (17 mg, 0.016 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







35




cyclopropanecarbonyl chloride (1.4 uL, 0.016 mmol)
2 TFA salt (14.1 mg) (m/z): [M + H]+ calcd for C42H47F3N8O5 801.36 found 801.2


 


36
NHCH3
1.0M methyl isocyanate in
2 TFA salt (12.3 mg)




toluene (16 uL, 0.016 mmol)
(m/z): [M + H]+ calcd for





C46H46F3N9O5 790.36 found 790.2


 


37




imidazol-4-carboxylic acid (2 mg, 0.02 mmol), EDC (4.5 mg, 0.024 mmol), and HOAt (3.2 mg, 0.024 mmol)
3 TFA salt (14.4 mg) (m/z): [M + H]+ calcd for C42H45F3N10O5 827.36 found 827.2


 


38




0.5M (S)-2-methyl-pyrrolidine- 1,2-dicarboxylic acid 1-methyl ester in DMA (31.6 uL, 0.016 mmol) HATU (9 mg, 0.024 mmol).
2 TFA salt (6.8 mg) (m/z): [M + H]+ calcd for C46H54F3N9O7 902.41 found 902.4









EXAMPLE 39
[(S)-1-((S)-2-{4-[4′-({6-[(2R,5S)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2,5-dimethyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2,2′-dimethyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a mixture of (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.39 mg, 0.021 mmol) and ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2,2′-dimethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tri-TFA (20 mg, 0.019 mmol, Preparation 30) in DMF (0.5 mL, 6 mmol) at RT was added HATU (7.98 mg, 0.021 mmol) followed by N,N-diisopropylethylamine (16.60 uL, 0.095 mmol). The reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL), filtered, and purified by preparative HPLC to provide the di-TFA salt of the title compound (15 mg).
(m/z): [M+H]+ calcd for C46H58N8O5 803.45 found 803.4.
EXAMPLE 40
Following the procedure of Example 39, the intermediate of Preparation 30 (20 mg, 0.019 mmol) was reacted with (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid (6 mg, 0.021 mmol) to provide the di-TFA salt of the following compound (6 mg) (m/z): [M+H]+ calcd for C53H70N10O8 975.45 found 975.6.




EXAMPLE41
[(S)-1-((S)-2-{5-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′,6′-difluoro-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(2′,6′-difluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tri-TFA (20 mg, 0.02 mmol; Preparation 32) and N,N-diisopropylethylamine (33.4 uL, 0.192 mmol) dissolved in DMA (0.6 mL, 7 mmol) was added 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (38 uL, 0.019 mmol) and HATU (11 mg, 0.029 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (10.1 mg). (m/z): [M+H]+ calcd for C43H50F2N8O5 797.39 found 797.4.
EXAMPLES 42-44
Following the procedure of Example 41, the intermediate of Preparation 32 (20 mg, 0.02 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex. No.
R
Reagent
Product







42




cyclopropanecarbonyl chloride (1.7 uL, 0.019 mmol)
2 TFA salt (7.2 mg) (m/z): [M + H]+ calcd for C41H44F2N8O5 769.36 found 769.2


 


43
NHCH3
1M methyl isocyanate in toluene
2 TFA salt (4.1 mg)




(19 uL, 0.19 mmol)
(m/z): [M + H]+ calcd for





C39H45F2N9O5 758.35 found 758.4


 


44




imidazol-4-carboxylic acid (2.1 mg, 0.019 mmol), EDC (5.5 mg, 0.029 mmol), and HOAt (3.9 mg, 0.029 mmol)
3 TFA salt (5.1 mg) (m/z): [M + H]+ calcd for C41H44F2N10O5 795.35 found 795.2









EXAMPLE 45
[(S)-1-((S)-2-{5-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′-fluoro-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(2′-fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 3[C2HF3O2] (15 mg, 0.015 mmol; Preparation 35) and N,N-diisopropylethylamine (25.5 uL, 0.146 mmol) dissolved in DMA (0.5 mL, 5 mmol) was added 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (29 uL, 0.015 mmol) and HATU (8.3 mg, 0.022 mmol). The reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (9.5 mg). (m/z): [M+H]+ calcd for C43H51FN8O5 779.40 found 779.4.
EXAMPLES 46-48
Following the procedure of Example 45, the intermediate of Preparation 35 (15 mg, 0.015 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex.





No.
R
Reagent
Product







46




cyclopropanecarbonyl chloride (1.3 uL, 0.015 mmol)
2 TFA salt (12 mg) (m/z): [M + H]+ calcd for C41H47FN8O5 751.37 found 751.2


 


47
NHCH3
1M methyl isocyanate in toluene
2 TFA salt (10.9 mg)




(15 uL, 0.15 mmol)
(m/z): [M + H]+ calcd for





C39H46FN9O5 740.36 found 740.4


 


48




imidazol-4-carboxylic acid (1.6 mg, 0.015 mmol), EDC (4.2 mg, 0.022 mmol), and HOAt (3.0 mg, 0.022 mmol)
3 TFA salt (10.7 mg) (m/z): [M + H]+ calcd for C41H45FN10O5 777.36 found 777.2









EXAMPLE 49
[(S)-1-((S)-2-{4-[2′-Chloro-4′-({6-[(R)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




A mixture of 6-[(R)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-nicotinic acid (4.54 mg, 0.014 mmol; Preparation 36), HCTU (8.0 mg, 0.019 mmol), N,N-diisopropylethylamine (0.013 mL, 0.072 mmol), and DMA (0.2 mL, 2 mmol) was stirred for 30 min at 50° C. and then ((S)-1-{(S)-2-[4-(4′-amino-2′-chloro-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (7.1 mg, 0.014 mmol; Preparation 37) was added. The reaction mixture was stirred overnight and then HCTU (8 mg) was added and the reaction mixture was heated to 55° C. After 5 h, the reaction mixture was cooled to RT, ethyl acetate and water were added. The organic layer was concentrated under vacuum and purified by preparative HPLC to provide the di-TFA salt of the title compound (1.3 mg). (m/z): [M+H]+ calcd for C43H51ClN8O5 795.37 found 795.4.
EXAMPLE 50
[(S)-1-((S)-2-{4-[4′-({6-[(R)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2,2′-difluoro-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamicacid methyl ester




To a solution of 6-[(R)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-nicotinic acid (6.4 mg, 0.020 mmol; Preparation 36) was added EDC (5.8 mg, 0.030 mmol) and HOAt (4.2 mg, 0.030 mmol) in DMA (0.5 mL, 5 mmol). The reaction mixture was stirred at RT for 30 min and then ((S)-1-{(S)-2-[4-(4′-amino-2,2′-difluoro-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (10 mg, 0.02 mmol; Preparation 38-B) and N,N-diisopropylethylamine (18 uL, 0.10 mmol) were added and the reaction mixture was stirred at RT overnight. The reaction mixture was concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the di-TFA salt of the title compound (6.8 mg). (m/z): [M+H]+ calcd for C43H50F2N8O5 797.39 found 797.4.
EXAMPLE 51
[(S)-1-((S)-2-{4-[4′-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-5′-fluoro-2′-trifluoromethyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




A mixture of (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.09 mg, 0.018 mmol) and HATU (8.35 mg, 0.022 mmol) was stirred in DMA (1.0 mL, 11 mmol) for 10 min. and then ((S)-1-{(S)-2-[4-(5′-fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tri-TFA (20.0 mg, 0.018 mmol, Preparation 41) and N,N-diisopropylethylamine (15.94 uL, 0.091 mmol) were added. The reaction mixture was stirred at RT overnight, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL), filtered, and purified by preparative HPLC to provide the di-TFA salt of the title compound (4.8 mg). (m/z): [M+H]+ calcd for C44H50F4N8O5 847.38 found 847.4.
EXAMPLE 52
Following the procedure of Example 51, the intermediate of Preparation 41 (20 mg, 0.019 mmol) was reacted with (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid (5.24 mg, 0.018 mmol) to provide the di-TFA salt of the following compound (2.8 mg) (m/z): [M+H]+ calcd for C51H62F4N10O8 1019.47 found 1019.4.




EXAMPLE 53
((S)-1-{(S)-2-[4-(5′-Fluoro-4′-{[6-((R)-2-methyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




To a solution of 1.0 M methyl isocyanate in toluene (11.4 uL, 0.011 mmol) dissolved in DMA (0.5 mL), was added ((S)-1-{(S)-2-[4-(5′-fluoro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tri-TFA (12.7 mg, 0.011 mmol; Preparation 44) and N,N-diisopropylethylamine (19.9 uL, 0.114 mmol) and the reaction mixture was stirred at room temperature overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt of the title compound (7.7 mg). (m/z): [M+H]+ calcd for C40H48F4N9O6 824.34 found 824.4.
EXAMPLES 54-55
Following the procedure of Example 53, the intermediate of Preparation 44 (12.7 mg, 0.011 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex.





No.
R
Reagent
Product







54




0.5M (S)-(+)-2,2-dimethyl- cyclopropane carboxylic acid in DMA (22.9 uL, 0.011 mmol) HATU (6.5 mg, 0.017)
2 TFA salt (11.8 mg) (m/z): [M + H]+ calcd for C44H50F4N8O6 863.38 found 863.4


 


55




(S)-1-((S)-2-methoxycarbonyl- amino-3-methyl-butyryl)-2- methyl-pyrrolidine-2-carboxylic acid (3.27 mg, 0.011 mmol) HATU (6.5 mg, 0.017)
2 TFA salt (6.7 mg) (m/z): [M + H]+ calcd for C51H62F4N10O9 1,035.46 found 1035.4









EXAMPLE 56




To a mixture of 4′-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carboxylic acid TFA (23.0 mg, 0.033 mmol; Preparation 46) and ((S)-1-{(S)-2-[(R)-4-(5-amino-pyridin-2-yl)-3-methyl-piperazine-1-carbonyl]-2-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (15.4 mg, 0.033 mmol; Preparation 48) in DMF (0.5 mL) at RT was added HATU (14.0 mg, 0.037 mmol) and N,N-diisopropylethylamine (29.1 μL, 0.167 mmol). The resulting mixture was stirred at RT for 2 h, and then partitioned between EtOAc (10 mL) and water (2 mL). The organic layer was washed with water (2 mL), dried over sodium sulfate, filtered and concentrated to give a brownish oil. The residue was dissolved in 1:1 acetic acid:water (1.5 mL), filtered and purified by reverse phase HPLC. Desired fractions were combined and freeze dried to give the di-TFA salt of the title compound (9.1 mg, 22% yield) as a light pinkish solid. (m/z): [M+H]+ calcd for C51H63F3N10O9 1,017.47 found 1017.9.
EXAMPLE 57
[(S)-1-((S)-2-{4-[4′-({6-[(2R),5S)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2,5-dimethyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-5′-fluoro-2′-trifluoromethyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of ((S)-1-{(S)-2-[4-(4′-{[6-(2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-5′-fluoro-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 3-TFA (15 mg, 0.013 mmol; Preparation 50) and N,N-diisopropylethylamine (23 uL, 0.13 mmol) dissolved in DMA (0.5 mL, 5 mmol;) was added 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (27 μL, 0.013 mmol) and HATU (7.6 mg, 0.020 mmol). The reaction mixture was stirred at 50° C. for 2 h, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the title compound (9.1 mg) as the di-TFA salt. (m/z): [M+H]+ calcd for C45H52F4N8O6 877.39 found 878.0.
EXAMPLES 58-60
Following the procedure of Example 57, the intermediate of Preparation 50 (15 mg, 0.013 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex.





No.
R
Reagent
Product







58
NHCH3
1M methyl isocyanate in toluene
2 TFA salt (4.5 mg)




(13 uL, 0.013 mmol)
(m/z): [M + H]+ calcd for





C41H47F4N9O6 838.36 found 839.0


 


59




imidazol-4-carboxylic acid (1.5 mg, 0.013 mmol), HATU (7.6 mg, 0.020 mmol)
3 TFA salt (6.6 mg) (m/z): [M + H]+ calcd for C43H46F4N10O6 875.35 found 876.0


 


60




4-pyrazolecarboxylic acid (1.5 mg, 0.013 mmol HATU (7.6 mg, 0.020 mmol)
3 TFA salt (6.7 mg) (m/z): [M + H]+ calcd for C43H46F4N10O6 875.35 found 876.0









EXAMPLE 61
[(S)-1-((S)-2-{4-[5′-Chloro-4′-({6-[(R)-4-((S)-2,2-dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2′-trifluoromethyl-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




To a solution of 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA (28.9 μL, 0.015 mmol;). and HATU (8.25 mg, 0.022 mmol) dissolved in DMA (0.5 mL), was added ((S)-1-{(S)-2-[4-(5′-Chloro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethyl-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 3 TFA (16 mg, 0.014 mmol; Preparation 53) and N,N-diisopropylethylamine (25.2 uL, 0.15 mmol) and the reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the title compound (8.6 mg) as the di-TFA salt. (m/z): [M+H]+ calcd for C44H50ClF3N8O5 863.35 found 863.4.
EXAMPLE 62
Following the procedure of Example 61 the intermediate of Preparation 53 (16 mg, 0.014 mmol) was reacted with (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-2-methyl-pyrrolidine-2-carboxylic acid (4.14 mg, 0.015 mmol) to provide the di-TFA salt of the following compound (6.5 mg) (m/z): [M+H]+ calcd for C51H62ClF3N10O8 1,035.44 found 1035.4.




EXAMPLE 63-65
Following the procedure of Example 57, substituting the intermediate of Preparation 55 (15 mg, 0.013 mmol) for the intermediate of Preparation 50 (15 mg, 0.013 mmol), the following compounds were prepared

















Ex.





No.
R
Reagent
Product







63




0.5M (S)-(+)-2,2-dimethyl- cyclopropane carboxylic acid in DMA (27 μL, 0.013 mmol) HATU (7.6 mg, 0.02)
2 TFA salt (14.6 mg) (m/z): [M + H]+ calcd for C45H52ClF3N8O5 877.37 found 878.0


 


64
NHCH3
1M methyl isocyanate in
2 TFA salt (15.3 mg)




toluene
(m/z): [M + H]+ calcd for




(13 uL, 0.013 mmol)
C43H46ClF3N10O5 875.33 found





876.0


 


65




imidazol-4-carboxylic acid (1.5 mg, 0.013 mmol), HATU (7.6 mg, 0.020 mmol)
3 TFA salt (15.3 mg) (m/z): [M + H]+ calcd for C43H46ClF3N10O5 875.33 found 876.0









EXAMPLE 66




Methoxyacetic acid (1.14 μL, 0.014 mmol) was dissolved in DMA (1 mL) and HATU (5.65 mg, 0.015 mmol) was added. The reaction mixture was stirred at RT for 15 min and then ((S)-2-methyl-1-{(S)-2-[4-(4′-{6-[(R)-2-methyl-4-((S)-2-methyl-pyrrolidine-2-carbonyl)-piperazin-1-yl]-pyridin-3-ylcarbamoyl}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-propyl)-carbamic acid methyl ester 3 HCl (12.0 mg, 0.012 mmol; Preparation 57) was added followed by N,N-diisopropylethylamine (10.8 μL, 0.062 mmol) and the reaction mixture was stirred at 55° C. overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the di-TFA salt of the title compound (8.3 mg) (m/z): [M+H]+ calcd for C47H56P3N9O8 932.42 found 932.4.
EXAMPLES 67-70
Following the procedure of Example 66, the intermediate of Preparation 57 (12.0 mg, 0.012 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex.





No.
R
Reagent
Product







67




(2S,3S)-3-hydroxy-2- methoxycarbonylamino-butyric acid (2.63 mg, 0.015 mmol) HATU (5.65 mg, 0.015 mmol)*
2 TFA salt (1.7 mg) (m/z): [M + H]+ calcd for C50H61F3N10O10 1,019.45 found 1019.4


 


68




glycolic acid (1.13 mg, 0.015 mmol) HATU (5.65 mg, 0.015 mmol)
2 TFA salt (1.5 mg) (m/z): [M + H]+ calcd for C46H54F3N9O8 918.41 found 918.4


 


69




2-hydroxy-2-methyl-propionic acid (1.55 mg, 0.015 mmol) HATU (5.65 mg, 0.015 mmol)
2 TFA salt (0.6 mg) (m/z): [M + H]+ calcd for C48H58F3N9O8 946.44 found 946.4


 


70




(S)-2-Methoxycarbonylamino-3,3- dimethyl-butyric acid (2.81 mg, 0.015 mmol) HATU (5.65 mg, 0.015 mmol)*
2 TFA salt (1 mg) (m/z): [M + H]+ calcd for C52H65F3N10O9 1,031.49 found 1031.4





*Prior to isolation and purification, another equivalent of the corresponding acid, along with HOAt (2.53 mg, 0.019 mmol) and EDC (3.56 mg, 0.019 mmol), previously stirred at RT for 15 min, were added to the reaction mixture which was stirred at 60° C. overnight






EXAMPLE 71
{(S)-1-[(S)-2-(4-{4-[5-({6-[(2R,5S)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2,5-dimethyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-6-methyl-pyridin-2-yl]-phenyl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




A mixture of (s)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.13 mg, 0.019 mmol), and HATU (8.52 mg, 0.022 mmol) was stirred in DMA (1 mL) for 10 min and then [(S)-1-((S)-2-{4-[4-(5-{[6-(2R,5S)-2,5-dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-6-methyl-pyridin-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester 4 HCl (15 mg, 0.018 mmol; Preparation 59) and N,N-diisopropylethylamine (16.3 μL, 0.093 mmol) were added. The reaction mixture was stirred at RT overnight, concentrated by rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the tri-TFA salt of the title compound (11 mg). m/z): [M+H]+ calcd for C44H55N9O5 790.43 found 790.4.
EXAMPLES 72-75
Following the procedure of Example S, the intermediate of Preparation 59 (15.0 mg, 0.018 mmol) was reacted with the appropriate reagents to provide the following compounds:

















Ex.





No.
R
Reagent
Product







72




(S)-1-((S)-2-methoxycarbonyl- amino-3-methyl-butyryl)-2- methyl-pyrrolidine-2-carboxylic acid (5.35 mg, 0.019 mmol) HATU (8.52 mg, 0.022 mmol)
3 TFA salt (1.7 mg) (m/z): [M + H]+ calcd for C51H67N11O8 962.52 found 962.4


 


73




cyclopropanecarbonyl chloride (1.95 mg, 0.019 mmol)
3 TFA salt (6.5 mg) (m/z): [M + H]+ calcd for C42H51N9O5 762.40 found 762.4


 


74
NHCH3
methylaminoformyl chloride
3 TFA salt (4 mg)




(1.75 mg, 0.019 mmol)
(m/z): [M + H]+ calcd for





C40H50N10O5 751.40 found 751.4


 


75




imidazol-4-carboxylic acid (2.09 mg, 0.019 mmol), EDC (5.37 mg, 0.028 mmol)
3 TFA salt (5.4 mg) (m/z): [M + H]+ calcd for C42H49N11O5 788.39 found 788.4









EXAMPLE 76
{(S)-1-[(S)-2-(4-{6-[4-({6-[(R)-4-((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-trifluoromethoxyphenyl]-pyridin-3-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester




To a mixture of [(S)-2-methyl-1-((S)-2-{4-[6-(4-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2-trifluoromethoxy-phenyl)-pyridin-3-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester 3-TFA (14.25 mg, 0.013 mmol; Preparation 61) and (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.2 mg, 0.020 mmol) and HATU (7.4 mg, 0.020 mmol) in DMF (0.5 mL) at RT was added N,N-diisopropylethylamine (11.37 μL, 0.065 mmol). The reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL), and purified by reverse phase HPLC to provide the tri-TFA salt of the title compound (10.8 mg). m/z): [M+H]+ calcd for C43H50F3N9O6 846.38 found 847.0.
EXAMPLE 77
(a) [(S)-1-((S)-2-{4-[5′-Chloro-2′-trifluoromethoxy-4′-({6-[(R)-2-methyl-4-((S)-2-methyl-pyrrolidine-2-carbonyl)-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-biphenyl-4-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester




A mixture of (S)-2-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (23.2 mg, 0.10 mmol) and HATU (38.5 mg, 0.10 mmol) in DMA (1 mL) was stirred at RT for 20 min and then ((S)-1-{(S)-2-[4-(5′-chloro-4′-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 3TFA (95.0 mg, 0.084 mmol; Preparation 62) was added followed by N,N-diisopropylethylamine (0.074 mL, 0.42 mmol) and the reaction mixture was stirred at 55° C. overnight. The reaction mixture was diluted in ethyl acetate and washed with water followed by brine. The organic layer was dried over sodium sulfate, filtered and concentrated to produce a yellow oil.
The oil from the previous step was treated with 4 M HCl in 1,4-dioxane (0.63 mL, 2.53 mmol) and HCl (0.16 mL) and the reaction mixture was stirred at RT for 1 h, concentrated, and evaporated with EtOAc (2×) to produce the tri-HCl salt of the title intermediate as a light yellow solid (87.3 mg).

    (b)






To the product of the previous step (22 mg, 0.022 mmol) dissolved in DMA was added 0.5 M methylaminoformyl chloride in DMA (52.6 μL, 0.026 mmol), followed by N,N-diisopropylethylamine (0.016 mL, 0.089 mmol) and the reaction mixture was stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the di-TFA salt of the title compound (14.4 mg). m/z): [M+H]+ calcd for C46H54ClF3N10O7 951.38 found 951.6.
EXAMPLE 78
Alternative synthesis of ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
(a) N-(4-Bromo-3-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide




To a solution of 4-bromo-3-trifluoromethoxy-phenylamine (3.15 g, 12.3 mmol) and triethylamine (3.43 mL, 24.6 mmol) in DCM (25 mL) was slowly added a solution of 2-fluoropyridine-5-carbonyl chloride (2.36 g, 14.8 mmol) in DCM (10 mL). After 2 h at RT, MTBE (90 mL) was added and the reaction mixture was washed with water, brine, and saturated sodium carbonate, dried, and evaporated to give a solid (5.4 g). Ethanol (43 mL) was added to the solid and then water (43 mL) was slowly added. The reaction mixture was stirred for 1.5 h, filtered, and washed with 1:4 ethanol:water (2×25 mL) to give the title intermediate as a white solid (3.87 g). HPLC method C: Retention time=21.3 min.
(b) (2S,5R)-4-[5-(4-Bromo-3-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




The product of the previous step (3.86 g, 10.2 mmol) (2S,5R)-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester (2.62 g, 12.2 mmol) and N,N-diisopropylethylamine (5.32 mL, 30.5) was dissolved in DMSO (12 mL). The reaction mixture heated at 120° C. for 3 h, diluted with EtOAc (100 mL), washed with water, and saturated NH4Cl, water, and brine. The reaction mixture was evaporated to about 40% volume and 3 M HCl in cyclopentyl methyl ether (4.24 mL, 12.7 mmol) was added slowly. Seeds from a previous run at smaller scale were added and the reaction mixture was stirred for 2 days and filtered to provide the HCl salt of the title intermediate (5.15 g, 83% yield). HPLC method C: Retention time=21.1 min
(c) (2S,5R)-4-[5-(4′-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-2,5-dimethyl-piperazine-1-carboxylic acid tert-butyl ester




To a solution of ((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (3.05 g, 6.8 mmol;), bis(pinacolato)diboron (1.81 g, 7.1 mmol) and potassium acetate (1,00 g, 10.2 mmol) was added nitrogen sparged toluene (15 mL). The resulting mixture was sparged with nitrogen and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane (Pd catalyst) (0.17 g, 0.204 mmol) was added. The reaction mixture was stirred at 90° C. overnight.
The reaction mixture was cooled to RT and to this mixture was added nitrogen sparged water (7.6 mL), potassium carbonate (5.16 g, 37.3 mmol). The reaction mixture was stirred at 95° C. overnight.
Another portion of the Pd catalyst used above (0.08 g, 0.10 mmol) was added to the reaction mixture. After 5 h, the reaction mixture was cooled to RT, diluted with EtOAc (150 mL), washed with water (150 mL) and brine (100 mL), dried over sodium sulfate, and evaporated to give a black residue (6.7 g), which was purified by silica gel chromatography (eluted with 50-100% EtOAc/hexane) to provide the title intermediate (5.3 g, 90% yield). HPLC method C: Retention time=14.7 min.
(d) ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester




Acetyl chloride (2.57 mL, 36.2 mmol) was added to ethanol (18 mL) and stirred at RT for 1 h. To the resulting HCl solution was added a solution of the product of the previous step (3.90 g, 4.5 mmol) in ethanol (18 mL). The reaction mixture was warmed to 35° C. and stirred overnight. Acetyl chloride (1.28 mL, 18.1 mmol) was added to ethanol (7.8 mL) and stirred for 30 min. The resulting HCl solution was added to the reaction mixture at 35° C. The temperature was raised to 40° C. The mixture was concentrated to dryness chased by dichloromethane to provide the crude tri-HCl salt of the title intermediate (5.4 g) which was used directly in the next step. HPLC method C: Retention time=10.1 min.
(e) ((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-Dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester  




To a solution of the product of the previous step (5.4 g crude, ca. 3.96 mmol) and N,N-diisopropylethylamine (6.89 mL, 39.6 mmol) in DCM (52 mL) was slowly added 1 M methylaminoformyl chloride in DMA (4.3 mL). The reaction mixture stirred at room temperature for 1 h, and then water (50 mL) was added. The organic layer was washed with saturated NH4Cl and then brine, dried over Na2SO4 and evaporated to give 5.2 g crude product, which was purified by silica gel chromatography (133 g silica, 2 to 8% methanol/DCM for 15 min then 8% methanol/DCM for 40 min) to provide the title compound (2.4 g, 74% yield). HPLC method C: Retention time 11.2 min.
Using similar synthetic methods, the compounds of Tables 1-34 were prepared where a blank in any column denotes hydrogen and further when more than one variable is listed in a single column, (e.g. Table 5) any variable not specified is hydrogen:







TABLE 1













 
















Calc
Found


Ex. No.
R5
R10
Formula
[M + H]+
[M + H]+















1-1 
OCH3

C39H45N7O6
708.34
708.2


1-2 
OCH2phenyl

C45H49N7O6
784.37
784.2


1-3 
CH3

C38H45N7O4
664.35
664.2


1-4 
CH2OCH3

C40H47N7O6
722.36
722.4


1-5 
CH((S)—iPr)NHC(O)OCH3

C44H54N8O7
807.41
807.4


1-6 
CH((S)—iPr)N(Et)2

C46H60N8O5
805.47
805.4


1-7 
CH((R)-phenyl)NH—C(O)OCH3

C47H52N8O7
841.4
841.4


1-8 
CH((R)-phenyl)N(Et)2

C49H58N8O5
839.45
839.4


1-9 
CH2N(CH3)C(O)OtBu

C45H56N8O7
821.43
821.4


1-10
CH2NHC(O)OtBu

C44H54N8O7
807.41
807.0


1-11
CH2N(CH3)2

C41H50N8O5
735.39
735.4


1-12
CH2NH2

C39H46N8O5
707.36
707.2


1-13
CH2NHCH3

C40H48N8O5
721.38
721.4


1-14
CH2OH

C39H45N7O6
708.34
708.2


1-15
NHCH3

C39H46N8O5
707.36
707.4


1-16
N(CH3)2

C40H48N8O5
721.38
721.2


 


1-17





C40H44N10O5
745.35
745.4


 


1-18





C42H45N7O6
744.34
744.2


 


1-19





C43H46N8O5
755.36
755.4


 


1-20





C42H45N7O6
744.34
744.2


 


1-21





C42H45N9O5
756.35
756.4


 


1-22





C41H45N9O5
744.35
744.2


 


1-23





C41H44N8O6
745.34
745.2


 


1-24
NH2

C38H44N8O5
693.34
693.4


1-25
cPr
Cl
C41H46ClN7O5
752.33
752.2


 


1-26





C41H48N8O6
749.37
749.2


 


1-27
CH((S)iPr)NHC(O)OtBu

C47H60N8O7
849.46
849.4


1-28
CH((S)iPr)NH2

C42H52N8O5
749.41
749.4


1-29
CH3

C39H45N7O5
692.35
692.2


 


1-30





C42H50N8O5
747.39
747.4


 


1-31
CH((S)OH)iPr

C42H51N7O6
750.39
750.2


 


1-32





C43H52N8O5
761.41
761.4


 


1-33
C(CH3)2NHCH3

C42H52N8O5
749.41
749.4


 


1-34





C41H47N7O6
734.36
734.2


 


1-35
CH2iPr

C42H49N7O5
732.38
732.4


 


1-36





C45H54N8O5
787.42
787.4


 


1-37
CH((R)OH)iPr

C42H51N7O6
750.39
750.4


1-38
NHiPr

C41H50N8O5
735.39
735.4


1-39
O—iPr

C41H49N7O6
736.37
736.2


 


1-40





C42H50N8O5
747.39
747.4


 


1-41
OCH2CH3

C40H47N7O6
722.36
722.2


1-42
NHCH2CH3

C40H48N8O5
721.38
721.4


1-43
NHCH2—iPr

C42H52N8O5
749.41
749.4


1-44
cPr
CH3
C42H49N7O5
732.38
732.7


1-45
NHCH3
CH3
C40H48N8O5
721.38
721.6


 


1-46





C41H48N8O5
733.38
733.4


 


1-47
NH—tBu

C42H52N8O5
749.41
749.4


 


1-48





C43H46N8O5
755.36
755.2


 


1-49
iPr

C41H49N7O5
720.38
720.2


 


1-50





C42H47N9O5
758.37
758.2


 


1-51





C42H45N9O5
756.35
756.2


 


1-52





C42H47N9O5
758.37
758.2


 


1-53





C43H46N8O5
755.36
755.2


 


1-54





C40H45N11O5
760.36
760.2


 


1-55
CH ((S)CH2OH)NH2

C40H48N8O6
737.37
737.4


 


1-56





C41H45N9O5
744.35
744.2


 


1-57





C41H45N9O5
744.35
744.2


 


1-58





C41H48N8O5
733.38
733.2


 


1-59
CH((S)CH2OH)NHC(O)OtBu

C45H56N8O8
837.42
837.4


 


1-60




Cl
C42H44ClN7O6
778.30
778.2


 


1-61




Cl
C42H44ClN9O5
790.32
790.4


 


1-62
CH((R))cPrNH2

C42H50N8O5
747.39
747.4


 


1-63





C43H50N8O6
775.39
775.4


 


1-64
CH((R)cPr)NHC(O)CH3

C44H52N8O6
789.40
789.4


 


1-65





C44H52N8O6
789.40
789.4


 


1-66
CH2N(CH3)C(O)CH3

C42H50N8O6
763.39
763.4


 


1-67





C46H56N8O7
833.43
833.4


 


1-68





C41H48N8O5
733.38
733.4


 


1-69
CH2NHC(O)CH3
Cl
C41H47ClN8O6
783.33
783.2


1-70
tBu
Cl
C42H50ClN7O5
768.36
768.2


1-71
CH((R)CH3)NH2

C40H48N8O5
721.38
721.2


1-72
CH((R)CH2OH)NHCH3

C41H50N8O6
751.39
751.2


1-73
CH((R)Pr)NHC(O)CH3

C44H54N8O6
791.42
791.4


1-74
CH((S)CH3)NHC(O)OtBu

C45H56N8O7
821.43
821.4


1-75
CH((S)CH3)N(CH3)C(O)OtBu

C46H58N8O7
835.44
835.4


1-76
CH((S)iPr)NHC(O)CH3

C45H56N8O6
805.43
805.4


1-77
CH((S)CH3)NHCH3

C41H50N8O5
735.39
735.4


1-78
CH((S)CH3)NH2

C40H48N8O5
721.38
721.2


1-79
CH((R)CH3)N(CH3)C(O)OtBu

C45H56N8O7
821.43
821.4
















TABLE 2













 














Calc
Found


Ex. No.
R6
Formula
[M + H]+
[M + H]+





2-1




C40H45N9O6S
780.32
780.4


 


2-2
NH2
C37H44N8O6S
729.31
729.2


2-3
cyclopropyl
C40H47N7O6S
754.33
754.2


2-4
phenyl
C43H47N7O6S
790.33
790.2
















TABLE 3













 


















Calc
Found


Ex. No.
R7a
R7b
R7c
Formula
[M + H]+
[M + H]+





3-1
F


C41H46FN7O5
736.35
736.4


3-2
OCH3


C42H49N7O6
748.37
748.4


3-3
F

F
C41H43F2N7O3
754.35
754.2


3-4
Cl


C41H46ClN7O5
752.33
752.4


3-5
Cl

Cl
C41H43Cl2N7O3
786.29
786.2


3-6

F

C41H46FN7O5
736.35
736.4


3-7

Cl

C41H46ClN7O5
752.33
752.2
















TABLE 4













 
















Calc
Found


Ex. No.
R
R10
Formula
[M + H]+
[M + H]+





4-1
CH((S)—iPr)NHSO2CH3

C40H47N7O5S
738.34
738.2


4-2
CH((S)—iPr)NHC(O)NHCH3

C41H48N8O4
717.38
717.2


4-3
CH((S)—iPr)N(C2H5)2

C43H53N7O3
716.42
716.4


4-4
CH((S)—iPr)NHC(O)OtBu

C44H53N7O5
760.41
760.4


4-5
CH((R)phenyl)NHC(O)OCH3

C44H45N7O5
752.35
752.2


4-6
CH((S)—iPr)NHC(O)cPr

C43H49N7O4
728.38
728.4


4-7
CH((S)—iPr)NH2

C39H45N7O3
660.36
660.2


4-8
CH((R)phenyl)N(C2H5)2
Cl
C46H50ClN7O3
784.37
785.2
















TABLE 5













 




















Calc
Found


Ex No.
R5
R10
T
R8a, R8b, R9a, R9d*
Formula
[M + H]+
[M + H]+





5-1 
OtBu

CH

C42H51N7O6
750.39
750.4


5-2 
cPr
Br
CH

C41H46BrN7O5
796.27
796.2


5-3 
OtBu
Br
CH

C42H50BrN7O6
828.30
828.5


5-4 
CH2iPr
Br
CH

C42H50BrN7O5
812.31
812.2


5-5 
CH3

CH

C39H45N7O5
692.35
692.4


5-6 
OtBu

N

C41H50N8O6
751.39
751.4


5-7 
OtBu

CH
R9a = (S)CH3
C43H53N7O6
764.41
764.4


5-8 
OtBu

CH
R9a = (R)CH3
C43H53N7O6
764.41
764.4


5-9 
cPr

C
R8b = F
C41H46FN7O5
736.35
736.4


5-10
OtBu

CH
R9b = (S)iPr
C45H57N7O6
792.44
792.4


5-11
cPr

C
R8b = OMe
C42H49N7O6
748.37
748.4


5-12
cPr

CH
R9a = (R)CH3
C42H49N7O5
732.38
732.4


5-13
cPr

CH
R9a = (S)CH3
C42H49N7O5
732.38
732.4


5-14
cPr

C
R8b = Me
C42H49N7O5
732.38
732.4


5-15
cPr

C
R8b = Cl
C41H46ClN7O5
752.33
752.2


5-16
cPr

CH
R9b = (S)iPr
C44H53N7O5
760.41
760.4


5-17
cPr

CH
R8a = Me
C42H49N7O5
732.38
732.4


5-18
OtBu

C
R8b = COOH
C43H51N7O8
794.38
794.2


5-19
cPr

CH
R8a = Cl
C41H46ClN7O5
752.33
752.2


5-20
OtBu

C
R8b = COOMe
C44H53N7O8
808.40
808.2


5-21
cPr
H
C
R8b = CH2NH2
C42H50N8O5
747.39
747.4





*R8a, R9a, R9b, R10 are each H where not specified













TABLE 6













 




















Calc
Found


Ex No.
R5
R9a
R9b
R9c
Formula
[M + H]+
[M + H]+





6-1
OMe



C37H43N9O6
710.33 
710.2


6-2
cPr



C39H45N9O5
720.35 
720.2


6-3
NHCH3



C37H44N10O5
709.35 
710.4


6-4
OtBu
(S)CH3

(R)CH3
C42H53N9O6
780.41 
780.4


6-5
OtBu
(R)CH3


C41H51N9O6
766.40 
766.4


6-6
OtBu



C40H49N9O6
752.38 
752.4


6-7
OtBu

(S)CH3

C41H51N9O6
766.40 
766.4


6-8
OtBu

(R)CH3

C41H51N9O6
766.40 
766.4


6-9
OtBu
(S)CH3


C41H51N9O6
766.40 
766.4
















TABLE 7













 


















Calc
Found


Ex No.
R5
R9a
R9b
Formula
[M + H]+
[M + H]+





7-1
OtBu
(R)CH3

C41H51N9O6
766.4
766.2


7-2
OtBu


C40H49N9O6
752.38
752.2


7-3
OtBu

(R)CH3
C41H51N9O6
766.40
766.4


7-4
cPr


C39H45N9O5
720.35
720.2


7-5
Me


C37H43N9O5
694.34
694.2


7-6
NHCH3


C37H44N10O5
709.35
709.2


7-7
Me

(R)CH3
C38H45N9O5
708.35
708.2


7-8
cPr

(R)CH3
C40H47N9O5
734.37
734.2


7-9
NHCH3

(R)CH3
C38H46N10O5
723.37
723.4


 7-10
cPr
(R)CH3

C40H47N9O5
734.37
734.2


 7-11
NHCH3
(R)CH3

C38H46N10O5
723.37
723.4
















TABLE 8













 
















Calc
Found


Ex No.
R5
R7b
Formula
[M + H]+
[M + H]+





8-1
cPr

C40H46N8O5
719.36
719.2


8-2
Me

C38H44N8O5
693.34
693.2


8-3
NHSO2CH3

C39H48N8O6S
757.34
757.2


8-4
OtBu
OCH3
C42H52N8O7
781.40
781.4


8-5
cPr
OCH3
C41H48N8O6
749.37
749.2
















TABLE 9













 


















Calc
Found


Ex No.
R9a
R9b
R10
Formula
[M + H]+
[M + H]+





9-1



C40H46N8O5
719.36
719.2


9-2
(S)CH3


C41H48N8O5
733.38
733.2


9-3
(R)CH3


C41H48N8O5
733.38
733.4


9-4

(R)CH3

C41H48N8O5
733.38
733.4


9-5

(S)CH3

C41H48N8O5
733.38
733.4


9-6
(R)CH2OH


C41H48N8O6
749.37
749.4


9-7
(S)CH2OH


C41H48N8O6
749.37
749.4


9-8

(S)CH2OH

C41H48N8O6
749.37
749.4


9-9

(R)CH2OH

C41H48N8O6
749.37
749.4


 9-10

(R)CH2OCH3

C42H50N8O6
763.39
763.4


 9-11


Cl
C40H45ClN8O5
753.32
753.2


 9-12

(S)C(O)NH2

C41H47N9O6
762.37
762.4


 9-13

(R)C(O)NH2

C41H47N9O6
762.37
762.4


 9-14

(S)C(O)N(CH3)2

C43H51N9O6
790.40
790.4


 9-15

(R)C(O)N(CH3)2

C43H51N9O6
790.40
790.4
















TABLE 10













 















Ex






Calc
Found


No.
R9a
R9b
R9c
R9d
R10
Formula
[M + H]+
[M + H]+


















10-1 





C42H50N8O5
747.39
747.4


10-2 

(R)CH3



C43H52N8O5
761.41
762.0


10-3 

(S)CH3



C43H52N8O5
761.41
761.4


10-4 

(S)CH2OH



C43H52N8O5
777.4
789.2


10-5 

(R)CH2OH



C43H52N8O5
777.4
799.4


10-6 

(R)CH2OCH3



C44H54N8O6
791.42
792.4


10-7 

(R)CH3


Cl
C43H51ClN8O5
795.37
795.4


10-8 

(S)C(O)N(CH3)2



C45H55N9O6
818.43
818.4


10-9 

(R)C(O)N(CH3)2



C45H55N9O6
818.43
818.4


10-10

(S)CH3
(R)CH3


C44H54N8O5
775.42
775.4


10-11

(S)CH3

(R)CH3

C44H54N8O5
775.42
775.4


10-12

(S)CH3


Cl
C43H51ClN8O5
795.37
795.4


10-13
(R)CH2OH




C43H52N8O6
777.40
777.3


10-14
(S)CH2OH




C43H52N8O6
777.40
777.4


10-15

(S)CH2OCH3



C44H54N8O6
791.42
791.4


10-16

(R)CH2OH


Cl
C43H51ClN8O6
811.36
811.2


10-17

(S)CH2OH


Cl
C43H51ClN8O6
811.36
811.2


10-18

(R)CH3


Et
C45H56N8O5
789.44
789.4


10-19

(S)C2H5



C44H54N8O5
775.42
775.4


10-20

(R)CH3
(S)CH3


C44H54N8O5
775.42
775.4


10-21
(S)CH3

(R)CH3


C44H54N8O5
775.42
775.4


10-22

(a)



C49H61N9O6
872.47
872.4


10-23
(R)C2H5




C44H54N8O5
775.42
775.4


10-24

(b)



C51H59N9O7
910.45
910.4


10-25

(R)CH2SCH3



C44H54N8O5S
807.39
807.2


10-26
(S)C2H5




C44H54N8O5
775.42
776.2


10-27

(R)CH2S(O)2CH3



C44H54N8O5S
839.38
839.4


10-28

(S)C(O)NH2



C43H51N9O6
790.40
790.4





(a) (R)CH2NH(S)C(O)(1,1-di-methylcyclopropyl)


(b) (R)CH2NHC(O)OCH2phenyl













TABLE 11













 




















Calc
Found


Ex No.
R9a
R9b
R9c
R9d
Formula
[M + H]+
[M + H]+





11-1 




C41H50N8O6
751.39
751.4


11-2 
CH3



C42H52N8O7
781.40
781.2


11-3 
(S)CH3



C42H52N8O6
765.40
765.4


11-4 
(R)CH3



C42H52N8O6
765.40
765.4


11-5 

(R)CH3


C42H52N8O6
765.40
765.2


11-6 

(S)CH3


C42H52N8O6
765.40
765.4


11-7 
(S)CH2OH



C42H52N8O7
781.40
781.7


11-8 

(S)CH2OH


C42H52N8O7
781.40
781.4


11-9 

(R)CH2OH


C42H52N8O7
781.40
781.4


11-10

(R)CH2OCH3


C43H54N8O7
795.41
795.4


 11-11*

(S)CH2OH


C42H51ClN8O7
815.36 
815.6


 11-12*

(R)CH2OH


C42H51ClN8O7
815.36 
815.7


11-13
(S)CONH2



C42H51N9O7
794.39
795.4


11-14

(S)CONH2


C42H51N9O7
794.39
794.4


11-15

(R)CONH2


C42H51N9O7
794.39
794.2


11-16
(R)COOH



C42H50N8O8
795.38 
795.4


11-17
(S)COOH



C42H50N8O8
795.38 
795.4


11-18

(R)COOH


C42H50N8O8
795.38 
795.4


11-19

(R)CH2CH3


C43H54N8O6
779.42
779.4


11-20

(S)CH2CH3


C43H54N8O6
779.42
779.4


11-21

COOCH3


C43H52N8O8
809.39
809.2


11-22

(R)COOCH3


C43H52N8O8
809.39
809.4


11-23

(S)COOCH3


C43H52N8O8
809.39
809.4


11-24

(S)CH(CH3)2


C44H56N8O6
793.43
793.4


11-25

(R)CH(CH3)2


C44H56N8O6
793.43
793.4


11-26

(S)CON(CH3)2


C44H55N9O7
822.42
822.4


11-27

(R)CON(CH3)2


C44H55N9O7
822.42
822.4


11-28
(S)CH3


(R)CH3
C43H54N8O6
779.42
780.0


11-29
(R)CH3


(S)CH3
C43H54N8O6
779.42
780.4


11-30
(R)CH3


(R)CH3
C43H54N8O6
779.42
779.4


11-31

(S)CH3

(R)CH3
C43H54N8O6
779.42
779.4


11-32
(S)CH3

(R)CH3

C43H54N8O6
779.42
779.4


11-33
(S)C(O)NH2



C42H51N9O7
794.39
795.4


11-34

(R)C(O)NH2


C42H51N9O7
794.39
794.2


11-35

(S)C(O)NH2


C42H51N9O7
794.39
794.4





*R10 is Cl; all other R10 are hydrogen













TABLE 12













 






















Calc
Found


Ex No.
R9a
R9b
R9c
R9d
R10
Formula
[M + H]+
[M + H]+





12-1


(R)CH3


C42H52N8O5
749.41
750.4


12-2


(S)CH3


C42H52N8O5
749.41
749.4


12-3


(R)CH2OH


C42H52N8O6
765.40
766.4


12-4

(S)CH3

(R)CH3

C43H54N8O5
763.42
763.4
















TABLE 13













 




















Calc
Found


Ex No.
R9a
R9b
R9d
R10
Formula
[M + H]+
[M + H]+





13-1 




C38H45N9O5
708.35
708.2


13-2 



CH3
C39H47N9O5
722.37
722.2


13-3 



Cl
C38H44ClN9O5
742.32
742.2


13-4 
(S)CH3



C39H47N9O5
722.37
722.2


13-5 
(R)CH3



C39H47N9O5
722.37
722.4


13-6 
(R)CH3


Cl
C39H46ClN9O6
772.33
772.2


13-7 

(R)CH3


C39H47N9O5
722.37
722.4


13-8 

(R)CH3

Cl
C39H46ClN9O5
756.33
756.2


13-9 

(S)CH3


C39H47N9O5
722.37
722.2


13-10

(S)CH3

Cl
C39H46ClN9O5
756.33
756.2


13-11
(R)CH2OH



C39H47N9O6
738.37
738.4


13-12
(S)CH2OH



C39H47N9O6
738.37
738.2


13-13

(S)CH2OH


C39H47N9O6
738.37
738.4


13-14

(R)CH2OH


C39H47N9O6
738.37
738.2


13-15

(S)CH2OCH3


C40H49N9O6
752.38
752.4


13-16

(S)CH3
(R)CH3

C40H49N9O5
736.39
736.4
















TABLE 14













 


















Calc
Found


Ex No.
R9a
R9b
R9d
Formula
[M + H]+
[M + H]+





14-1 



C41H44N10O5
757.35
757.4


14-2 
(S)CH3


C42H46N10O5
771.37
771.4


14-3 
(R)CH3


C42H46N10O5
771.37
771.4


14-4 

(R)CH3

C42H46N10O5
771.37
771.4


14-5 

(S)CH3

C42H46N10O5
771.37
771.4


14-6 
(R)CH2OH


C42H46N10O6
787.36
787.4


14-7 
(S)CH2OH


C42H46N10O6
787.36
787.4


14-8 

(S)CH2OH

C42H46N10O6
787.36
788.2


14-9 

(R)CH2OH

C42H46N10O6
787.36
787.4


14-10

(S)CH2OCH3

C43H48N10O6
801.38
801.4


14-11

(S)CH3
(R)CH3
C43H48N10O5
785.38
785.4
















TABLE 15













 


















Calc
Found


Ex No.
R9a
R9b
R9d
Formula
[M + H]+
[M + H]+





15-1 



C40H44N10O5
745.35
745.4


15-2 
(S)CH3


C41H46N10O5
759.37
759.2


15-3 
(R)CH3


C41H46N10O5
759.37
759.4


15-4 

(R)CH3

C41H46N10O5
759.37
759.4


15-5 

(S)CH3

C41H46N10O5
759.37
759.2


15-6 
(R)CH2OH


C41H46N10O6
775.36
775.4


15-7 
(S)CH2OH


C41H46N10O6
775.36
775.2


15-8 

(S)CH2OH

C41H46N10O6
775.36
775.2


15-9 

(R)CH2OH

C41H46N10O6
775.36
775.2


15-10

(S)CH2OCH3

C42H48N10O6
789.38
789.4


15-11

(S)CH3
(R)CH3
C42H48N10O5
773.38
773.4
















TABLE 16













 




















Calc
Found


Ex No.
R9a
R9b
R9d
R10
Formula
[M + H]+
[M + H]+





16-1 




C40H44N10O5
745.35
745.4


16-2 
(S)CH3



C41H46N10O5
759.37
759.4


16-3 
(R)CH3



C41H46N10O5
759.37
759.2


16-4 

(R)CH3


C41H46N10O5
759.37
759.4


16-5 

(R)CH3

Cl
C41H45ClN10O5
793.33
793.4


16-6 

(S)CH3


C41H46N10O5
759.37
759.4


16-7 

(S)CH3

Cl
C41H45ClN10O5
793.33
793.2


16-8 
(R)CH2OH



C41H46N10O5
775.36
775.4


16-9 
(S)CH2OH



C41H46N10O5
775.36
775.4


16-10

(S)CH2OH


C41H46N10O5
775.36
775.4


16-11

(R)CH2OH


C41H46N10O5
775.36
775.4


16-12

(S)CH2OCH3


C42H48N10O6
789.38
789.4


16-13

(S)CH3
(R)CH3

C42H48N10O5
773.38
773.4
















TABLE 17













 














Ex





Calc
Found


No.
R9a
R9b
R9c
R9d
Formula
[M + H]+
[M + H]+





17-1




C40H47N9O6
750.37
750.3


17-2(b)




C41H49N9O6
764.38
764.4


17-3
(S)CH3



C41H49N9O6
764.38
764.2


17-4(a)
(S)CH3



C41H48ClN9O6
798.34
798.2


17-5
(R)CH3



C41H49N9O6
764.38
764.2


17-6

(R)CH3


C41H49N9O6
764.38
764.8


17-7(a)

(R)CH3


C41H48ClN9O6
798.34
798.2


17-8

(S)CH3


C41H49N9O6
764.38
764.4


17-9(a)

(S)CH3


C41H48ClN9O6
798.34
798.2


17-10
(R)CH2OH



C41H49N9O7
780.38
780.4


17-11
(S)CH2OH



C41H49N9O7
780.38
780.4


17-12

(S)CH2OH


C41H49N9O7
780.38
780.4


17-13

(R)CH2OH


C41H49N9O7
780.38
780.4


17-14

(S)CH3
(R)CH3

C42H48N10O6
789.38
789.2


17-15

(S)CH2OCH3


C42H51N9O7
794.39
795.4


17-16

(S)CH3

(R)CH3
C42H51N9O6
778.4
778.4


17-17

(S)C(O)NH2


C41H48N10O7
793.37
793.2


17-18

(R)C(O)NH2


C41H48N10O7
793.37
793.4


17-19

(S)CON(CH3)2


C43H52N10O7
821.4
821.4


17-20

(R)CON(CH3)2


C43H52N10O7
821.4
821.4





(a)R10 is Cl


(b)R10 is CH3













TABLE 18













 




















Calc
Found


Ex No.
R9a
R9b
R9d
R10
Formula
[M + H]+
[M + H]+

















18-1 




C41H46N10O5
759.37
759.4


18-2 
(S)CH3



C42H48N10O5
773.38
774


18-3 
(R)CH3



C42H48N10O5
773.38
773.4


18-4 

(R)CH3


C42H48N10O5
773.38
774.4


18-5 

(R)CH3

Cl
C42H47ClN10O5
807.34
807.2


18-6 

(S)CH3


C42H48N10O5
773.38
773.4


18-7 

(S)CH3

Cl
C42H47ClN10O5
807.34
807.4


18-8 
(R)CH2OH



C42H48N10O6
789.38
789.4


18-9 
(S)CH2OH



C42H48N10O6
789.38
789.4


18-10

(S)CH2OH


C42H48N10O6
789.38
789.4


18-11

(S)CH2OH

Cl
C42H47ClN10O6
823.34
823.2


18-12

(R)CH2OH


C42H48N10O6
789.38
789.4


18-13

(R)CH2OH

Cl
C42H47ClN10O6
823.34
823.2


18-14

(R)CH2OCH3


C43H50N10O6
803.39
803.4


18-15

(S)CH2OCH3


C43H50N10O6
803.39
803.4


18-16

(S)CH3
(R)CH3

C43H50N10O5
787.40
787.4


18-17

(S)CON(CH3)2


C44H51N11O6
830.40
830.4


18-18

(R)CON(CH3)2


C44H51N11O6
830.40
830.4
















TABLE 19













 















Ex






Calc
Found


No.
R9a
R9b
R9c
R9d
*
Formula
[M + H]+
[M + H]+





19-1




(R)
C43H51N9O6
790.4 
790.4


19-2




(S)
C43H51N9O6
790.4 
790.4


19-3
(R)CH3



(R)
C44H53N9O6
804.41
804.4


19-4

(R)CH3


(R)
C44H53N9O6
804.41
804.4


19-5

(S)CH3


(R)
C44H53N9O6
804.41
804.4


19-6

(S)CH2OH


(R)
C44H53N9O7
820.41
820.4


19-7

(R)CH2OH


(R)
C44H53N9O7
820.41
820.4


19-8

(R)CH3
(R)CH3

(R)
C45H55N9O6
818.43
818.4


19-9

(S)CH3

(R)CH3
(R)
C45H55N9O6
818.43
818.4
















TABLE 20













 
















Calc
Found


Ex No.
R
R10
Formula
[M + H]+
[M + H]+





20-1 





C41H49N9O6
764.38
764.2


 


20-2 





C41H48N8O6
749.37
749.6


 


20-3 
CH2SO2CH3
CH3
C40H48N8O7S
785.34
785.2


 


20-4 





C41H46N10O5
759.37
759.4


 


20-5 
C(CH3)2OH

C40H48N8O6
737.37
737.2


20-6 
CH(CH2OH)NHC(O)CH3

C41H49N9O7
780.38
780.2


20-7 
CH((R)iPr)NHC(O)CH3

C43H53N9O6
792.41
792.4


20-8 
CH((S)CH3)NHC(O)CH3

C41H49N9O6
764.38
764.2


20-9 
NHiPr

C40H49N9O5
736.39
736.4


 


20-10





C43H48N10O5
785.38
785.4


 


20-11





C45H46N10O5
807.37
807.4


 


20-12





C41H46N10O5
759.37
759.4


 


20-13





C42H44ClN9O5
790.32
790.2


 


20-14





C42H44FN9O5
774.35
774.3


 


20-15





C42H44ClN9O5
790.32
790.2


 


20-16





C40H43N9O5S
762.31
762.2


 


20-17





C44H46N10O5
795.37
795.4


 


20-18





C40H43N9O5S
762.31
762.2


 


20-19
phenyl

C43H46N8O5
755.36
755.4


20-20
CH2SO2CH3

C39H46N8O7S
771.32
771.2
















TABLE 21













 


















Calc
Found


Ex No.
R7a, R7c
R9a, R9b, R9c, R9d
R5
Formula
[M + H]+
[M + H]+





21-1 
R7a = CH3
R9a = (R)CH3
OtBu
C43H54N8O6
779.42
779.4


 


21-2 
R7a = CH3
R9a = (R)CH3




C44H54N8O5
775.42
775.4


 


21-3 
R7a = CH3
R9a = (R)CH3




C42H50N8O5
747.39
747.4


 


21-4 
R7a = CH3
R9a = (R)CH3
NHCH3
C40H49N9O5
736.39
736.4


 


21-5 
R7a = CH3
R9a = (R)CH3




C42H48N10O5
773.38
773.4


 


21-6 
R7a = CH3
R9a = (R)CH3




C46H57N9O6
832.44
832.4


 


21-7 
R7a = CH3
R9a = (R)CH3




C46H57N9O6
832.44
832.4


 


21-8 

R9b = (S)CH3, R9c = (R)CH3




C46H57N9O6
832.44
832.4


 


21-9 

R9b = (S)CH3, R9c = (R)CH3




C46H57N9O6
832.44
832.4


 


21-10
R7a = CH3, R7c = CH3
R9a = (R)CH3
NHCH3
C41H51N9O5
750.40
750.4


 


21-11
R7a = CH3, R7c = CH3
R9a = (R)CH3




C45H56N8O5
789.44
789.4


 


21-12
R7a = CH3, R7c = CH3
R9a = (R)CH3




C43H50N10O5
787.40
787.4


 


21-13
R7a = CH3, R7c = CH3
R9a = (R)CH3




C43H52N8O5
761.41
761.4


 


21-14
R7a = CH3
R9a = (R)CH3




C46H57N9O7
848.44
848.4


 


21-15
R7a = CH3
R9b = (S)CH3, R9d = (R)CH3




C43H50N10O5
787.40
787.2


 


21-16
R7a = CH3
R9b = (S)CH3, R9d = (R)CH3
NHCH3
C41H51N9O5
750.40
750.4


 


21-17
R7a = CH3
R9b = (S)CH3, R9d = (R)CH3




C45H56N8O5
789.44
789.4


 


21-18
R7a = CH3
R9b = (S)CH3, R9d = (R)CH3




C43H52N8O5
761.41
761.4


 


21-19
R7a = CH3
R9a = (R)CH3, R9d = (S)CH3




C47H59N9O7
862.45
862.4


 


21-20
R7a = CH3
R9a = (R)CH3, R9d = (S)CH3




C45H56N8O5
789.44
789.4


 


21-21
R7a = CH3
R9a = (R)CH3, R9d = (S)CH3




C43H52N8O5
761.41
761.4


 


21-22
R7a = CH3
R9a = (R)CH3, R9d = (S)CH3
NHCH3
C41H51N9O5
750.40
750.4


 


21-23
R7a = CH3
R9a = (R)CH3, R9d = (S)CH3




C43H50N10O5
787.40
787.4


 


21-24
R7a = CF3
R9a = (R)CH3




C42H47F3N8O5
801.36
801.2


 


21-25
R7a = CF3
R9a = (R)CH3




C44H51F3N8O5
829.39
829.4


 


21-26
R7a = CF3
R9a = (R)CH3
NHCH3
C40H46F3N9O5
790.36
790.2


 


21-27
R7a = CF3
R9a = (R)CH3




C42H45F3N10O5
827.35
827.4


 


21-28
R7a = CF3
R9a = (R)CH3




C46H54F3N9O7
902.41
902.4


 


21-29
R7a = CF3
R9a = (R)CH3
NHCH3
C40H46N10O5
747.37
747.4


 


21-30
R7a = CN
R9a = (R)CH3




C44H51N9O5
786.40
786.4


 


21-31
R7a = CN
R9a = (R)CH3




C42H45N11O5
784.36
784.4


 


21-32
R7a = CN
R9a = (R)CH3




C46H54N10O7
859.42
859.4


 


21-33
R7a = CH3
R9a = (R)CH2SO2CH3




C45H56N8O7S
853.40
853.4


 


21-34
R7a = OCF3
R9a = (R)CH3




C44H51F3N8O6
845.39
845.4


 


21-35
R7a = OCF3
R9a = (R)CH3
NHCH3
C40H46F3N9O6
806.35
806.4


 


21-36
R7a = OCF3
R9a = (R)CH3




C42H45F3N10O6
843.35
843.2


 


21-37
R7a = OCF3
R9a = (R)CH3




C42H47F3N8O6
817.36
817.2


 


21-38
R7a = OCH3
R9a = (R)CH3




C46H57N9O8
864.43
864.4


 


21-39
R7a = OCH3
R9a = (R)CH3
NHCH3
C40H49N9O6
752.38
752.4


 


21-40
R7a = OCH3
R9a = (R)CH3




C44H54N8O6
791.42
791.4


 


21-41
R7a = OCF3
R9a = (R)CH3




C46H54F3N9O8
918.41
918.4


 


21-42
R7a = OCF3
R9a = (R)CH3




C43H48F3N9O7
860.36
860.4


 


21-43
R7a = OCF3
R9a = (R)CH3, R9d = (S)CH3




C43H49F3N8O6
831.37
831.2


 


21-44
R7a = OCF3
R9a = (R)CH3, R9d = (S)CH3




C47H56F3N9O8
932.42
932.4


 


21-45
R7a = OCF3
R9a = (R)CH3, R9d = (S)CH3




C43H47F3N10O6
857.36
857.2


 


21-46
R7a = OCF3
R9a = (R)CH3, R9d = (S)CH3




C45H53F3N8O6 
859.40
859.4


 


21-47
R7a = OCF3
R9a = (R)CH3, R9d = (S)CH3
NHCH3
C41H48F3N9O6
820.37
820.5


 


21-48
R7a = OCF3
R9b = (R)CH3, R9d = (S)CH3




C43H49F3N8O6
831.37
831.4


 


21-49
R7a = OCF3
R9b = (R)CH3, R9d = (S)CH3
NHCH3
C41H48F3N9O6
820.37
820.4


 


21-50
R7a = OCF3
R9b = (R)CH3, R9d = (S)CH3




C43H47F3N10O6
857.36
857.4


 


21-51
R7a = OCF3
R9b = (R)CH3, R9d = (S)CH3




C45H53F3N8O6 
859.40
860.2


 


21-52
R7a = F
R9a = (R)CH3




C41H47FN8O5
751.37 
751.2


 


21-53
R7a = F
R9a = (R)CH3
NHCH3
C39H46FN9O5
740.36
740.4


 


21-54
R7a = F
R9a = (R)CH3




C41H45FN10O5 
777.36
777.2


 


21-55
R7a = F
R9a = (R)CH3




C43H51FN8O5
779.40
779.4


 


21-56
R7a = F, R7c = F
R9a = (R)CH3




C41H46F2N8O5
769.36
769.2


 


21-57
R7a = F, R7c = F
R9a = (R)CH3




C43H50F2N8O5
797.39
797.4


 


21-58
R7a = F, R7c = F
R9a = (R)CH3
NHCH3
C39H45F2N9O5
758.35 
758.4


 


21-59
R7a = F, R7c = F
R9a = (R)CH3




C41H44F2N10O5
795.35
795.2


 


21-60






C45H53N9O6
816.41
816.4


 


21-61






C47H57N9O6
844.44
844.4


 


21-62






C44H53N9O6
804.41
804.4


 


21-63






C44H53N9O6
804.41
804.2


 


21-64






C46H55N9O6
830.43
830.4


 


21-65






C48H59N9O6
858.46
858.4


 


21-66

R9a = (S)CH3




C45H55N9O6
818.43
818.4


 


21-67

R9b = (S)CH2OCH3




C46H57N9O7
848.44
848.4


 


21-68

R9b = (R)CH2OH




C45H55N9O7
834.42
834.4


 


21-69

R9b = (S)CH2OH




C45H55N9O7
834.42
834.4


 


21-70

R9a = (R)CH3




C45H55N9O6
818.43
818.4


 


21-71






C43H50FN9O6
808.39
808.4


 


21-72

R9a = (R)CH3




C45H55N9O7
834.42
834.4


 


21-73

R9a = (R)CH2CH3




C46H57N9O6
832.44
832.4


 


21-74

R9a = (R)CH2CH3




C46H57N9O6
832.44
832.4


 


21-75

R9a = (R)CH3
(b)
C50H64N10O8
933.49
933.4


21-76

R9a = (R)CH3
(a)
C50H64N10O8
933.49
933.4


21-77
R7a = OCH3
R9a = (R)CH3
(a)
C51H66N10O9
963.50
963.4





(a) 


(b) 
















TABLE 22













 


















Calc
Found


Ex No.
R1
R9a
R5
Formula
[M + H]+
[M + H]+





22-1 
(S)CH3





C38H42N8O5
691.33
691.2


 


22-2 
(S)CH2OH





C38H42N8O6
707.32
707.7


 


22-3 
(S)C(CH3)2OH





C40H46N8O6
735.35
735.2


 


22-4 
(R)phenyl





C43H44N8O5
753.34
753.2


 


22-5 
(S)CH2((S)CH3)OCH3





C40H46N8O6
735.35
735.2


 


22-6 
(S)CH3
(R)CH3




C41H48N8O5
733.38
733.4


 


22-7 
(S)CH2OH
(R)CH3




C41H48N8O6
749.37
749.4


 


22-8 
(R)phenyl
(R)CH3




C46H50N8O5
795.39
795.4


 


22-9 
(S)CH2((S)CH3)OCH3
(R)CH3




C43H52N8O6
777.40
777.4


 


22-10
(S)C(CH3)3
(R)CH3




C44H54N8O5
775.42
775.4


 


22-11
(S)cPr
(R)CH3




C43H50N8O5
759.39
759.4


 


22-12
(R)CH(CH3)2
(R)CH3




C43H52N8O5
761.41
761.4
















TABLE 23













 


















Calc
Found


Ex No.
R7a, R7c
R9a, R9b, R9d
R5
Formula
[M + H]+
[M + H]+


 


23-1 

R9a = (R)CH3




C43H52N8O5
761.41
761.7


 


23-2 

R9a = (R)CH3




C44H56N8O6
793.43
793.4


 


23-3 

R9a = (R)CH3




C41H46N10O5
759.37
759.4


 


23-4 

R9a = (R)CH3




C45H55N9O7
834.42
834.4


 


23-5 

R9a = (R)CH3
NHCH3
C39H47N9O5
722.37
722.4


 


23-6 

R9a = (R)CH3




C44H54N8O5
775.42
775.4


 


23-7 

R9a = (R)CH3 R9d = (S)CH3




C42H48N10O5
773.38
773.4


 


23-8 

R9a = (R)CH3 R9d = (S)CH3
(a)
C51H66N10O8
947.51
947.6


23-9 

R9a = (R)CH3 R9d = (S)CH3
NHCH3
C40H49N9O5
736.39
736.4


23-10

R9a = (R)CH3
(a)
C50H64N10O8
933.49
933.4


 


23-11
R7a = OCH3
R9a = (R)CH3




C44H54N8O6
791.42
791.4


 


23-12
R7a = CH3
R9a = (R)CH3
NHCH3
C40H49N9O5
736.39
736.4


 


23-13
R7a = OCF3
R9a = (R)CH3




C44H51F3N8O6
845.39
845.8


 


23-14
R7a = OCF3
R9a = (R)CH3
(a)
C51H63F3N10O9
1017.47
1017.9





(a) 
















TABLE 24













 













Ex
R11a R11b
R7a R7b R7c


Calc
Found


No.
R11c R11d
R7d
R5
Formula
[M + H]+
[M + H]+
















24-1 






C46H55N9O7
846.42
846.4


 


24-2 






C46H55N9O6
830.43
830.4


 


24-3 






C51H64N10O8
945.49
945.4


 


24-4 






C47H60N10O6
861.47
861.4


 


24-5 






C49H62N10O7
903.48
903.4


 


24-6 






C51H66N10O8
947.51
945.4


 


24-7 






C43H52N8O5
761.41
761.4


 


24-8 






C49H62N10O8
919.48
919.6


 


24-9 






C43H53N9O5
776.42
776.4


 


24-10


CH2t-Bu
C43H54N8O5
763.42
763.4


 


24-11






C41H49N9O5
748.39
748.4


 


24-12


NHC(CH3)2CH2OH
C42H53N9O6
780.41
780.4


 


24-13






C47H57N9O8
876.43
876.4


 


24-14






C43H52N8O6
777.4
777.4


 


24-15

R7a = OiPr
NHCH3
C42H53N9O6
780.41
780.4


 


24-16






C47H60N10O6
861.47
861.6


 


24-17






C47H60N10O7
877.47
877.4


 


24-18






C48H62N10O6
875.49
875.6


 


24-19






C49H62N10O8
919.48
919.4


 


24-20
R11b = CH3





C46H55N9O6
830.43
830.7


 


24-21






C43H53N9O5
776.42
776.4


 


24-22

R7a = OCHF2
NHCH3
C40H47F2N9O6
788.36
788.4


24-23
R11b = OCF3

NHCH3
C40H46F3N9O6
806.35
806.4


24-24

R7a = CH3 R7d = F
NHCH3
C40H48FN9O5
754.38
754.8


 


24-25

R7a = OCH3 R7d = Cl




C42H49ClN8O6
797.35
798.0


 


24-26

R7b = OH
NHCH3
C39H47N9O6
738.37
738.8


 


24-27

R7b = CH2CH3




C43H50N10O5
787.4
787.8


 


24-28

R7b = CH2CH3
NHCH3
C41H51N9O5
750.4
750.8


 


24-29

R7a = Cl R7b = F




C41H44ClFN10O5
811.32
811.6


 


24-30

R7a = Cl R7b = F
NHCH3
C39H45ClFN9O5
774.32
774.8


 


24-31

R7a = Cl R7b = F




C43H50ClFN8O5
813.36
813.6


 


24-32

R7a = Cl R7b = F




C50H62ClFN10O8
985.44
985.6


 


24-33

R7a = OCH3




C48H61N9O9
908.46
907.8
















TABLE 25













 
















Calc
Found


Ex No.
R11a R11b R11c R11d
R7a R7b R7c R7d
Formula
[M + H]+
[M + H]+















25-1 

R7a = CF3
C51H63F3N10O8
1,001.48
1001.4


25-2 

R7a = CN
C51H63N11O8
958.49
958.4


25-3 
R11b = CH3

C51H66N10O8
947.51
947.8


25-4 

R7a = CH3
C51H66N10O8
947.51
947.4


25-5 

R7a = O(CH2)2OCH3
C53H70N10O10
1,007.53
1007.4


25-6 

R7a = OiPr
C53H70N10O9
991.53
991.6


25-7 
R11b = F

C50H63FN10O8
951.48
951.4


25-8 
R11b = CF3

C51H63F3N10O8
1,001.48
1001.4


25-9 

R7b = F R7d = F
C50H62F2N10O8
969.47
969.4


25-10
R11b = OCH3

C51H66N10O9
963.5
963.4


25-11
R11b = F
R7a = F
C50H62F2N10O8
969.47
969.6


25-12

R7a = CH3 R7c = CH3
C52H68N10O8
961.52
961.6


25-13

R7a = Cl
C50H63ClN10O8
967.45
967.4


25-14

R7a = F R7c = F
C50H62F2N10O8
969.47
969.4


25-15
R11b = OCF3

C51H63F3N10O9
1,017.47
1017.4


25-16
R11a = CH3
R7c = F
C51H65FN10O8
965.5
965.4


25-17
R11b = CF3
R7a = F
C51H62F4N10O8
1,019.47
1019.4


25-18

R7b = OCH3
C51H66N10O9
963.5
963.4


25-19

R7b = CF3
C51H63F3N10O8
1,001.48
1001.4


25-20
R11a = CH3

C51H66N10O8
947.51
947.6


25-21

R7b = F
C50H63FN10O8
951.48
951.4


25-22

R7b = Cl
C50H63ClN10O8
967.45
967.6


25-23
R11b = OCHF2

C51H64F2N10O9
999.48
999.6


25-24

R7a = CF3 R7b = F
C51H62F4N10O8
1,019.47
1019.4


25-25

R7a = OCF3 R7b = F
C51H62F4N10O9
1,035.46
1035.4


25-26
R11b = CH3
R7a = F
C51H65FN10O8
965.5
965.4


25-27
R11a = CF3

C51H63F3N10O8
1,001.48
1001.4


25-28
R11a = F

C50H63FN10O8
951.48
951.4


25-29
R11a = OCF3

C51H63F3N10O9
1,017.47
1017.4


25-30

R7b = CN
C51H63N11O8
958.49
958.4


25-31

R7a = Cl R7d = OCH3
C51H65ClN10O9
997.46
997.6


25-32
R11b = CH3
R7a = F R7c = F
C51H64F2N10O8
983.49
983.4


25-33

R7a = F R7d = F
C50H62F2N10O8
969.47
969.6


25-34

R7a = Cl R7d = F
C50H62ClFN10O8
985.44
985.4


25-35

R7a = CH3 R7d = F
C51H65FN10O8
965.5
965.6


25-36

R7a = OCH3 R7d = Cl
C51H65ClN10O9
997.46
998.2


25-37

R7b = OH
C50H64N10O9
949.49
950.2


25-38

R7a = OCH3
C52H68N10O10
993.51
994.2




R7c = OCH3





25-39

R7a = F R7b = F
C50H62F2N10O8
969.47
969.4


25-40

R7a = F R7d = Cl
C50H62ClFN10O8
985.44
985.4


25-41

R7b = CH2CH3
C52H68N10O8
961.52
961.6
















TABLE 26













 












Ex.



Calc
Found


No.
R11a R11b R11c R11d
R7a R7b R7c R7d
Formula
[M + H]+
[M + H]+















26-1 
R11b = CH3

C44H54N8O5
775.42
775.4


26-2 

R7a = O(CH2)2OCH3
C46H58N8O7
835.44
835.4


26-3 

R7a = OiPr
C46H58N8O6
819.45
819.4


26-4 
R11b = F

C43H51FN8O5
779.4
779.4


26-5 

R7b = F R7d = F
C43H50F2N8O5
797.39
797.4


26-6 
R11b = OCH3

C44H54N8O6
791.42
791.4


26-7 
R11b = CF3
R7a = F
C44H50F4N8O5
847.38
847.4


26-8 
R11b = CF3

C44H51F3N8O5
829.39
829.6


26-9 
R11a = CH3
R7c = F
C44H53FN8O5
793.41
793.4


26-10
R11b = OCF3

C44H51F3N8O6
845.39
845.0


26-11

R7b = OCH3
C44H54N8O6
791.42
791.4


26-12

R7b = CF3
C44H51F3N8O5
829.39
829.4


26-13
R11a = CH3

C44H54N8O5
775.42
775.4


26-14

R7b = F
C43H51FN8O5
779.4
779.4


26-15

R7b = Cl
C43H51ClN8O5
795.37
795.4


26-16

R7ab = OCHF2
C44H52F2N8O6
827.4
827.4


26-17
R11a = CF3

C44H51F3N8O5
829.39
829.4


26-18
R11a = OCF3

C44H51F3N8O6
845.39
845.4


26-19
R11a = F

C43H51FN8O5
779.4
779.4


26-20

R7a = CF3 R7b = F
C44H50F4N8O5
847.38
847.4


26-21

R7a = OCF3 R7b = F
C44H50F4N8O6
863.38
863.4


26-22

R7b = CN
C44H51N9O5
786.4
786.4


26-23

R7a = Cl R7d = OCH3
C44H53ClN8O6
825.38
825.4


26-24
R11b = CH3
R7a = F
C44H53FN8O5
793.41
793.0


26-25
R11b = CH3
R7a = F R7c = F
C44H52F2N8O5
811.4
811.4


26-26

R7a = F R7d = F
C43H50F2N8O5
797.39
797.4


26-27

R7a = Cl R7d = F
C43H50ClFN8O5
813.36
813.4


26-28

R7a = F R7b = F
C43H50F2N8O5
797.39
797.4


26-29

R7a = F R7d = Cl
C43H50ClFN8O5
813.36
813.4


26-30

R7a = CH3 R7d = F
C44H53FN8O5
793.41
793.8


26-31

R7a = OCH3 R7d = Cl
C44H53ClN8O6
825.38
826.0


26-32

R7b = OH
C43H52N8O6
777.4
778.0


26-33

R7a = OCH3
C45H56N8O7
821.43
822.0




R7c = OCH3





26-34

R7b = CH2CH3
C45H56N8O5
789.44
789.8
















TABLE 27













 
















Calc
Found


Ex No.
R7d
R5
Formula
[M + H]+
[M + H]+















27-1 





C51H63F3N10O9
1,017.47
1017.4


 


27-2 

NH(CH2)2OCH3
C42H50F3N9O7
850.38
850.4


 


27-3 





C43H52F3N9O6
848.40
848.4


 


27-4 





C42H50F3N9O6
834.38
834.4


 


27-5 

t-Bu
C43H51F3N8O6
833.39
833.4


 


27-6 





C42H48F3N9O6
832.37
832.4


 


27-7 





C43H47F3N10O6
857.36
857.4


 


27-8 
F




C49H59F4N9O8
978.44
977.6


 


27-9 
F




C44H51F4N9O6
878.39
877.8


 


27-10





C44H50F3N9O6
858.38
857.6


 


27-11





C43H47F3N10O6
857.36
856.6


 


27-12





C42H52F3N9O8
904.39
903.6


 


27-13

O(CH2)2OCH3
C42H49F3N8O8
851.36
850.6


 


27-14





C43H49F3N8O6
831.37
830.6


 


27-15





C48H59F3N10O8
961.45
961.6


 


27-16





C47H56F3N9O8
932.42
932.6


 


27-17





C48H59F3N10O7
945.45
945.6


 


27-18





C48H59F3N10O7
945.45
945.6


 


27-19





C46H55F3N10O7
917.42
917.6


 


27-20





C48H58F3N9O9
962.43
962.6


 


27-21





C48H58F3N9O8
946.44
946.6


 


27-22





C49H61F3N10O7
959.47
959.6


 


27-23





C48H57F3N10O7
943.44
943.6


 


27-24





C44H50F3N9O6
858.38
858.6


 


27-25





C46H56F3N9O8
920.42
920.6


 


27-26





C45H54F3N9O6
874.42
874.6


 


27-27





C46H56F3N9O8
920.42
920.6


 


27-28
OCH3




C52H65F3N10O10
1,047.48
1046.6


 


27-29
OCH3




C43H47F3N10O7
873.36
872.6


 


27-30
OCH3




C43H53F3N8O7
875.4
874.6


 


27-31
OCH3




C48H58F3N9O9
962.43
961.6


 


27-32
OCH3
NHCH3
C41H48F3N9O7
836.36
835.8


 


27-33
F




C42H44F4N10O6
861.34
862.0


 


27-34
F




C42H44F4N10O6
861.34
862.0


 


27-35
F




C43H44F4N10O6
873.34
874.0


 


27-36
F




C43H46F4N10O6
875.35
876.0


 


27-37
F




C42H47F4N9O7
866.35
867.0


 


27-38
F




C42H49F4N9O7
868.37
869.0


 


27-39
F




C42H49F4N9O6
852.37
853.0


 


27-40
F




C42H47F4N9O6
850.36
851.0


 


27-41
F
O(CH2)2OCH3
C42H48F4N8O8
869.35
870.0


 


27-42
F




C46H53F4N9O8
936.40
937.0


 


27-43
F




C48H58F4N10O7
963.44
964.2


 


27-44
F




C49H60F4N10O7
977.46
978.2


 


27-45
F




C48H58F4N10O8
979.44
980.0


 


27-46
F




C47H55F4N9O8
950.41
951.0


 


27-47
F




C46H54F4N10O7
935.41
937.0


 


27-48
F




C46H53F4N9O8
936.4
936.0


 


27-49
F




C47H55F4N9O8
950.41
951.0


 


27-50
F




C48H58F4N10O7
963.44
964.0


 


27-51





C47H57F3N10O7
931.44
932.0


 


27-52





C48H57F3N10O9
975.43
976.0


 


27-53





C42H48F3N9O8
864.36
865.0


 


27-54





C44H51F3N8O7
861.38
862.0


 


27-55





C43H50F3N9O8
878.37
879.0


 


27-56





C45H54F3N9O9
922.4
923.0


 


27-57





C43H50F3N9O8
878.37
879.0


 


27-58





C51H63F3N10O9
1,017.47
1018.2


 


27-59





C47H56F3N9O8
932.42
933.0


 


27-60





C47H56F3N9O8
932.42
933.0


 


27-61

CH2N(CH3)2
C42H50F3N9O6
834.38
834.8


 


27-62





C44H50F3N9O6
858.38
858.8


 


27-63

CH2Oi-Pr
C43H51F3N8O7
849.38
849.8


27-64

CH(CH3)OCH3
C42H49F3N8O7
835.37
835.8


27-65

NH(CH2)3OCH3
C43H52F3N9O7
864.39
864.8


 


27-66
Cl




C42H44ClF3N10O6
877.31
887.6


 


27-67
Cl
NH(CH2)3OCH3
C42H49ClF3N9O7
884.34
884.6


27-68
Cl
NHCH3
C40H45ClF3N9O6
840.31
840.6


 


27-69
Cl




C44H50ClF3N8O6
879.35
879.6


 


27-70
Cl




C44H49ClF3N9O6
892.35
892.6


 


27-71
Cl




C48H53ClF3N11O7
988.38
989.6


 


27-72
Cl




C48H58ClF3N10O7
979.41
979.6


 


27-73
Cl




C46H54ClF3N10O7
951.38
951.6


 


27-74
Cl




C48H58ClF3N10O8
995.41
995.6


 


27-75
Cl




C49H60ClF3N10O7
993.43
993.5


 


27-76
Cl




C46H53ClF3N9O8
952.37
952.9
















TABLE 28













 
















Calc
Found


Ex No.
R7d
R5
Formula
[M + H]+
[M + H]+















28-1 





C43H47F5N8O6
867.35
867.4


 


28-2 





C43H50F3N9O7
862.38
862.4


 


28-3 





C44H47F3N10O6
869.36
869.4


 


28-4 





C43H47F3N10O6
857.36
857.4


 


28-5 

C(CH3)2OH
C43H51F3N8O7
849.38
849.4


 


28-6 





C43H49F3N8O7
847.37
847.4


 


28-7 





C45H53F3N8O7
875.4
875.4


 


28-8 





C46H56F3N9O8
920.42
920.4


 


28-9 





C44H54F3N9O6
862.42
862.4


 


28-10





C43H52F3N9O6
848.4
848.4


 


28-11

NH(CH2)2OCH3
C43H52F3N9O7
864.39
864.4


 


28-12





C43H50F3N9O6
846.38
846.4


 


28-13





C44H49F3N10O6
871.38
871.4


 


28-14





C44H51F3N8O6
845.39
845.4


 


28-15





C44H49F3N10O6
871.38
871.4


 


28-16





C48H58F3N9O8
946.44
946.4


 


28-17





C49H61F3N10O7
959.47
959.4


 


28-18





C49H61F3N10O7
959.47
959.4


 


28-19





C49H61F3N10O8
975.46
975.4


 


28-20





C49H59F3N10O7
957.45
957.4


 


28-21

O(CH2)2OCH3
C43H51F3N8O8
865.38
865.4


 


28-22





C45H52F3N9O6
872.40
872.4


 


28-23

tBu
C44H53F3N8O6
847.40
848.4


 


28-24





C46H54F3N9O8
918.41
918.6


 


28-25





C50H63F3N10O7
973.48
973.6


 


28-26





C47H57F3N10O7
931.44
931.6


 


28-27





C46H56F3N9O6
888.43
888.6


 


28-28





C47H58F3N9O8
934.44
934.6


 


28-29





C45H52F3N9O6
872.40
872.6


 


28-30





C47H58F3N9O8
934.44
934.6


 


28-31





C44H49F5N8O6
881.37
882.0


 


28-32





C48H58F3N9O8
946.44
947.0


 


28-33





C52H65F3N10O9
1,031.49
1032.2


 


28-34





C47H56F3N9O8
932.42
933.0


 


28-35

CH2N(CH3)2
C43H52F3N9O6
848.4
848.8


28-36
Cl
NHCH3
C41H47ClF3N9O6
854.33
854.6


28-37
Cl
NH(CH2)2OCH3
C43H51ClF3N9O7
898.36
898.6


 


28-38
Cl




C45H52ClF3N8O6
893.37
893.6


 


28-39
Cl




C43H46ClF3N10O6
891.32
891.6


 


28-40
Cl




C45H51ClF3N9O6
906.36
906.6


 


28-41
Cl




C49H60ClF3N10O7
993.43
993.4


 


28-42
Cl




C47H56ClF3N10O7
965.4
965.4


 


28-43
Cl




C49H60ClF3N10O8
1,009.42
1009.5
















TABLE 29













 













Ex




Calc
Found


No.
R11a R11b R11c R11d
R7a R7b R7c R7d
R5
Formula
[M + H]+
[M + H]+
















29-1 

R7a = CF3




C51H63F3N10O8
1,001.48
1001.4


 


29-2 

R7a = CF3




C42H47F3N8O5
801.36
801.4


 


29-3 

R7a = CF3
NHCH3
C40H46F3N9O5
790.36
790.2


 


29-4 

R7a = CF3




C42H45F3N10O5
827.35
827.2


 


29-5 

R7a = CF3




C44H51F3N8O5
829.39
829.4


 


29-6 

R7a = CH3




C44H54N8O5
775.42
775.4


 


29-7 

R7a = OCH2CHF2




C52H66F2N10O9
1,013.50
1013.6


 


29-8 
R11b = CH3





C44H54N8O5
775.42
775.4


 


29-9 

R7a = OCH2cPr




C45H52N10O6
829.41
829.4


 


29-10

R7a = OCH2cPr




C54H70N10O9
1,003.53
1004.0


 


29-11

R7a = OCH3




C51H66N10O9
963.5
963.6


 


29-12

R7a = O(CH2)2OCH3




C46H58N8O7
835.44
835.4


 


29-13

R7a = Oi-Pr
NHCH3
C42H53N9O6
780.41
780.4


 


29-14
R11d = CH3
R7a = OCF3




C45H53F3N8O6
859.4
859.4


 


29-15

R7a = OCH2t-Bu




C55H74N10O9
1,019.56
1019.6


 


29-16

R7a = OcPr




C46H56N8O6
817.43
817.4


 


29-17

R7a = OCF3




C49H60F3N9O8
960.45
960.4


 


29-18

R7a = OCF3




C48H59F3N10O7
945.45
945.4


 


29-19

R7a = OCF3




C46H54F3N9O7
902.41
902.4


 


29-2-

R7a = OCF3




C46H54F3N9O8
918.41
918.4


 


29-21

R7a = OCF3




C48H56F3N9O7
928.43
928.4


 


29-22
R11b = CF3





C51H63F3N10O8
1,001.48
1001.4


 


29-23
R11b = OCH3





C44H54N8O6
791.42
791.4


 


29-24
R11b = F





C43H51FN8O5
779.4
779.4


 


29-25

R7a = OCH3 R7c = OCH3




C52H68N10O10
993.51
993.4


 


29-26
R11b = OCF3





C44H51F3N8O6
845.39
845.4


 


29-27
R11a = CH3





C51H66N10O8
947.51
947.6


 


29-28

R7a = OCHF2




C51H64F2N10O9
999.48
999.4


 


29-29

R7a = OCF3




C48H57F3N10O7
943.44
943.4


 


29-30

R7a = OCF3




C47H56F3N9O8
932.42
932.4


 


29-31

R7a = OCF3




C51H63F3N10O9
1,017.47
1017.4


 


29-32
R11a = OCF3





C51H63F3N10O9
1,017.47
1017.4


 


29-33
R11a = CF3





C51H63F3N10O8
1,001.48
1001.4


 


29-34
R11d = CH3
R7a = CH3




C45H56N8O5
789.44
789.4


 


29-35
R11a = OCH3





C44H54N8O6
791.42
792.0


 


29-36

R7b = F




C50H63FN10O8
951.48
952.2


 


29-37
R11a = Cl





C45H55ClN10O6
867.4
867.0
















TABLE 30













 













Ex




Calc
Found


No.
R11a R11b R11c R11d
R7a R7b R7c R7d
R5
Formula
[M + H]+
[M + H]+
















30-1


CH((R)OH)CH2OH
C41H50N8O7
767.38
767.6


 


30-2
R11b = CH3





C45H56N8O5
789.44
789.4


 


30-3

R7a = OCH2CHF2




C44H50F2N10O6
853.39
853.4


 


30-4

R7a = OCH2CHF2




C46H56F2N8O6
855.43
855.4


 


30-5
R11b = CH3





C52H68N10O8
961.52
961.6


 


30-6

R7a = OCH3




C45H56N8O6
805.43
805.4


 


30-7

R7a = CF3




C45H53F3N8O5
843.41
843.4


 


30-8

R7a = OCH2CH3




C53H70N10O9
991.53
991.4


 


30-9

R7a = OCF3




C45H53F3N8O6
859.4
859.4
















TABLE 31













 
















Calc
Found


Ex No.
R9a
R9b
Formula
[M + H]+
[M + H]+





31-1

(R)CH3
C44H51F3N8O6
845.39
845.4


31-2

(S)CH3
C44H51F3N8O6
845.39
845.4


31-3
(S)CH3

C44H51F3N8O6
845.39
845.4
















TABLE 32













 












Ex



Calc
Found


No.
R9a R9b R9c R9d
R5
Formula
[M + H]+
[M + H]+















32-1 
R9b = (S)CH2OCH3




C45H55N7O6
790.42
790.4


 


32-2 
R9b = (R)CH3
CH2NHC(O)CH3
C42H50N8O6
763.39
763.4


 


32-3 
R9b = (R)CH3




C43H49N9O5
772.39
772.4


 


32-4 
R9b = (R)CH3




C44H53N7O5
760.41
760.4


 


32-5 
R9b = (S)CH3
CH2NHC(O)CH3
C42H47N9O5
758.37
758.4


 


32-6 
R9b = (S)CH3




C44H53N7O5
760.41
760.4


 


32-7 
R9a = (R)CH3
tBu
C43H53N7O5
748.41
748.4


32-8 
R9a = (R)CH3
NHCH3
C40H48N8O5
721.38
721.2


 


32-9 
R9a = (R)CH3




C44H53N7O5
760.41
760.4


 


32-10
R9a = (R)CH3




C45H54N8O6
803.42
803.4


 


32-11
R9a = (S)CH3




C45H54N8O6
803.42
803.4


 


32-12
R9a = (S)CH3




C44H53N7O5
760.41
760.4


 


32-13
R9b = (S)CH2OCH3




C46H56N8O7
833.43
833.4


 


32-14
R9b = (R)CH2OCH3




C44H51N9O6
802.4
802.4


 


32-15
R9b = (R)CH2OCH3
CH2NHC(O)CH3
C43H52N8O7
793.4
793.4


 


32-16
R9a = (S)CH3 R9c = (R)CH3




C43H51N7O5
746.4
746.4


 


32-17
R9a = (R)CH3




C46H56N8O6
817.43
817.4


 


32-18
R9b = (S)CH2OH




C44H53N7O6
776.41
776.2


 


32-19
R9b = (S)CH3 R9d = (R)CH3




C43H51N7O5
746.4
746.4


 


32-20
R9b = (S)CH3 R9c = (R)CH3




C45H55N7O5
774.43
774.4


 


32-21
R9a = (R)CH3




C46H56N8O7
833.43
833.4


 


32-22
R9b = (R)CH3 R9c = (S)CH3




C45H55N7O5
774.43
774.4


 


32-23
R9b = (R)CH3 R9c = (S)CH3




C47H58N8O6
831.45
831.4
















TABLE 33













 
















Calc
Found


Ex No.
R7b R7c R7d
R5
Formula
[M + H]+
[M + H]+















33-1
R7c = CH3




C50H65N11O8
948.5
948.4


 


33-2
R7c = CH3




C43H53N9O5
776.42
776.4


 


33-3
R7c = CF3




C43H50F3N9O5
830.39
830.4


 


33-4
R7c = CF3




C50H62F3N11O8
1,002.47
1002.4


 


33-5
R7c = CF3




C41H44F3N11O5
828.35
828.4


 


33-6
R7b = OCH3




C50H65N11O9
964.5
964.6


 


33-7





C42H51N9O5
762.40
762.9


 


33-8





C49H63N11O8
934.49
934.1
















TABLE 34













 
















Calc
Found


Ex No.
R9d
R5
Formula
[M + H]+
[M + H]+





34-1
(S)CH3




C44H48F4N10O6
889.37
889.6


 


34-2
(S)CH3




C46H54F4N8O6
891.41
891.6


 


34-3
(S)CH3
NHCH3
C42H49F4N9O6
852.37
852.6


 


34-4





C45H52F4N8O6
877.39
877.6


 


34-5





C43H46F4N10O6
875.35
875.4


 


34-6

NHCH3
C41H47F4N9O6
838.36
838.4









Biological Assays

The hepatitis C virus has been classified into six major different genotypes on the basis of nucleotide sequence, and further divided into subtypes within genotypes. Compounds of the invention demonstrated inhibition of HCV replication in one or more of the following HCV replicon assays.
Assay 1: HCV Genotype 1b Replicon Assay
The HCV genotype 1b replicon cell line was obtained from Apath LLC (Brooklyn, N.Y.) (APC144; Huh7 cell background). This subgenomic replicon contains the N-terminus of the HCV core protein fused to the neomycin-resistance selectable marker. The EMCV IRES lies downstream and drives expression of humanized Renilla luciferase fused to the non-structural proteins NS3-NS5B. This cell line was used to determine compound potency using the luciferase activity readout as a measurement of compound inhibition of replicon levels.
Cells were grown at 37° C. in a 5% CO2 humidified incubator in DMEM (Invitrogen) with 10% FBS (HyClone), 1×NEAA (Invitrogen), 1× Pen-Strep (Invitrogen), and 500 μg/mL G418 (Invitrogen). On day 1 of the assay, cells were plated at 10,000 cells/well in white 96-well tissue culture plates (Costar) in 200 μL media lacking G418. Four hours later, once the cells have adhered, the media was removed and replaced with media (no G418) containing dose-responses of test compounds. Compounds were initially diluted in DMSO and then diluted another 200× in media to bring the final DMSO concentration down to 0.5%. The cells were incubated with test compounds for 48 hours. At the end of the incubation period, media and compound were removed from the plates and the luciferase activity was determined using Promega Renilla-Glo reagents.
To analyze the data, the luciferase activity was plotted vs. the compound concentration, and EC50 values were determined from a 4-parameter robust fit model with the GraphPad Prism software package (GraphPad Software, Inc., San Diego, Calif.). Results are expressed as the negative decadic logarithm of the EC50 value, pEC50.
Test compounds having a higher pEC50 value in this assay show greater inhibition of HCV genotype 1b replication. Compounds of the invention tested in this assay typically exhibited pEC50 values between about 7 and about 12.
Assay 2: HCV Genotype 1a Replicon Assay
The HCV genotype 1a replicon cell line was obtained from Apath LLC (APC89; Huh7.5 cell background). This subgenomic replicon contains the N-terminus of the HCV core protein fused to the neomycin-resistance selectable marker. The EMCV IRES lies downstream and drives expression of the non-structural proteins NS3-NS5B. Compound potencies were determined using the NS3-specific protease activity in lysates as a measurement of compound inhibition of replicon levels.
Cells were grown at 37° C. in a 5% CO2 humidified incubator in DMEM (Invitrogen) with 10% FBS (HyClone), 1×NEAA (Invitrogen), 1× Pen-Strep (Invitrogen), and 850 μg/mL G418 (Invitrogen). On day 1 of the assay, cells were plated at 15,000 cells/well in black 96-well tissue culture plates (Costar) in 200 μL media lacking G418. Four hours later, once the cells had adhered, the media was removed and replaced with media (no G418) containing dose-responses of test compounds. Compounds were initially diluted in DMSO and then diluted another 200× in media to bring the final DMSO concentration down to 0.5%. The cells were incubated with test compounds for 48 or 72 hours. At the end of the incubation period, media and compound were removed from the plates.
To determine the NS3-specific protease activity in lysates, the cells were lysed at room temperature in 50 μL/well of 50 mM Hepes pH 7.5, 150 mM NaCl, 15% Glycerol, 0.15% Triton X-100, 10 mM DTT for 20 minutes with shaking. 50 μL of an NS3/4a protease-specific FRET substrate (Anaspec RET 51 Cat#22991) was then added to the wells at a final concentration of 15 μM. The plates were incubated at 37° C. for 20 minutes, which corresponds to a timepoint at which the protease activity is still in the linear phase. Protease activity was determined by measuring fluorescence (Excitation: 340 nm; Emission: 509 nm).
To analyze the data, the fluorescence was plotted vs. the compound concentration, and EC50 values were determined from a 4-parameter robust fit model using GraphPad Prism software. Compounds of the invention tested in this assay typically exhibited pEC50 values between about 7 and about 11.5.
Assay 3: Replicon Assays Against Resistant Mutants
To create replicon cells with resistant mutations of interest, the mutation was first introduced into the parental plasmid by site-directed mutagenesis. Mutations in genotype 1b included L31V, Y93H, and the L31V/Y93H double mutant. Mutations in genotype 1a included Q30R and L31V. The replicon plasmid was then linearized and in vitro transcribed to RNA. The RNA was used to stably transfect Huh7 cells by electroporation, and new cell lines were selected with 500 μg/mL G418. Potencies of test compounds against these mutant cell lines were determined as previously described above for the HCV Genotype 1b and 1a replicon assays.
Potencies of test compounds against additional mutations of interest were determined using transient transfection assays. These mutants included and genotype 1a Y93C, Y93H, M28T, Q30E, Q30K. The mutation was first introduced into the parental plasmid by site-directed mutagenesis. The replicon plasmid was then linearized and in vitro transcribed to RNA. The RNA was used to transiently transfect Huh-LUNET cells (obtained from ReBLikon GmbH, Schriesheim, Germany) by electroporation, and the potencies of test compounds against the mutants were determined as previously described.
Assay 4: Colony Formation Assay
Colony formation assays were used to assess overall genetic barrier of resistance of test compounds. Replicon cells were plated in tissue culture flasks and treated with various concentrations of test compound(s) (or DMSO control) in the presence of G418 (500-850 μg/mL) for 3-4 weeks. The media was replaced with fresh media containing compound and G418 twice per week. Cells were split as necessary. During this time, many cells died, and resistant colonies emerged. The colonies were then fixed and stained with crystal violet/methanol. The combination of a compound of the invention and danoprevir (an NS3 protease inhibitor) was able to significantly suppress the emergence of resistant mutants to a greater degree than either single compound alone.
Assay 5: Replicon Assays of Combinations of Agents
Combinations of a compound of the invention and another therapeutic agent were tested as described for the HCV genotype 1b and 1a replicon assays. Cells were incubated with various combinations (in a checkerboard matrix) of test compounds for 48 hours. Potencies of either compound alone were determined as described above, and MacSynergy II software was used to determine if the combination of test compounds exhibited synergy vs additivity vs antagonism. The combination of a compound of the invention and danoprevir (an NS3 protease inhibitor) showed an additive antiviral effect. Similarly, the combination of a compound of the invention and interferon alpha2b showed an additive antiviral effect.
Assay Results
All of the compounds of Examples 1 to 77 and Tables 1 to 33 were tested in one or more of the assays described above. For example, the following results were obtained in the HCV genotype 1b and 1a replicon assays where A represents a pEC50 value between 7 and 8 (EC50 between 100 nM and 10 nM), B represents pEC50 between 8 and 9 (EC50 between 1 and 10 nM), C represents pEC50 between and 9 and about 10, (EC50 between 1 nM and 0.1 nM), and D represents pEC50>10 (EC50<0.1 nM).















Example
Genotype
Genotype



No.
1b
1a









 1
D
B



 2
D
B*



 3
D
B*



 4
D
A*



 5
D
B



 6
D
A*



 7
D
B*



 8
D
B



 9
D
C*



10
D
C*



11
D
C*



12
D
C



13
D
D



14
D
D



15
D
D



16
D
D



17
D
C



18
D
C



19
D
C



20

B



21
D
D



22
D
D



23

C



24

C



25
D
D



26
D
D



27
D
D



28
D
C



29
D
D



30
D
D



31
D
D



32
D
D



33
D
D



34
D
D



35
D
C



36
D
C



37
D
C



38
D
D



39
D
D



40
D
C



41
D
D



42
D
C



43
D
C



44
D
C



45
D
D



46
D
C



47
D
C



48
D
C



49
D
D



50
D
D



51
D
D



52
D
D



53
D
D



54
D
D



55
D
D



56
D
C



57
D
D



58
D
D



59
D
D



60
D
D



61
D
D



62
D
D



63
D
D



64
D
D



65
D
D



66
D
D



67

C



68
D
C



69
D
C



70

C



71
D
C



72
C
B



73

B



74

B



75

B



76

C



77
D
D



27-1

D



27-2

C



27-3

C



27-4

C



27-5
D
D



27-6

C



27-7
D
D



27-8

D



27-9

B



27-10
D
D



27-11

C



27-12
D
D



27-13

C



27-14

D



27-15
D
D



27-16
D
D



27-17
D
D



27-18
D
D



27-19

D



27-20
D
D



27-21
D
D



27-22
D
D



27-23
D
D



27-24

C



27-25

B



27-26

C



27-27

B



27-28
D
D



27-29

C



27-30

D



27-31
D
D



27-32

C



27-33
D
D



27-34
D
D



27-35

C



27-36
D
D



27-37
D
D



27-38
D
D



27-39

C



27-40

C



27-41

C



27-42
D
D



27-43
D
D



27-44
D
D



27-45
D
D



27-46
D
D



27-47
D
D



27-48
D
D



27-49

D



27-50
D
D



27-51

C



27-52
D
D



27-53

C



27-54

C



27-55

D



27-56

C



27-57

B



27-58

D



27-59

D



27-60

D



27-61

C



27-62

C



27-63

C



27-64

D



27-65

C



27-66

D



27-67
D
C



27-68
D
D



27-69
D
D



27-70

C



27-71

D



27-72
D
D



27-73
D
D



27-74

D



27-75

D



27-76

D



28-1
D
D



28-2
D
D



28-3

C



28-4

D



28-5
D
D



28-6

C



28-7

D



28-8
D
D



28-9

C



28-10

C



28-11

C



28-12

C



28-13

D



28-14
D
D



28-15
D
D



28-16
D
D



28-17
D
D



28-18
D
D



28-19
D
D



28-20
D
D



28-21

C



28-22
D
D



28-23
D
D



28-24
D
D



28-25
D
D



28-26
D
D



27-27

B



28-28

B



28-29
D
D



28-30

B



28-31

C



28-32

D



28-32

D



28-34

D



28-35

C



28-36
D
D



28-37

D



28-38
D
D



28-39
D
D



28-40
D
D



28-41

D



28-42

D



28-43

D







*Compounds incubated for 48 hours; all other Genotype 1a results for 72 hour incubation






While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. Additionally, all publications, patents, and patent documents cited hereinabove are incorporated by reference herein in full, as though individually incorporated by reference.

## Claims

1. A method of treating hepatitis C viral infection in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (III):



wherein
R1 is selected from C1-6alkyl, phenyl, and C3-6cycloalkyl, wherein C1-6alkyl is optionally substituted with —ORq, wherein Rq is hydrogen or C1-3alkyl;
R2 is selected from hydrogen and C1-6alkyl;
R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)NRaRb, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl;
wherein
Ra and Rb are independently hydrogen or C1-6alkyl;

R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, and —CH2-heteroaryl;
wherein:
any heteroaryl or heterocycle has 5 or 6 ring atoms;
C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORc, —NHC(O)C1-3alkyl, and —NHC(O)OC1-3alkyl;
C1-6alkoxy is optionally substituted with —ORd;
C3-6cycloalkyl is optionally substituted with one or two substituents independently selected from C1-3alkyl and halo;
any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, 13 C(O)OC1-3alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, and —C(O)NHC3-6cycloalkyl;
wherein any —C(O)C1-6alkyl is optionally substituted with 13 NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle,
any —C(O)C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl, and
any —C(O)NHC1-6alkyl is optionally substituted with —ORn or C3-6cycloalkyl;


any heteroaryl is optionally substituted with C1-3alkyl;
Rc is independently selected from hydrogen, C1-6alkyl, and phenyl;
Rk, Rd, Re, Rg, and Rh are each independently hydrogen or C1-3alkyl;
Rf is selected from hydrogen and —C(O)C1-3alkyl;
Rn is independently hydrogen or C1-3alkyl;
R7 is selected from halo, C1-3alkyl, and C1-3alkoxy wherein C1-3alkyl, and C1-3alkoxy are optionally substituted with one, two, or three halo; and
R9 is C1-3alkyl;
a is 1 or 2; and
c is 1 or 2.

2. The method of claim 1 wherein R5 is selected from C3-4cycloalkyl, —CH2NReRf, —NRgRh, imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl;
wherein:
C3-4cycloalkyl is optionally substituted with one or two C1-3alkyl;
pyrrolidinyl is substituted with methyl and a substituent selected from —C(O)OC1-3alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl, wherein
—C(O)C1-6alkyl is substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle.

3. The method of claim 1 wherein:
R1 is C1-6alkyl, R2 is hydrogen; and R3 is —C(O)OC1-6alkyl; and
R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl,

4. The method of claim 1 wherein:
Rl is isopropyl, R2 is hydrogen; and R3 is —C(O)OCH3;
R7 is selected from fluoro, chloro, —CF3, and —OCF3; and R9 is methyl; and
R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl, and

5. The method of claim 1 wherein the compound is selected from:





















and pharmaceutically-acceptable salts thereof.

6. The method of claim 1 wherein the method further comprises administering to the mammal one or more other therapeutic agents useful for treating hepatitis C viral infections.

7. The method of claim 6 wherein the one or more other therapeutic agents is selected from HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase inhibitors, interferons and pegylated interferons, and ribavirin.

8. A method of inhibiting replication of the hepatitis C virus in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (III):



wherein
R1 is selected from C1-6alkyl, phenyl, and C3-6cycloalkyl, wherein C1-6alkyl is optionally substituted with —ORq, wherein Rq is hydrogen or C1-3alkyl;
R2 is selected from hydrogen and C1-6alkyl;
R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, —C(O)NRaRb, —C(O)C 3-6cycloalkyl, and —S(O)2C1-3alkyl;
wherein
Ra and Rb are independently hydrogen or C1-6alkyl;

R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, and —CH2-heteroaryl;
wherein:
any heteroaryl or heterocycle has 5 or 6 ring atoms;
C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORc, —NHC(O)C1-3alkyl, and —NHC(O)OC1-3alkyl;
C1-6alkoxy is optionally substituted with —ORd;
C3-6cycloalkyl is optionally substituted with one or two substituents independently selected from C1-3alkyl and halo;
any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —C(O)OC1-3 alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, and —C(O)NHC3-6cycloalkyl;
wherein any —C(O)C1-6alkyl is optionally substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle,
any —C(O)C3-6cycloalkyl is optionally substituted with one or two Ci -3 alkyl, and
any —C(O)NHC 1-6alkyl is optionally substituted with —ORn or C3-6cycloalkyl;


any heteroaryl is optionally substituted with C1-3alkyl;
Rc is independently selected from hydrogen, C1-6alkyl, and phenyl;
Rk, Rd, Re, Rg, and Rh are each independently hydrogen or C1-3alkyl;
Rf is selected from hydrogen and —C(O)C1-3alkyl;
Rn is independently hydrogen or C1-3alkyl;
R7 is selected from halo, C1-3alkyl, and C1-3alkoxy wherein C1-3alkyl, and C1-3alkoxy are optionally substituted with one, two, or three halo; and
R9 is C1-3alkyl;
a is 1 or 2; and
c is 1 or 2.

9. The method of claim 8 wherein R5 is selected from C3-4cycloalkyl, —CH2NReRf, —NRgRh, imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl;
wherein:
C3-4cycloalkyl is optionally substituted with one or two C1-3alkyl;
pyrrolidinyl is substituted with methyl and a substituent selected from —C(O)OC1-3alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl, wherein
—C(O)C1-6alkyl is substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle.

10. The method of claim 8 wherein:
Rl is C1-6alkyl, R2 is hydrogen; and R3 is —C(O)OC1-6alkyl; and
R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl,

11. The method of claim 8 wherein:
R1 is isopropyl, R2 is hydrogen; and R3 is —C(O)OCH3;
R7 is selected from fluoro, chloro, —CF3, and —OCF3; and R9 is methyl; and
R5 is selected from —NHCH3, 2,2-dimethylcyclopropyl, and

12. The method of claim 8 wherein the compound is selected from:





















and pharmaceutically-acceptable salts thereof.

13. The method of claim 8 wherein the method further comprises administering to the mammal one or more other therapeutic agents useful for inhibiting replication of the hepatitis C virus in a mammal.

14. The method of claim 13 wherein the one or more other therapeutic agents is selected from HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase inhibitors, interferons and pegylated interferons, and ribavirin.